Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1219
Encontrada(s) 13 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Tesis doctoral (DoctoralThesis)

Efecto de la actividad física, la obesidad y el sueño en la calidad de vida relacionada con la salud en Individuos con Síndrome Metabólico, Effect of physical activity, obesity and sleep on health-related quality of life in individuals with Metabolic Syndrome

  • Marcos Delgado, Alba
218 p., [ES] Introducción La calidad de vida relacionada con la salud (CVRS) se ha convertido en un parámetro indispensable para la salud pública, pudiendo estimar la carga de enfermedad global en las poblaciones, siendo un buen predictor de mortalidad. Debido al aumento en la prevalencia del síndrome metabólico (SMet) en la población resulta imprescindible averiguar cuál es la relación entre el SMet y la CVRS. Por este motivo, el objetivo principal de la presente tesis doctoral es estimar la CVRS en adultos que padecen SMet y los factores relacionados que influyen en la misma. Metodología Se utilizó la información disponible del estudio PREDIMED-Plus, un ensayo clínico aleatorizado multicéntrico, que recoge los datos sobre CVRS mediante el cuestionario SF-36, así como medidas antropométricas, nivel de actividad física y duración de sueño mediante acelerometría. Se realizó un análisis descriptivo transversal de la CVRS. Mediante modelos de regresión lineal ajustados por potenciales factores confusores, se evaluó la asociación entre la CVRS, el nivel de actividad física, el grado de obesidad y la duración del sueño, al comienzo del estudio y al año de seguimiento. Además, se realizaron modelos de regresión logística para averiguar si la actividad física, el índice de masa corporal (IMC) y la duración del sueño predicen cambios clínicamente significativos en la CVRS. Resultados Nuestros resultados reflejan que el aumento en la actividad física conlleva un incremento en las puntuaciones medias de la CVRS. En las mujeres, se encontraron hasta 10 puntos de diferencia entre la actividad física ligera y la moderada-vigorosa en la función física, rol físico, vitalidad, función social y rol emocional. Además, aquellos sujetos que mejoraron sus niveles de actividad física a lo largo del año de seguimiento, tuvieron un 91% de posibilidades de mejora clínicamente significativa de su componente agregado físico (PCS), respecto a aquellos que se mantuvieron inactivos durante un año (OR = 1,91; IC 95%: 1,23-2,96). En cuanto al grado de obesidad, cuanto mayor es el IMC, menores son las puntuaciones medias en las esferas físicas. Sin embargo, un IMC >30kg/m2, predice una mejora de dichas esferas a un año y son aquellos sujetos que pierden peso a lo largo del año los que más probabilidades tienen de mejorar su CVRS, respecto a aquellos que no modificaron su IMC (PCS OR = 1,85; IC 95% = 1,43-2,40). Se observa que los valores extremos en la duración de sueño de noche (<6h/>9h) afectan negativamente a la PCS. También, se ha encontrado una correlación entre dormir la siesta y la mejora del componente agregado mental (MCS) en aquellos individuos con un sueño nocturno corto (<7h) (Coeficiente β = 6,3 (1,3-11,3) p= 0,01). Conclusiones Nuestros resultados ponen de manifiesto que el SMets afecta negativamente en las esferas físicas de la CVRS. El nivel de actividad física, el IMC y la duración del sueño son factores relacionados que influyen en la misma. Se sugiere que una mejora en estos factores provoca una mejoría de la CVRS en individuos que padecen SMets. No obstante, se precisan más ensayos clínicos para evaluar estas asociaciones., [EN] Introduction Health-related quality of life (HRQoL) has become an essential parameter for public health, given its ability to estimate the global burden of disease in populations makes it a good predictor of mortality. Due to the increased prevalence of metabolic syndrome (MetS) in the population, it is vital to discern the relationship between MetS and HRQoL. As such, the main objective of this doctoral thesis is to estimate HRQoL in adults with MetS and the related factors that influence it. Methods Available information was used from the PREDIMED-Plus study, a multicenter randomized clinical trial that collects data on HRQoL using the SF-36 questionnaire, anthropometric measurements, level of physical activity and sleep duration using accelerometry. A cross-sectional descriptive analysis of HRQoL was performed. Through linear regression models adjusted for potential confounding factors, the association between HRQoL, level of physical activity, degree of obesity, and sleep duration was evaluated at the start of the study and at a one-year follow-up. Additionally, logistic regression models were fit to discern whether physical activity, body mass index (BMI), and sleep duration predict clinically significant changes in HRQoL. Results Our results reflect that increased physical activity leads to an increase in the mean HRQoL scores. In women, up to a 10-point difference was found between light and moderate-to-vigorous physical activity in physical function, physical role, vitality, social function, and emotional role. Furthermore, subjects who improved their physical activity levels throughout the follow-up year had a 91% chance of clinically significant improvement in their physical aggregate component (PCS), compared to those who remained inactive during that year (OR = 1.91; 95% CI: 1.23-2.96). In terms of obesity, the higher the BMI, the lower the average scores in physical areas. However, a BMI >30kg/m2 predicts an improvement in these areas at one year and subjects who lose weight throughout the year are more likely to improve their HRQoL, compared to those whose BMI was unchanged (PCS OR = 1.85, 95% CI = 1.43-2.40). We observed that extreme values in nightly sleep duration (<6h/>9h) negatively affect the PCS. A correlation was also found between napping and improving the physical aggregate component (MCS) in individuals with a short night's sleep (<7h) (Coefficient β = 6.3 (1.3-11.3) p= 0.01). Conclusions Our results show that MetS negatively affects the physical domains of HRQoL and physical activity level, BMI and sleep duration are related factors that influence it. Results suggest that improving these factors leads to an improved HRQoL in individuals with MetS. However, more clinical trials are needed to evaluate these associations.
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Tesis doctoral (DoctoralThesis)

Efecto de la ingesta de polifenoles en biomarcadores y riesgo cardiovascular, Effect of polyphenol intake on biomarkers and cardiovascular risk

  • Rubín García, María
174 p., [ES] Introducción La enfermedad cardiovascular es la principal causa de muerte en todo el mundo y, a pesar de las estrategias preventivas llevadas a cabo, continúa siendo un problema de salud pública. La dieta mediterránea ha demostrado numerosos beneficios cardiosaludables dada su riqueza en moléculas antioxidantes y antiinflamatorias y, muy especialmente, en polifenoles. Estos compuestos bioactivos han mostrado beneficios a nivel cardiovascular debido a sus propiedades antitrombóticas, antiinflamatorias y antiagregantes. Sin embargo, el estudio de su potencial en humanos es limitado. Dado el gran número de compuestos que existen, y, por ende, sus variadas biodisponibilidades y mecanismos de acción, aún hay muchos puntos que necesitan ser esclarecidos. Por este motivo, el objetivo principal de la presente tesis doctoral es evaluar la asociación entre el consumo de polifenoles, y el riesgo y biomarcadores de riesgo cardiovascular (RCV). Metodología Se utilizó la información disponible de 6.633 participantes del estudio PREDIMED-Plus, un ensayo clínico aleatorizado multicéntrico, que recopiló información sobre hábitos alimentarios y estilos de vida, así como muestras sanguíneas para análisis bioquímicos. El consumo de polifenoles se estimó utilizando los datos de consumo de alimentos del cuestionario semicuantitativo de frecuencia alimentaria de 143 ítems y el contenido de polifenoles de cada alimento contenido en la base de datos Phenol-Explorer. Los consumos estimados se ajustaron por la ingesta total de energía de acuerdo al método de residuales. Mediante modelos de regresión lineal multivariante, se evaluó la asociación entre la ingesta de polifenoles y el RCV (estimado mediante ecuaciones de riesgo). Además, se evaluó la asociación entre la ingesta de polifenoles y, el ácido úrico (mediante regresión lineal multivariante) y, mediante modelos de regresión de Cox con un tiempo de seguimiento constante (t=1) se estimó los Prevalence Ratio de la hiperuricemia. Por otro lado, se establecieron patrones de consumo de polifenoles mediante análisis factorial y análisis clúster, comparando ambos métodos y relacionando la adherencia a cada patrón con el RCV estimado. Todos los análisis se realizaron para hombres y mujeres por separado, además de en la población total. Resultados La ingesta total de polifenoles (βQ5vs.Q1= 0,10, IC 95%: 0,04 a 0,17) y flavonoides (βQ5vs.Q1= 0,17, IC 95%: 0,10 a 0,24) se asoció directa y significativamente con una mejor salud cardiovascular óptima (Life’s Simple 7). Se encontraron asociaciones inversas entre el consumo de la clase otros polifenoles y, el RCV estimado mediante Framingham (βQ5vs.Q1= -1,22%, IC 95%: -2,37 a -0,07) y SCORE (βQ5vs.Q1=-0,32, IC 95%: -2,37 a -0,07). En las mujeres, las asociaciones entre el consumo de polifenoles y todas las ecuaciones de riesgo, tienden a ser protectoras. La ingesta de ácidos fenólicos (βQ5vs.Q1= -0,17, IC 95%: -0,27 a -0,06), ácidos hidroxicinámicos (βQ5vs.Q1= -0,19, IC 95%: -0,3 a -0,09), alquilmetoxifenoles (βQ5vs.Q1= 0,2, IC 95%: -0,31 a -0. 1) y metoxifenoles (βQ5vs.Q1= -0,24, IC 95%: -0,34 a -0,13) -0,24, IC 95%: -0,34 a -0,13) mostró una asociación inversa con los niveles de ácido úrico en suero y, la hiperuricemia (PRQ5vs.Q1=0,82, IC 95%:0,71-0,95; PRQ5vs.Q1=0,82, IC 95%:0,71-0,95; PRQ5vs.Q1=0,80, IC 95%:0,70-0,92 y PR=0,79, IC 95%:0,69-0,91, respectivamente). Los patrones de polifenoles revelaron diferencias entre hombres y mujeres, así como en su asociación con el RCV. Respecto a aquellos derivados del análisis factorial: para el total de la muestra, y los hombres, el patrón 3 (aceitunas y aceite de oliva) se asoció positivamente con el RCV, también presentaron, mayor prevalencia de diabetes y mayores consumos de sodio. El patrón 4 formado por el café en todos los grupos, también se asoció con mayor RCV. En cuanto al análisis clúster, el clúster 2 en el total y en hombres, caracterizados por consumo de polifenoles del café y las aceitunas y aceite de oliva, también mostraron mayor RCV. Conclusiones La clase otros polifenoles mostró asociaciones inversas con el riesgo cardiovascular estimado, encontrándose resultados similares con las ecuaciones de Framingham, Framingham-REGICOR y Life’s Simple 7 (después de eliminar el componente de dieta) y diferentes con la SCORE, pero los predictores que se incluyen en esta herramienta son escasos. Una mayor ingesta subclases de polifenoles presentes en el café: ácidos hidroxicinámicos, alquilmetoxifenoles y metoxifenoles se asoció de forma inversa a los niveles de ácido úrico y la hiperuricemia. Encontramos diferencias en los patrones de ingesta de polifenoles entre hombres y mujeres, y en sus asociaciones con la RCV. Estas diferencias de sexo pueden explicarse por el hecho de que llevan estilos de vida diferentes, ya que un patrón no se refiere sólo a los hábitos dietéticos. Además, los sujetos que presentaban un mayor riesgo al inicio del estudio podrían sentirse más motivados para mejorar su hábito dietético (causalidad inversa). Nuestros hallazgos añaden nuevos conocimientos en el estudio de los compuestos fenólicos, destacando la importancia de analizarlos por sexo y de estudiar los determinantes de las elecciones alimentarias y los patrones dietéticos en relación con la percepción de riesgo y los estilos de vida específicos., [EN] Introduction Cardiovascular disease is the leading cause of death worldwide and, despite preventive strategies, continues to be a public health problem. The Mediterranean diet has demonstrated numerous benefits in this regard given its richness in antioxidant and anti-inflammatory molecules, and most especially, in polyphenols. These bioactive compounds have shown cardiovascular benefits due to their antithrombotic, anti-inflammatory and antiplatelet properties. However, the study of their potential in humans is limited. Given the large number of compounds that exist and, therefore, their varied bioavailability and mechanisms of action, there are still many points that need to be clarified. For this reason, the main objective of this doctoral thesis is to evaluate the association between polyphenol intake and cardiovascular risk (CVR) and biomarkers. Methods The information available from 6,633 participants in the PREDIMED-Plus study was used, it is a multicenter randomized clinical trial, which collected information on dietary habits and lifestyles, as well as blood samples for biochemical analysis. Polyphenol intakes were estimated using food consumption data from the 143-item semi-quantitative food frequency questionnaire and the polyphenol content of each food contained in the Phenol-Explorer database. Estimated intakes were adjusted for total energy intake according to the residuals method. The association between polyphenol intake and CVR (estimated using risk equations) was evaluated using multivariate linear regression models. In addition, the association between polyphenol intake and uric acid was evaluated (using multivariate linear regression) and, using Cox regression models with a constant follow-up time (t=1), the prevalence ratio of hyperuricemia was estimated. On the other hand, polyphenol consumption patterns were established by factor analysis and cluster analysis, comparing both methods and relating adherence to each pattern with the estimated CVR. All analyses were performed for men and women separately, as well as in the total population. Results Total polyphenol (βQ5vs.Q1= 0.10, 95% CI: 0.04 to 0.17) and flavonoid (βQ5vs.Q1= 0.17, 95% CI: 0.10 to 0.24) intakes were directly and significantly associated with improved optimal cardiovascular health (Life's Simple 7). Inverse associations were found between other polyphenols class intake and, CVR estimated by Framingham (βQ5vs.Q1= -1.22%, 95% CI: -2.37 to -0.07) and SCORE (βQ5vs.Q1=-0.32, 95% CI: -2.37 to -0.07). In women, the associations between polyphenol intake and all risk equations tended to be protective. The intake of phenolic acids (βQ5vs.Q1= -0.17, 95% CI: -0.27 to -0.06), hydroxycinnamic acids (βQ5vs.Q1= -0.19, 95% CI: -0.3 to -0.09), alkylmethoxyphenols (βQ5vs.Q1= 0.2, 95% CI: -0.31 to -0. 1) and methoxyphenols (βQ5vs.Q1= -0.24, 95% CI -0.34 to -0.13) showed an inverse association with serum uric acid levels and, hyperuricemia (PRQ5vs.Q1=0.82, 95% CI:0.71-0.95; PRQ5vs.Q1=0.82, 95% CI:0.71-0.95; PRQ5vs.Q1=0.80, 95% CI:0.70-0.92 and PRQ5vs.Q1=0.79, 95% CI:0.69-0.91, respectively). The polyphenol patterns revealed differences between men and women, as well as, in their association with CVR. Regarding those derived from the factorial analysis: for the total sample and the men, pattern 3 (olives and olive oil poyphenols) was positively associated with CVR, they also had a higher prevalence of diabetes and higher sodium intake. Pattern 4, formed by coffee polyphenols in all groups, was also associated with higher CVR. As for the cluster analysis, cluster 2 in the total and in men, characterized by consumption of coffee polyphenols and olives and olive oil, also showed higher CVR. Conclusions The other polyphenols class showed inverse associations with estimated cardiovascular risk, finding similar results with the Framingham, Framingham-REGICOR and Life's Simple 7 equations (after eliminating the diet component), and different with the SCORE, but predictors included in this scale are scarce. Higher intakes of polyphenols present in coffee: hydroxycinnamic acids, alkylmethoxyphenols, and methoxyphenols, were inversely associated with serum uric acid levels and hyperuricemia. We found differences in polyphenol intake patterns between men and women, and in their associations with CVR. These sex differences may be explained by the fact that they lead different lifestyles, since a pattern does not refer only to dietary habits. Moreover, subjects who were at higher risk at baseline might be more motivated to improve their dietary habit (reverse causality). Our findings add new insights in the study of phenolic compounds, highlighting the importance of analyzing them by sex and studying the determinants of food choices and dietary patterns in relation to risk perception and specific lifestyles.
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

  • Payo Serafín, Tania
  • Méndez Blanco, Carolina
  • Fernández Palanca, Paula
  • Martínez Geijo, Jennifer
  • Reviejo, María
  • Ortiz de Urbina, Juan José
  • González Gallego, Javier
  • García Marín, José Juan
  • Mauriz Gutiérrez, José Luis
  • San Miguel de Vega, Beatriz
[EN]Although the treatment landscape has rapidly evolved over the last years, hepatocellular carcinoma (HCC) is one of the most lethal cancers. With recent advances, both immunotherapy and tyrosine kinase inhibitors (TKIs)-based chemotherapy constitute the standard treatment for advanced HCC. A systematic search of randomized clinical trials employing TKIs was performed in 17 databases, obtaining 25 studies evaluating the prognosis, tumor response, and presence of adverse events (AEs) related to TKIs in HCC. Overall effect sizes were estimated for the hazard ratios (HR) and odds ratios (OR) with 95% confidence interval (CI), either extracted or calculated with the Parmar method, employing STATA 16. Heterogeneity was assessed by Chi-square-based Q-test and inconsistency (I2) statistic; source of heterogeneity by meta-regression and subgroup analysis; and publication bias by funnel plot asymmetry and Egger's test. The research protocol was registered in PROSPERO (CRD42023397263). Meta-analysis revealed a correlation between survival and tumor response parameters and TKI treatment vs. placebo, despite detecting high heterogeneity. Combined TKI treatment showed a significantly better objective response rate (ORR) with no heterogeneity, whereas publication bias was only detected with time to progression (TTP). Few gastrointestinal and neurological disorders were associated with TKI treatment vs. placebo or with combined treatment. However, a higher number of serious AEs were related to TKI treatment vs. sorafenib alone. Results show positive clinical benefits from TKI treatment, supporting the approval and maintenance of TKI-based therapy for advanced HCC, while establishing appropriate strategies to maximize efficacy and minimize toxicity., SI, Publicación en abierto financiada por el Consorcio de Bibliotecas Universitarias de Castilla y León (BUCLE), con cargo al Programa Operativo 2014ES16RFOP009 FEDER 2014-2020 DE CASTILLA Y LEÓN, Actuación:20007-CL - Apoyo Consorcio BUCLE
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Metabolic syndrome criteria and severity and carbon dioxide (CO2) emissions in an adult population

  • García, Silvia
  • Pastor, Rosario
  • Monserrat Mesquida, Margalida
  • Álvarez Álvarez, Laura
  • Rubín García, María
  • Martínez González, Miguel Ángel
  • Salas Salvadó, Jordi
  • Corella, Dolores
  • Goday, Albert
  • Martínez, J. Alfredo
  • Alonso Gómez, Ángel M.
  • Wärnberg, Julia
  • Vioque, Jesús
  • Romaguera, Dora
  • Lopez Miranda, José
  • Estruch, Ramon
  • Tinahones, Francisco J.
  • Lapetra, José
  • Serra Majem, Lluís
  • Riquelme Gallego, Blanca
  • Pintó, Xavier
  • Gaforio, José J.
  • Matía, Pilar
  • Vidal, Josep
  • Vázquez, Clotilde
  • Daimiel, Lidia
  • Ros, Emilio
  • Sayón Orea, Carmen
  • Guillem Saiz, Patricia
  • Valle Hita, Cristina
  • Cabanes, Robert
  • Abete, Itziar
  • Goicolea Güemez, Leire
  • Gómez Gracia, Enrique
  • Tercero Maciá, Cristina
  • Colom, Antoni
  • García Ríos, Antonio
  • Castro Barquero, Sara
  • Fernández García, José C.
  • Santos Lozano, José Manuel
  • Cenoz, Juan Carlos
  • Barragán, Rocío
  • Khoury, Nadine
  • Castañer, Olga
  • Zulet, María Ángeles
  • Vaquero Luna, Jessica
  • Bes-Rastrollo, Maira
  • Heras Delgado, Sara de las
  • Ciurana, Ramón
  • Martín Sánchez, Vicente
  • Tur, Josep A.
  • Bouzas, Cristina
[EN] Background Metabolic syndrome (MetS) has become a growing risk factor of some non-communicable diseases. Increase of greenhouse gas emissions affects the planet. Aims To assess the association between MetS severity and amount of carbon dioxide ( CO2) emitted in an adult population. Design Cross-sectional study (n = 6646; 55-76-year-old-men; 60-75-year-old-women with MetS). Methods Dietary habits were assessed using a pre-validated semi quantitative 143-item food frequency questionnaire. The amount of CO2 emitted due to the production of food consumed by person and day was calculated using a European database, and the severity of the MetS was calculated with the MetS Severity Score. Results Higher glycaemia levels were found in people with higher CO2 emissions. The risk of having high severe MetS was related to high CO2 emissions. Conclusions Low CO2 emissions diet would help to reduce MetS severity. Advantages for both health and the environment were found following a more sustainable diet. Trial registration ISRCTN, ISRCT N8989 8870. Registered 05 September 2013., SI, We thank all PREDIMED-Plus participants and investigators. CIBEROBN, CIBERESP, and CIBERDEM are initiatives of the Instituto de Salud Carlos III (ISCIII), Madrid, Spain. The Hojiblanca (Lucena, Spain) and Patrimonio Comunal Olivarero (Madrid, Spain) food companies donated extra-virgin olive oil. The Almond Board of California (Modesto, CA), American Pistachio Growers (Fresno, CA), and Paramount Farms (Wonderful Company, LLC, Los Angeles, CA) donated nuts for the PREDIMED-Plus pilot study., Funding This work was supported by the official Spanish Institutions for funding scientific biomedical research, CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) and Instituto de Salud Carlos III (ISCIII), through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund (six coordinated FIS projects leaded by JS-S and JVi, including the following projects: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI14/00972, PI14/00728, PI14/01471, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926, PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/01560, PI19/01332, PI20/01802, PI20/00138, PI20/01532, PI20/00456, PI20/00339, PI20/00557, PI20/00886, PI20/01158); the Especial Action Project entitled: Implementación y evaluación de una intervención intensiva sobre la actividad física Cohorte PREDIMED-Plus grant to JS-S; the European Research Council (Advanced Research Grant 2014–2019; agreement #340918) granted to MÁM-G.; the Recercaixa (number 2013ACUP00194) grant to JS-S; grants from the Consejería de Salud de la Junta de Andalucía (PI0458/2013, PS0358/2016, PI0137/2018); the PROMETEO/2017/017 grant from the Generalitat Valenciana; the SEMERGEN grant. J.S-S is partially supported by ICREA under the ICREA Academia programme. C.B. was granted by Juan de la Cierva grant. None of the funding sources took part in the design, collection, analysis, interpretation of the data, or writing the report, or in the decision to submit the manuscript for publication., info:eu-repo/grantAgreement/MINECO/ Programa Estatal de I+D+I Orientada a los Retos de la Sociedad /PI16/01120/ES/ Efecto de una pérdida de peso con dieta mediterránea hipocalórica y promoción de la actividad física en la prevención primaria cardiovascular: Estudio PREDIMED-PLUS, info:eu-repo/grantAgreement/MINECO/ Programa Estatal de I+D+I Orientada a los Retos de la Sociedad /PI16/01522//ES/ Efecto de una pérdida de peso con dieta mediterránea hipocalórica y promoción de la actividad física en la prevención primaria cardiovascular: Estudio PREDIMED-PLUS
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

  • Fernández Tussy, Pablo
  • Rodríguez Agudo, Rubén
  • Fernández Ramos, David
  • Barbier Torres, Lucía
  • Zubiete Franco, Imanol
  • Davalillo, Sergio López de
  • Herráez, Elisa
  • Goikoetxea Usandizaga, Naroa
  • Lachiondo Ortega, Sofía
  • Simón, Jorge
  • Lopitz Otsoa, Fernando
  • Gutiérrez de Juan, Virginia
  • McCain, Misti V.
  • Perugorría, María J.
  • Mabe, Jon
  • Navasa Mayo, Nicolás
  • Rodrigues, Cecilia M. P.
  • Fabregat, Isabel
  • Boix, Loreto
  • Sapena, Víctor
  • Anguita, Juan
  • Lu, Shelly C.
  • Mato, José M.
  • Banales, Jesus M.
  • Villa, Erica
  • Reeves, Helen L.
  • Bruix, Jordi
  • Reig, María
  • Marín, José J. G.
  • Delgado, Teresa C.
  • Martínez Chantar, María L.
[EN]Dysregulation of miRNAs is a hallmark of cancer, modulating oncogenes, tumor suppressors, and drug responsiveness. The multi-kinase inhibitor sorafenib is one of the first-line drugs for advanced hepatocellular carcinoma (HCC), although the outcome for treated patients is heterogeneous. The identification of predictive biomarkers and targets of sorafenib efficacy are sorely needed. Thus, selected top upregulated miRNAs from the C19MC cluster were analyzed in different hepatoma cell lines compared to immortalized liver human cells, THLE-2 as control. MiR-518d-5p showed the most consistent upregulation among them. Thus, miR-518d-5p was measured in liver tumor/non-tumor samples of two distinct cohorts of HCC patients (n = 16 and n = 20, respectively). Circulating miR-518d-5p was measured in an independent cohort of HCC patients receiving sorafenib treatment (n = 100), where miR-518d-5p was analyzed in relation to treatment duration and patient’s overall survival. In vitro and in vivo studies were performed in human hepatoma BCLC3 and Huh7 cells to analyze the effect of miR-518d-5p inhibition/overexpression during the response to sorafenib. Compared with healthy individuals, miR-518d-5p levels were higher in hepatic and serum samples from HCC patients (n = 16) and in an additional cohort of tumor/non-tumor paired samples (n = 20). MiR-518d-5p, through the inhibition of c-Jun and its mitochondrial target PUMA, desensitized human hepatoma cells and mouse xenograft to sorafenib-induced apoptosis. Finally, serum miR-518d-5p was assessed in 100 patients with HCC of different etiologies and BCLC-stage treated with sorafenib. In BCLC-C patients, higher serum miR-518d-5p at diagnosis was associated with shorter sorafenib treatment duration and survival. Hence, hepatic miR-518d-5p modulates sorafenib resistance in HCC through inhibition of c-Jun/PUMA-induced apoptosis. Circulating miR-518d-5p emerges as a potential lack of response biomarker to sorafenib in BCLC-C HCC patients., SI, This work was supported by grants from NIH (US Department of Health and Human services) R01CA172086 (to S.C.L., J.M.M. and M.L.M.-C.) and P01CA233452 (to S.C.L.), Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C), MINECO: SAF2017-87301-R, SAF2014-52097-R, RTI2018-096759-A-100, SAF2016-75197-R and SAF2015-64149-R, integrated in the Plan Estatal de Investigación Cientifica y Técnica e Innovación 2017-2020 cofounded by FEDER funds/Development Fund—a way to build Europe (to M.L.M.-C., J.M.M., T.C.D., J.J.G.M., and I.F., respectively), Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain: PI16/00598 and PI19/00819 (to J.J.G.M.), PI15/01132 and PI18/01075 (to J.M.B.), PI14/00399 and PI17/00022 (to M.J.P.), PI18/0358 (to M.R.), BIOEF (Basque Foundation for Innovation and Health Research): EITB Maratoia BIO15/CA/014 and BIO15/CA/016/BD (to M.L.M.-C and J.M.B., respectively); Mitotherapeutix (to M.L.M.-C), Consejería de Educación, Junta de Castilla y León: SA063P17 (J.J.G.M.), Asociación Española Contra el Cáncer (T.C. D, P.F.-T., and M.L.M-C), Basque Government Postdoctoral Program (P.F.-T.), Daniel Alagille award from EASL (to T.C.D.), Asociación Española contra el Cáncer, Canceres raros (M.L.M.-C., J.M.B., and J.J.G.M.), La Caixa Foundation (to M.L.M.-C. and J.M.B.), Ayudas Fundación BBVA a equipos de Investigación Científica 2018 (to M.L.M.-C.), Fondo Europeo de Desarrollo Regional’ (FEDER) (to J.M.B.); CIBERehd, Spain (to J.M.B.); IKERBASQUE, Basque foundation for Science, Spain (to J.M.B.), Department of Health of the Basque Country (2017111010) (to J.M.B.), Euskadi RIS3 (2019222054, 2020333010) (to J.M.B.); Department of Industry of the Basque Country (J.M.B.: Elkartek: KK-2020/00008) (to J.M.B.), Ayudas para apoyar grupos de investigación del sistema Universitario Vasco IT971, Instituto de Salud Carlos III PI18/00768 (J.B.), AECC PI044031 (J.B.), Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement 2014 SGR 605 (J.B.), WCR (AICR) 16-0026 (J.B.), Programma di ricerca Regione-Università 2007–2009 and 2011–2012, Regione Emilia- Romagna (E.V.).
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Prospective association of changes in (poly)phenol intake, body weight and physical activity with inflammatory profile

  • Rubín García, María
  • Vitelli Storelli, Facundo Ezequiel
  • Álvarez Álvarez, Laura
  • Fitó, Montserrat
  • Vázquez Ruiz, Zenaida
  • Salas Salvadó, Jordi
  • Corella, Dolores
  • Serra-Majem, Lluis
  • Wärnberg, Julia
  • Romaguera, Dora
  • Estruch, Ramón
  • Pintó, Xavier
  • Martínez, José Alfredo
  • Vázquez, Clotilde
  • Vidal, Josep
  • Tur, Josep A.
  • Alonso Gómez, Ángel M.
  • Ros, Emilio
  • Vioque, Jesús
  • López Miranda, José
  • Bueno Cavanillas, Aurora
  • Tinahones, Francisco J.
  • Lapetra, José
  • Daimiel, Lidia
  • Delgado Rodríguez, Miguel
  • Matía Martín, Pilar
  • Babio, Nancy
  • Schröder, Helmut
  • Lamuela Raventós, Rosa M.
  • Martín Sánchez, Vicente
  • Zamora Ros, Raúl
[EN] Backgrounds and aim: To prospectively evaluate the associations between changes in (poly)phenol intake, body weight(BW), and physical activity(PA) with changes in an inflammatory score after 1-year. Methods and results: This is a prospective observational analysis involving 484 participants from the PREDIMED-Plus with available inflammatory measurements. (Poly)phenol intake was estimated using a validated semi-quantitative food frequency questionnaire and the Phenol-Explorer database. An inflammatory score was calculated based on 8 blood biomarkers (IL-6, IL-8, IL-18, MCP-1, C-peptide, hs-CRP, leptin, and RANTES). The association between BW, PA, (poly)phenol intake and inflammatory score was evaluated using structural equations. Mediation analyses were performed to assess the relationship between change in (poly)phenol intake and inflammatory score was mediated by the change in BW. A higher increase in total (poly)phenol intake was related to a decrease in the inflammatory score (β = −0.005mg/1000 Kcal; CI95 % = -0.100,0.000) along with a decrease in BW (β = −0.006mg/1000 Kcal; CI95 % = -0.010,-0.003). Increased PA was associated with a lower inflammatory score (β = −0.129MET-min/d; CI95 % = −0.238,-0.021) and BW (β = −0.248MET-min/d; CI95 % = -0.343,-0.152). Finally, a decrease in BW was associated with a decrease in the inflammatory score (β = 0.240 kg; CI95 % = 0.155,0.325). Mediation analyses revealed that changes in BW explained 22 % of the overall association between changes in (poly)phenol intake and inflammatory score. Conclusions: An inverse association between changes in (poly)phenol intake and inflammatory status was observed, with BW playing a significant mediating role, emphasising the impact of BW reduction on inflammation reduction, SI, This work was supported by the Spanish Ministry of Health (Carlos III Health Institute) through the Fondo de Investigaci´on para la Salud (FIS), which is cofounded by the European Regional Development Fund (2 coordinated FIS projects [led by J.S.-S. and J.V.] funded by the following grant codes: PI13/00673, PI13/00492, PI13/00272, PI13/ 01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/ 01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/ 00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI16/ 00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/ 00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/ 00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/ 01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/ 01732, PI17/00926, PI19/00957, PI19/00386, PI19/00309, PI19/ 01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/ 01560, PI19/01332, PI20/01802, PI20/00138, PI20/01532, PI20/ 00456, PI20/00339, PI20/00557, PI20/00886, PI20/01158); the Eu- ropean Research Council (Advanced Research Grant 2013–2018, grant number 340918); Recercaixa (2013ACUP00194); Consejería de Salud de la Junta de Andalucía (PI0458/2013); and a SEMERGEN grant. CIBERobn (Centros de Investigaci´on Biom´edica en Red: Obesidad y Nutrici´on), CIBEResp (Centros de Investigaci´on Biom´edica en Red: Epidemiologia y Salud Publica), and CIBERdem (Centros de Inves- tigaci´on Biom´edica en Red: Diabetes y Enfermedades Metab´olicas aso- ciadas) are initiatives of Carlos III Health Institute, Madrid, Spain. We thank CERCA Program/Generalitat de Catalunya for the institutional support to IDIBELL and IISPV, and PROMETEO 21/2021 from the Generalitat Valenciana. RZ-R was supported by the “Miguel Servet II” (CPII20/00009) program from the Instituto de Salud Carlos III (Co- funded by European Social Fund (ESF) investing in your future). J.S.-S. is partially supported by the ICREA Academia program. None of the funding sources took part in the design, collection, analysis or inter- pretation of the data, or in the decision to submit the manuscript for publication. The remaining authors have no disclosures to report
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Exposure to a mixture of arsenic species and growth indicators in 6–12-year-old children from the cycles 2007–2020 NHANES

  • García Villarino, Miguel
  • Fernández Iglesias, Rocío
  • García, Ana Victoria
  • Villa Fernández, Elsa
  • Fernández Arce, Lucía
  • Riaño Galán, Isolina
  • Lambert, Carmen
  • Martín Sánchez, Vicente
  • Karagas, Margaret R.
  • Delgado Álvarez, Elías
  • Fernández Somoano, Ana
  • Signes Pastor, Antonio José
[EN] Background: Exposure to arsenic (As) and its metabolites can affect normal growth in children, but the combine effects at simultaneous low-level exposures, remain uncertain. Hence, this study aims to analyze how the combined effects of As and its metabolites can impact growth indicators in 1,792 US children aged 6–12 years, from the NHANES. Methods: Levels of arsenic species in urine were measured using HPLC coupled with ICP-DRC-MS during the 2007–2020 NHANES cycles. The sum of iAs ([AsIII + AsV]), MMA, and DMA was used as a biomarker of internal iAs exposure (∑As), and methylation efficiency was assessed using the primary and secondary methylation indices (PMI, SMI). Linear regression and BKMR models were applied to identify adverse effects, nonlinear associations, interactions, and combined effects. Results: Median concentrations of MMA, DMA, iAs, and ∑As were 0.56 μg/L, 4.07 μg/L, 1.33 μg/L, and 6.40 μg/L, respectively. In the linear regression analyses, higher urinary concentrations of MMA were associated with reductions in several growth indicators. Specifically, each interquartile range (IQR) increase in MMA concentration was linked to decreases of −0.18 (95 % CI: −0.29, −0.06) in Body Mass Index (BMI) Z-score, −0.18 (95 % CI: −0.29, −0.06) in Weight Z-score, and −0.01 (95 % CI: −0.02, −0.01) in Waist circumference/Height ratio. Additionally, higher DMA concentrations were negatively associated with Height Z-score, with a reduction of −0.08 (95 % CI: −0.15, −0.01). In the BKMR analysis, DMA consistently emerged as the dominant contributor across multiple outcomes, showing the highest Posterior Inclusion Probabilities (PIPs) for indicators such as BMI Z-score and Waist circumference/Height ratio. While MMA exhibited notable PIPs in certain models, its influence was generally weaker than that of DMA. Conclusion: Childhood exposure to a mixture of arsenic species, even at low levels, appears to influence growth indicators and adversely affect physical development in children enrolled in NHANES, SI, This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/01162 and co-funded by the European Union and Universidad de Oviedo. This study was also funded by grants from CIDEGENT/2020/050 (Antonio J. Signes-Pastor); P01ES022832, RD83544201, and R25CA134286 (Margaret R. Karagas)
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Sarcopenic Obesity and Longitudinal Trajectories on Cognitive Performance and Subtle Cognitive Impairment Over 6 Years in Older Adults

  • Vázquez Lorente, Héctor
  • Paz Graniel, Indira
  • Margara Escudero, Hernando J.
  • Martínez González, Miguel Ángel
  • Romaguera, Dora
  • Martínez Urbistondo, Diego
  • Estruch, Ramón
  • Martín Sánchez, Vicente
  • Vidal, Josep
  • Fitó, Montserrat
  • Goñi, Nuria
  • Chaplin, Alice
  • Zulet, María Ángeles
  • Sacanella, Emilio
  • Paz Fernández, José Antonio de
  • Altés, Andreu
  • García Gavilán, Jesús Francisco
  • Konieczna, Jadwiga
  • Martínez, J. Alfredo
  • Salas Salvadó, Jordi
[EN] Background: Sarcopenic obesity has been suggested as a potential risk factor for cognitive decline; however, few prospective studies have been conducted to test this hypothesis. We aimed to assess the relationship between baseline sarcopenic obesity and 6-year trajectories of cognitive performance and subtle cognitive impairment in older adults. Methods: This longitudinal study comprised 1097 older adults aged 55–75 years (mean [SD] age, 65.3 [4.9] years; 506 females [46.1%] and 591 males [53.9%]) exhibiting baseline overweight/obesity and metabolic syndrome. Baseline lower-limb muscle strength was determined by the validated 30-s Chair Stand Test. Baseline total body weight, fat mass percentage and appendicular lean mass were obtained through dual-energy x-ray absorptiometry scans. Baseline sarcopenic obesity (n = 364 [33.2%]) was subsequently defined based on the new European Society for Clinical Nutrition and Metabolism and the European Association for the Study of Obesity consensus criteria. Cognitive performance was assessed at baseline, 2, 4 and 6 years of follow-up through five composite scores derived from a comprehensive battery of eight validated neuropsychological tests, encompassing global cognitive function, general cognitive function, executive function, attention and language. Subtle cognitive impairment was defined for those z-scores 0.5 standard deviations below the mean for each cognitive performance composite score at baseline. Linear and logistic two-level mixed models including lost to follow-up participants were fitted as main analyses. Complete case analyses were additionally performed. Results: After adjusting for multiple covariates, main analyses showed that, compared to older adults without sarcopenic obesity, those with sarcopenic obesity showed a higher decline in global cognitive function (between-group difference, −1.0 [95% CI, −2.2 to 0.2] after 6 years; overall p = 0.048) and general cognitive function (between-group difference, −2.5 [95% CI, −4.4 to 0.5] after 6 years; overall p = 0.028) and had a higher risk of subtle global cognitive function impairment (between-group difference, 2.3 [95% CI, 0.9 to 5.6] after 6 years; overall p = 0.038) over 6 years of follow-up. Associations remained consistent in the complete case analysis and attenuated when comparing those participants with baseline sarcopenic obesity with those only presenting sarcopenia, obesity or overweight. Of note, participants with baseline sarcopenia or obesity, compared to the absence of these conditions, showed no relationship with cognitive performance and subtle cognitive impairment over 6 years of follow-up. Conclusions: Sarcopenic obesity may be considered a potential independent risk factor for cognitive decline over the long term that warrants further evaluation in clinical settings, SI, This study was supported by the official Spanish Institutions for FundingScientific Biomedical Research, CIBER Fisiopatología de la Obesidad yNutrición (CIBEROBN) and Instituto de Salud Carlos III (ISCIII), throughthe Fondo de Investigación para la Salud (FIS), which is co-funded bythe European Regional Development Fund (six coordinated FIS proj-ects led by J.S.-S. and J.V., including the following projects: PI13/00673,PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184,PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618,PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI14/00972,PI14/00728, PI14/01471, PI16/00473, PI16/00662, PI16/01873, PI16/01094,PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120,PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827,PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926,PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017,PI19/01226, PI19/00781, PI19/01560, PI19/01332, PI20/01802, PI20/00138,PI20/01532, PI20/00456, PI20/00339, PI20/00557, PI20/00886, PI20/01158and PI23/00220); the Especial Action Project entitled: Implementación yevaluación de una intervención intensiva sobre la actividad física CohortePREDIMED-Plus grant to J.S.-S.; the European Research Council(Advanced Research Grant 2014–2019; agreement #340918) grantedto M.A.M.-G.; the Agencia Catalana de Recerca i Universitats, AGAUR(2021SGR00336 to J.S.-S; the Recercaixa (number 2013ACUP00194) grantto J.S.-S.; grants from the Consejería de Salud de la Junta de Andalucía(PI0458/2013, PS0358/2016 and PI0137/2018); the PROMETEO/21/2021and the AICO/2021/347 grants from the Generalitat Valenciana; theMINECO (CNS2022–135862) grant to D.R. and the Horizon 2020 PRIMEstudy (Prevention and Remediation of Insulin Multimorbidity in Europe;grant agreement #847879). J.K. received funding from ISCIII, throughthe Miguel Servet Project (CP24/00089), co-funded by the EuropeanUnion. H.V.-L. was funded by a research grant from the Agència de Gestiód‘Ajuts Universitaris de Recerca via Unión Europea, Next Generation EU(AGAUR, record number: 2023POST-INV- 01).H.J.M.-E holds a ContratoPre-doctoral de Formacion en Investigacion en Salud (PFIS FI24/00038)funded by the ISCIII. None of the funding sources took part in the design,collection, analysis, interpretation of the data or writing of the report orin the decision to submit the manuscript for publication. J.S.-S., senior au-thor, gratefully acknowledges the financial support by ICREA under theICREA Academia program.Ethics StatementThe study protocol was approved by the Research Ethics Committees ofall recruiting centres. In addition, all participants signed an informedconsent form upon entry into the study.Conflicts of InterestThe authors declare no conflicts of interest.Data Availability StatementData described in the manuscript, codebook and analytic code will bemade available upon request pending application and approval of thePREDIMED-Plus Steering Committee. There are restrictions on theavailability of data for the PREDIMED-Plus trial, due to the signed con-sent agreements around data sharing, which only allow access to exter-nal researchers for studies following the project purposes. Requestorswishing to access the PREDIMED-Plus trial data used in this study canmake a request to the PREDIMED-Plus trial Steering Committee chair:jordi.salas@urv.cat. The request will then be passed to members of thePREDIMED-Plus Steering Committee for deliberation
Docta Complutense
Publicación Artículo científico (JournalArticle)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study

  • Ayala Díaz, Rosa María
  • Martínez López, Joaquín
This phase Ib, non-randomized, open-label study evaluates the safety and tolerability of ruxolitinib in combination with nilotinib and prednisone in patients with naïve or ruxolitinib-resistant myelofibrosis (MF). A total of 15 patients with primary or secondary MF received the study treatment; 13 patients had received prior ruxolitinib treatment (86.7%). Eight patients completed seven cycles (53.3%) and six patients completed twelve cycles of treatment (40%). All the patients experienced at least one adverse event (AE) during the study (the most common AEs were hyperglycemia, asthenia, and thrombocytopenia), and 14 patients registered at least one treatment-related AE (the most common treatment-related AEs were hyperglycemia (22.2%; three grade 3 cases). Five treatment-related serious AEs (SAEs) were reported in two patients (13.3%). No deaths were registered throughout the study. No dose-limiting toxicity was observed. Four out of fifteen (27%) patients experienced a 100% spleen size reduction at Cycle 7, and two additional patients achieved a >50% spleen size reduction, representing an overall response rate of 40% at Cycle 7. In conclusion, the tolerability of this combination was acceptable, and hyperglycemia was the most frequent treatment-related AE. Ruxolitinib in combination with nilotinib and prednisone showed relevant clinical activity in patients with MF. This trial was registered with EudraCT Number 2016-005214-21.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Antipsychotic medication influences the discriminative value of acylethanolamides as biomarkers of substance use disorder

  • Herrera-Imbroda, Jesús
  • Flores-López, María
  • Requena-Ocaña, Nerea
  • Araos, Pedro
  • Ropero, Jessica
  • García Marchena, Nuria
  • Bordallo, Antonio
  • Suarez, Juan
  • Pavón-Morón, Francisco Javier
  • Serrano, Antonia
  • Mayoral, Fermín
  • Rodríguez De Fonseca, Fernando Antonio
Plasma acylethanolamides (NAEs), including the endocannabinoid anandamide (AEA), have been proposed as circulating biomarkers of substance use disorders. However, the concentration of these lipid transmitters might be influenced by the use of drugs prescribed for either the treatment of addiction or the associated psychiatric co-morbidities such as psychosis. As an example, neuroleptics, used for attenuation of psychotic symptoms and sedation, might theoretically interfere with the monoamine-mediated production of NAEs, obstructing the interpretation of plasma NAEsasclinical biomarkers. To solve the lack of information on the impact of neuroleptics on the concentration of NAEs, we evaluated the concentrations of NAEs in a control group and compared them to those present in (a) substance use disorders (SUD) patients that are not prescribed with neuroleptics, and (b) SUD patients (both alcohol use disorder and cocaine use disorder patients) using neuroleptics. The results demonstrate that SUD patients exhibited greater concentrations of NAEsthan the control population, affecting all species with the exception of stearoylethanolamide (SEA) and palmitoleoylethanolamide (POEA). Neuroleptic treatment enhanced the concentrations of NAEs, especially those of AEA, linoleoylethanolamide (LEA), and oleoylethanolamide (OEA). This effect of neuroleptic treatment was observed independently of the drug addiction that motivated the demand for treatment (either alcohol or cocaine). This study remarks the need to control the current use of psychotropic medication as a potential confounding variable when considering the use of NAEsasbiomarkers in SUD.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Candida genotyping of blood culture isolates from patients admitted to 16 hospitals in Madrid: genotype spreading during the COVID-19 pandemic driven by fluconazole-resistant C. parapsilosis

  • Díaz García, Judith
  • Gómez, Ana
  • Machado, Marina
  • Alcalá, Luis
  • Reigadas Ramírez, Elena Manuela
  • Sánchez Carrillo, Carlos
  • Pérez Ayala, Ana
  • Gómez García De La Pedrosa, María Elia
  • González Romo, Fernando
  • Cuétara, María Soledad
  • García Esteban, Coral
  • Quiles Melero, Inmaculada
  • Zurita, Nelly Daniela
  • Muñoz Algarra, María
  • Durán Valle, María Teresa
  • Sánchez García, Aída
  • Muñoz García, Patricia Carmen
  • Escribano Subías, María Pilar
  • Guinea, Jesús
Background: Candidaemia and invasive candidiasis are typically hospital-acquired. Genotyping isolates from patients admitted to different hospitals may be helpful in tracking clones spreading across hospitals, especially those showing antifungal resistance. Methods: We characterized Candida clusters by studying Candida isolates (C. albicans, n = 1041; C. parapsilosis, n = 354, and C. tropicalis, n = 125) from blood cultures (53.8%) and intra-abdominal samples (46.2%) collected as part of the CANDIMAD (Candida in Madrid) study in Madrid (2019–2021). Species-specific microsatellite markers were used to define the genotypes of Candida spp. found in a single patient (singleton) or several patients (cluster) from a single hospital (intra-hospital cluster) or different hospitals (widespread cluster). Results: We found 83 clusters, of which 20 were intra-hospital, 49 were widespread, and 14 were intra-hospital and widespread. Some intra-hospital clusters were first detected before the onset of the COVID-19 pandemic, but the number of clusters increased during the pandemic, especially for C. parapsilosis. The proportion of widespread clusters was significantly higher for genotypes found in both compartments than those exclusively found in either the blood cultures or intra-abdominal samples. Most C. albicans- and C. tropicalis-resistant genotypes were singleton and presented exclusively in either blood cultures or intra-abdominal samples. Fluconazole-resistant C. parapsilosis isolates belonged to intra-hospital clusters harboring either the Y132F or G458S ERG11p substitutions; the dominant genotype was also widespread. Conclusions: the number of clusters—and patients involved—increased during the COVID-19 pandemic mainly due to the emergence of fluconazole-resistant C. parapsilosis genotypes.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables

  • Wicke, Pablo Delgado
  • Fernández de Córdoba Oñate, Sara
  • Roy Vallejo, Emilia
  • Alegría Carrasco, Estibaliz
  • Rodríguez Serrano, Diego A.
  • Lamana Domínguez, Amalia
  • Montes, Nuria
  • Nicolao Gómez, Ana
  • Carracedo Rodríguez, Rosa
  • Marcos Jiménez, Ana
  • Díaz Fernández, Paula
  • Galván Román, José M.
  • Rabes Rodríguez, Laura
  • Sanz Alba, Marta
  • Álvarez Rodríguez, Jesús
  • Villa Martí, Almudena
  • Rodríguez Franco, Carlos
  • Villapalos García, Gonzalo
  • Zubiaur, Pablo
  • Abad Santos, Francisco
  • De los Santos, Ignacio
  • Pérez Gomáriz, Rosa María
  • García Vicuña, Rosario
  • Muñoz Calleja, Cecilia
  • González Álvaro, Isidoro
  • Fernández Ruiz, Elena
  • Suárez Fernández, Carmen
  • Barrios, Ana
  • Sanz, Jesús
  • Casado, Pedro
  • Gutiérrez, Ángela
  • Bautista, Azucena
  • Hernández, Pilar
  • Ruiz Giménez, Nuria
  • Moyano, Berta
  • Gil, Paloma
  • Delgado, María Jesús
  • Parra, Pedro
  • Sánchez, Beatriz
  • Sáez, Carmen
  • Fernández Rico, Marta
  • Arévalo Román, Cristina
  • Ciudad, Marianela
  • Castañeda, Santos
  • Llorente, Irene
  • Tomero, Eva G.
  • García Castañeda, Noelia
  • Uriarte, Miren
  • Cardeñoso, Laura
  • Fontán García-Rodrigo, Leticia
  • Domingo García, Diego
  • Alarcón Cavero, Teresa
  • Semiglia Chong, María Auxiliadora
  • Gutiérrez Cobos, Ainhoa
  • Zurita Cruz, Nelly D.
  • Sánchez Madrid, Francisco
  • Martín Gayo, Enrique
  • Sánchez Cerrillo, Ildefonso
  • Martínez Fleta, Pedro
  • López Sanz, Celia
  • Gabrie, Ligia
  • Del Campo Guerola, Luciana
  • Tejedor, Reyes
  • Ancochea, Julio
  • García Castillo, Elena
  • Ávalos, Elena
  • Sánchez Azofra, Ana
  • Alonso, Tamara
  • Cisneros, Carolina
  • Valenzuela, Claudia
  • García Pérez, Francisco J.
  • Girón, Rosa M.
  • Aspa, Javier
  • Marcos, Celeste
  • Socorro Churruca, M. del Perpetuo
  • Zamora, Enrique
  • Martínez, Adrián
  • Barrio Mayo, Mar
  • Henares Espi, Rosalina
  • Méndez, Rosa
  • Arribas, David
  • Chicot Llano, Marta
  • González, Begoña
  • Quicios, Begoña
  • Patiño, Pablo
  • Trigueros, Marina
  • Dominguez Peña, Cristina
  • Jiménez Jiménez, David
  • Villamayor, Pablo
  • Canabal, Alfonso
  • De la Cámara, Rafael
  • Ortiz, Javier
  • Iturrate, Isabel
The characteristics of the host are crucial in the final outcome of COVID-19. Herein, the influence of genetic and clinical variants in COVID-19 severity was investigated in a total of 1350 patients. Twenty-one single nucleotide polymorphisms of genes involved in SARS-CoV-2 sensing as Toll-like-Receptor 7, antiviral immunity as the type I interferon signalling pathway (TYK2, STAT1, STAT4, OAS1, SOCS) and the vasoactive intestinal peptide and its receptors (VIP/VIPR1,2) were studied. To analyse the association between polymorphisms and severity, a model adjusted by age, sex and different comorbidities was generated by ordinal logistic regression. The genotypes rs8108236-AA (OR 0.12 [95% CI 0.02–0.53]; p = 0.007) and rs280519-AG (OR 0.74 [95% CI 0.56–0.99]; p = 0.03) in TYK2, and rs688136-CC (OR 0.7 [95% CI 0.5–0.99]; p = 0.046) in VIP, were associated with lower severity; in contrast, rs3853839-GG in TLR7 (OR 1.44 [95% CI 1.07–1.94]; p = 0.016), rs280500-AG (OR 1.33 [95% CI 0.97–1.82]; p = 0.078) in TYK2 and rs1131454-AA in OAS1 (OR 1.29 [95% CI 0.95–1.75]; p = 0.110) were associated with higher severity. Therefore, these variants could influence the risk of severe COVID-19.
Docta Complutense
Publicación Artículo científico (JournalArticle)

BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury

  • Saiz, M. L.
  • Lozano-Chamizo, L.
  • Florez, A. B.
  • Marciello, Marzia
  • Diaz-Bulnes, P.
  • Corte-Iglesias, V.
  • Bernet, C. R.
  • Rodrigues-Diez, R. R.
  • Martin-Martin, C.
  • Rodriguez-Santamaria, M.
  • Fernandez-Vega, I.
  • Rodriguez, R. M.
  • Diaz-Corte, C.
  • Suarez-Alvarez, B.
  • Filice, Marco
  • Lopez-Larrea, C.
Targeting epigenetic mechanisms has emerged as a potential therapeutic approach for the treatment of kidney diseases. Specifically, inhibiting the bromodomain and extra-terminal (BET) domain proteins using the small molecule inhibitor JQ1 has shown promise in preclinical models of acute kidney injury (AKI) and chronic kidney disease (CKD). However, its clinical translation faces challenges due to issues with poor pharmacokinetics and side effects. Here, we developed engineered liposomes loaded with JQ1 with the aim of enhancing kidney drug delivery and reducing the required minimum effective dose by leveraging cargo protection. These liposomes efficiently encapsulated JQ1 in both the membrane and core, demonstrating superior therapeutic efficacy compared to freely delivered JQ1 in a mouse model of kidney ischemia-reperfusion injury. JQ1-loaded liposomes (JQ1-NPs) effectively targeted the kidneys and only one administration, one-hour after injury, was enough to decrease the immune cell (neutrophils and monocytes) infiltration to the kidney—an early and pivotal step to prevent damage progression. By inhibiting BRD4, JQ1-NPs suppress the transcription of pro-inflammatory genes, such as cytokines (il-6) and chemokines (ccl2, ccl5). This success not only improved early the kidney function, as evidenced by decreased serum levels of BUN and creatinine in JQ1-NPs-treated mice, along with reduced tissue expression of the damage marker, NGAL, but also halted the production of extracellular matrix proteins (Fsp-1, Fn-1, α-SMA and Col1a1) and the fibrosis development. In summary, this work presents a promising nanotherapeutic strategy for AKI treatment and its progression and provides new insights into renal drug delivery.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Relationship between the feeling of emptiness and suicide reattempt: Conclusions from cross-sectional and longitudinal analyses

  • Pemau Gurumeta, Andrés
  • Marín Martín, Carolina
  • De La-Torre Luque, Alejandro Francisco
  • Ayad Ahmed, Wala
  • López Villatoro, José Manuel
  • Fernández Rodrigues, Verónica
  • Mola Cárdenes, Pablo
  • Carrasco Perera, José Luis
  • Díaz Marsa, Marina Francisca
Introduction: The feeling of emptiness is a complex subjective experience considered relevant in the suicidal process, acting as a risk factor for suicide ideation, attempts and even reattempts. However, empirical studies are still scarce. Objectives: This study has three objectives: to compare emptiness levels in healthy people and those with suicide attempts; to compare the emptiness level between people with a single suicide attempt and multiple suicide attempts at baseline; and to study emptiness as a risk factor for the appearance of new suicidal attempts after an index one. Methodology: In the study, 382 healthy controls and 58 participants with a recent suicide attempt (in the past 15 days) participated. All completed the feeling of emptiness scale (FES). Information was also collected on sociodemographic characteristics and history of suicide attempts. First, the control sample scores were compared with those of the clinical sample. Later, the single attempt and reattempt groups (any amount greater than one attempt at baseline) were compared. Finally, the clinical sample was followed for 1 year and 3 months (through clinical records). Survival analysis was performed. Results: The clinical group obtained higher scores across the FES subscales, even when controlling for other relevant variables (p < 0.01). When comparing people with one versus several attempts, differences were also observed in all subscales except one, the reattempt group getting higher scores (p < 0.05). Regarding the survival analysis, the feeling of emptiness was significantly associated with the risk of reattempt (HR = 1.04; p < 0.05). All people who reattempted during follow-up belonged to the reattempt group at baseline. Conclusions: People who have attempted suicide present higher emptiness scores. Furthermore, emptiness appears to significantly predict the occurrence of new attempts at follow-up. The feeling of emptiness may be associated with the lack of vital meaning and disconnection from others, fundamental aspects of the ideation-to-action suicide models. Including emptiness in suicide assessments could increase clinicians' predictive ability.
Docta Complutense
Publicación Artículo científico (JournalArticle)

The mediating role of reflective functioning in the association between childhood trauma and suicide attempt

  • Andreo Jover, J.
  • De La-Torre Luque, Alejandro Francisco
  • Díaz Marsa, Marina Francisca
  • Fernández Rodrigues, Verónica
  • Pemau Gurumeta, Andrés
  • Diaz Carracedo, Patricia Cristina
  • Saiz González, María Dolores
  • Ayad Ahmed, Wala
  • Carrasco Perera, José Luis
Background: Childhood trauma is intimately related with suicidal behaviour. Patients who have suffered childhood trauma develop impaired Reflective Functioning (RF), which refers to the capacity to understand ourselves and others in terms of intentional mental states. An improvement in RF has been associated with a reduction in suicidal attempts, but the mediating role of RF between childhood trauma and suicidal behaviour has not been addressed so far. Objective: We aim to examine the potential mediating effect of RF among childhood trauma and suicide attempts. Method: We included 748 patients who had attempted suicide at least once. They were asked to complete the Reflective Functioning Questionnaire (RFQ-8), the Columbia-Suicide Severity Rating scale (CSSRS), and the Childhood Trauma Questionnaire-Short Form (CTQ-SF). We conducted linear regressions by simple mediating model to examine the role of RF in the indirect association between childhood trauma and the number of suicide attempts. Results: Our results show significant indirect effects through hypo and hypermentalizing between Emotional Abuse (EA) and Sexual Abuse (SA) in childhood and the number of suicide attempts in lifetime. These results indicate that ineffective RF significantly mediates the association between childhood trauma and suicidality. Conclusion: This is the first study supporting the mediational role of RF in the relationship between EA and SA, and the number of suicide attempt in lifetime. These findings have important implications for reducing suicide rates and preventing future re-attempts. Further studies analysing this mediating role and focusing efforts on increasing RF-based interventions are required.
Docta Complutense
Publicación Contribución de congreso (ConferenceOutput)

Abordaje de las úlceras venosas de pacientes incluidos en un ensayo clínico

  • Herraiz Ahijado, Borja Jesús
  • Folguera Álvarez, María Del Carmen
  • Mori Vara, Pilar
  • Rodriguez Vegue, Mónica
  • Lopez Sanchez, Rocio
  • Muñoz Caballero, Eva Rocio
  • Navarro Mallén, Beatriz
  • Hita Urias, María José
  • Peláez Raposo, Belen
Describe el abordaje de las úlceras venosas de pacientes incluidos en ensayo clínico aleatorio, cuyo objetivo es evaluar la efectividad de una intervención educativa estructurada en ejercicio físico como tratamiento coadyuvante del tratamiento habitual, en la cicatrización de las úlceras venosas en atención primaria. Comunicación oral.
Docta Complutense
Publicación Artículo científico (JournalArticle)

C-glycosides analogues of the okadaic acid central fragment exert neuroprotection via restoration of PP2A-phosphatase activity: A rational design of potential drugs for Alzheimer’s disease targeting tauopathies

  • Arribas, Raquel L.
  • Viejo, Lucía
  • Bravo, Isaac
  • Martínez, Minerva
  • Ramos Alonso, Eva
  • Romero Martínez, Manuel Alejandro
  • García-Frutos, Eva María
  • Janssens, Veerle
  • Montiel, Carmen
  • De Los Ríos, Cristobal
Protein phosphatase 2A (PP2A) is an important Ser/Thr phosphatase that participates in the regulation of multiple cellular processes. This implies that any deficient activity of PP2A is the responsible of severe pathologies. For instance, one of the main histopathological features of Alzheimer’s disease is neurofibrillary tangles, which are mainly comprised by hyperphosphorylated forms of tau protein. This altered rate of tau phosphorylation has been correlated with PP2A depression AD patients. With the goal of preventing PP2A inactivation in neurodegeneration scenarios, we have aimed to design, synthesize and evaluate new ligands of PP2A capable of preventing its inhibition. To achieve this goal, the new PP2A ligands present structural similarities with the central fragment C19–C27 of the well-established PP2A inhibitor okadaic acid (OA). Indeed, this central moiety of OA does not exert inhibitory actions. Hence, these compounds lack PP2A-inhibiting structural motifs but, in contrast, compete with PP2A inhibitors, thus recovering phosphatase activity. Proving this hypothesis, most compounds showed a good neuroprotective profile in neurodegeneration models related to PP2A impairment, highlighting derivative 10, named ITH12711, as the most promising one. This compound (1) restored in vitro and cellular PP2A catalytic activity, measured on a phospho-peptide substrate and by western-blot analyses, (2) proved good brain penetration measured by PAMPA, and (3) prevented LPS-induced memory impairment of mice in the object recognition test. Thus, the promising outcomes of the compound 10 validate our rational approach to design new PP2A-activating drugs based on OA central fragment.
Docta Complutense
Publicación Artículo científico (JournalArticle)

An immuno-fragile profile is associated with mortality risk in patients with chronic kidney disease

  • Ceprián, Noemí
  • Martínez De Toda Cabeza, Irene
  • Jara Caro, Paula
  • Yuste, Claudia
  • Valera Arévalo, Gemma
  • González de Pablos, Ignacio
  • Figuer, Andrea
  • Alique, Matilde
  • Ramírez, Rafael
  • Morales Ruiz, Enrique
  • Carracedo, Julia
Background/Objectives: Patients with chronic kidney disease (CKD) face higher risks of infections, poor vaccine responses, and cardiovascular diseases, leading to increased morbidity and mortality due to immune dysfunction and frailty. This study aims to evaluate immune status and frailty in CKD patients across different treatments, examine the influence of frailty on immune status, and link these factors to mortality. Methods: A total of 174 participants were included (end-stage renal disease, ESRD n = 40; hemodialysis, HD n = 40; peritoneal dialysis, n = 36; kidney transplant patients, n = 40; healthy subjects n = 18). Immunophenotyping of lymphocyte and monocyte subpopulations was performed, and frailty was assessed using the Edmonton Frail Scale. Principal component analysis (PCA) integrated immune and frailty variables to define an “immuno-fragile profile,” and survival was monitored for up to six years. Results: CKD patients, especially those on HD, showed decreased lymphocyte counts and proinflammatory monocyte subpopulations with increased expression of costimulatory molecules B7.2/CD86 and ICAM-1/CD54). Frailty was most prevalent in HD patients (53%), with notable sex differences. PCA identified three components—lymphocyte counts, monocyte co-stimulatory expression, and frailty—that together explained 70% of the variance. Survival analysis revealed that patients with lower lymphocyte counts and higher frailty scores had increased mortality risk, especially in the HD and ESRD groups. Cox regression confirmed that the immuno-fragile profile independently predictedmortality. Conclusions: The integration of immune alterations and frailty defines an immuno-fragile profile strongly associated with mortality in CKD patients, which may serve as a robust prognostic tool to improve risk stratification and guide personalized interventions in clinical practice.
Docta Complutense
Publicación Artículo científico (JournalArticle)

New mechanisms involved in the development of cardiovascular disease in chronic kidney disease

  • Figuer, Andrea
  • Alique, Matilde
  • Valera Arévalo, Gemma
  • Serroukh, Nadia
  • Ceprían, Noemí
  • De Sequera Ortiz, Patricia
  • Morales Ruiz, Enrique
  • Carracedo Añón, Julia María
  • Ramírez, Rafael
  • Bodega, Guillermo
Chronic kidney disease (CKD) is a pathology with a high worldwide incidence and an upward trend affecting the elderly. When CKD is very advanced, the use of renal replacement therapies is required to prolong its life (dialysis or kidney transplantation). Although dialysis improves many complications of CKD, the disease does not reverse completely. These patients present an increase in oxidative stress, chronic inflammation and the release of extracellular vesicles (EVs), which cause endothelial damage and the development of different cardiovascular diseases (CVD). CKD patients develop premature diseases associated with advanced age, such as CVD. EVs play an essential role in developing CVD in patients with CKD since their number increases in plasma and their content is modified. The EVs of patients with CKD cause endothelial dysfunction, senescence and vascular calcification. In addition, miRNAs free or transported in EVs together with other components carried in these EVs promote endothelial dysfunction, thrombotic and vascular calcification in CKD, among other effects. This review describes the classic factors and focuses on the role of new mechanisms involved in the development of CVD associated with CKD, emphasizing the role of EVs in the development of cardiovascular pathologies in the context of CKD. Moreover, the review summarized the EVs’ role as diagnostic and therapeutic tools, acting on EV release or content to avoid the development of CVD in CKD patients
Docta Complutense
Publicación Artículo científico (JournalArticle)

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer

  • Tapia Galisteo, Antonio
  • Aguilar Sopeña, Óscar
  • Narbona Corral, Javier
  • Lacadena García-Gallo, Francisco Javier
  • Roda Navarro, Pedro
  • Sanz, Laura
Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment of acute lymphoblastic leukemia (blinatumomab) and several other in clinical trials. However, improvement of their efficacy and selectivity for solid tumors is still required. Here, we describe a novel tandem T-cell recruiting trispecific antibody for the treatment of colorectal cancer (CRC). This construct, termed trispecific T-cell engager (TriTE), consists of a CD3-specific single-chain Fv (scFv) flanked by anti-epidermal growth factor receptor (EGFR) and anti-epithelial cell adhesion molecule (EpCAM) single-domain V antibodies. The TriTE was well expressed in mammalian and yeast cells, bound the cognate antigens of the three parental antibodies, and enabled the specific cytolysis of EGFR- and/or EpCAM-expressing cancer cells, without inducing T cell activation and cytoxicity against double-negative (EGFREpCAM) cancer cells. Bivalent bispecific targeting of double-positive HCT116 cells by TriTE improved potency up to 100-fold compared to single-positive cells and significantly prolonged survival . In addition, it was less efficient at killing single-positive target cells than the corresponding bispecific controls, leading to potentially enhanced tumor specificity. Moreover, dual targeting of two tumor-associated antigens may contribute toward preventing the tumor escape by antigen loss caused by selective pressures from conventional single-targeting T-cell engagers, and may help to overcome antigenic heterogeneity.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Risk factors for suicide reattempt: a systematic review and meta-analysis

  • Pemau Gurumeta, Andrés
  • Marín Martín, Carolina
  • Díaz Marsa, Marina Francisca
  • De La-Torre Luque, Alejandro Francisco
  • Ayad Ahmed, Wala
  • González Pinto, Ana
  • Garrido Torres, Nathalia
  • Garrido Sanchez, Lucia
  • Roberto, Natalia
  • Lopez Peña, Purificacion
  • Mar Barrutia, Lorea
  • Grande, Iria
  • Guinovart, Marti
  • Hernandez Calle, Daniel
  • Jimenez Treviño, Luis
  • Lopez Sola, Clara
  • Mediavilla, Roberto
  • Perez Aranda, Adrian
  • Ruiz Veguilla, Miguel
  • Seijo Zazo, Elisa
  • Toll, Alba
  • Elices, Matilde
  • Perez Sola, Victor
  • Ayuso Mateos, Jose Luis
  • SURVIVE Consortium
Background Suicide is one of the main external causes of death worldwide. People who have already attempted suicide are at high risk of new suicidal behavior. However, there is a lack of information on the risk factors that facilitate the appearance of reattempts. The aim of this study was to calculate the risk of suicide reattempt in the presence of suicidal history and psychosocial risk factors and to estimate the effect of each individual risk factor. Methods This systematic review and meta-analysis were conducted following the PRISMA-2020 guidelines. Studies on suicide reattempt that measured risk factors were searched from inception to 2022. The risk factors studied were those directly related to suicide history: history of suicide prior to the index attempt, and those that mediate the transition from suicidal ideation to attempt (alcohol or drug misuse, impulsivity, trauma, and non-suicidal self-injury). Results The initial search resulted in 11 905 articles. Of these, 34 articles were selected for this meta-analysis, jointly presenting 52 different effect sizes. The pooled effect size across the risk factors was significant (OR 2.16). Reattempt risk may be increased in presence of any of the following risk factors: previous history, active suicidal ideation, trauma, alcohol misuse, and drug misuse. However, impulsivity, and non-suicidal self-injury did not show a significant effect on reattempt. Conclusion Most of the risk factors traditionally associated with suicide are also relevant when talking about suicide reattempts. Knowing the traits that define reattempters can help develop better preventive and intervention plans.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Validation of the cross-cultural dementia screening test in Alzheimer’s disease and Parkinson’s disease

  • Delgado Álvarez, Alfonso
  • Delgado Alonso, Cristina
  • Goudsmit, Miriam
  • García-Ramos García, María Del Rocío
  • Gil Moreno, María José
  • Valles Salgado, María
  • Díez Cirarda, María
  • Zamarrón Cassinello, María Dolores
  • Matías-Guiu Guía, Jorge
  • Matias-Guiu Antem, Jordi
Objective: The Cross-Cultural Dementia (CCD) is a new screening tool to evaluate cognitive impairment based on a cross-cultural perspective to reduce the bias of education, and language and cultural differences. We aimed to evaluate the diagnostic properties of the CCD in Spaniards for the assessment of patients with Alzheimer’s disease in mild cognitive impairment (AD-MCI) and mild dementia stages (AD-D) and patients with mild cognitive impairment associated with Parkinson’s disease (PD-MCI). Methods: Sixty participants with AD (50% MCI) and thirty with PD-MCI were enrolled. Each clinical group was compared against a healthy control group (HC) with the same number of participants and no significant differences in age, education, and sex. A comprehensive neuropsychological test battery and CCD were completed. Intergroup comparisons, ROC curves, and cut-off scores were calculated for the study of diagnostic properties. Results: Intergroup differences were found in accordance with the cognitive profile of each clinical condition. Memory measures (Objects test) were especially relevant for the classification between AD and HC. Memory and executive function scores (Sun-Moon and Dots tests) were useful in the case of PD-MCI and HC. Furthermore, CCD described differences in executive functions and speed scores comparing AD-MCI and PD-MCI. Correlations between standardized neuropsychological tests and CCD measures supported the convergent validity of the test. Conclusion: CCD showed good discrimination properties and cut-off scores for dementia and extended its application to a sample of prodromal stages of AD and PD with mild cognitive impairment.
Docta Complutense
Publicación Artículo científico (JournalArticle)

The role of the dopamine system in post-stroke mood disorders in newborn rats.

  • Villa, M
  • Martinez Vega, M
  • del Pozo, A
  • Muneta Arrate, I
  • Gómez Soria, A
  • Muguruza, C
  • de Hoz Rivera, M
  • Romero, A
  • Silva, L
  • Callado, L F
  • Casarejos, M J
  • Martínez Orgado, José Antonio
Post-stroke mood disorders (PSMD) affect disease prognosis in adults. Adult rodent models underlie the importance of the dopamine (DA) system in PSMD pathophysiology. There are no studies on PSMD after neonatal stroke. We induced neonatal stroke in 7-day-old (P7) rats by temporal left middle cerebral artery occlusion (MCAO). Performance in the tail suspension test (TST) at P14 and the forced swimming test (FST) and open field test (OFT) at P37 were studied to assess PSMD. DA neuron density in the ventral tegmental area, brain DA concentration and DA transporter (DAT) expression as well as D2 receptor (D2R) expression and G-protein functional coupling were also studied. MCAO animals revealed depressive-like symptoms at P14 associated with decreased DA concentration and reduced DA neuron population and DAT expression. At P37, MCAO rats showed hyperactive behavior associated with increased DA concentration, normalization of DA neuron density and decreased DAT expression. MCAO did not modify D2R expression but reduced D2R functionality at P37. MCAO-induced depressive-like symptoms were reversed by the DA reuptake inhibitor GBR-12909. In conclusion, MCAO in newborn rats induced depressive-like symptoms and hyperactive behavior in the medium and long term, respectively, that were associated with alterations in the DA system.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Brain metabolism response to intrahospital transfers in neurocritical ill patients and the impact of microdialysis probe location

  • Pedrosa, Leire|||0000-0002-1852-4975
  • Hoyos, Jhon
  • Reyes, Luís
  • Mosteiro, Alejandra|||0000-0001-7170-0635
  • Zattera, Luigi
  • Topczewski, Tthomaz
  • Rodríguez-Hernández, Ana|||0000-0002-2992-2557
  • Amaro, Sergio|||0009-0008-9728-3823
  • Torné, Ramon|||0000-0001-7932-2528
  • Enseñat, Joaquim|||0000-0002-5812-0991
Intrahospital transfer (IHT), a routine in the management of neurocritical patients requiring imaging or interventions, might affect brain metabolism. Studies about IHT effects using microdialysis (MD) have produced conflicting results. In these studies, only the most damaged hemisphere was monitored, and those may not reflect the impact of IHT on overall brain metabolism, nor do they address differences between the hemispheres. Herein we aimed to quantify the effect of IHT on brain metabolism by monitoring both hemispheres with bilateral MD. In this study, 27 patients with severe brain injury (10 traumatic brain injury and 17 subarachnoid hemorrhage patients) were included, with a total of 67 IHT. Glucose, glycerol, pyruvate and lactate were measured by MD in both hemispheres for 10 h pre- and post-IHT. Alterations in metabolite levels after IHT were observed on both hemispheres; although these changes were more marked in hemisphere A (most damaged) than B (less damaged). Our results suggest that brain metabolism is altered after an IHT of neurocritical ill patients particularly but not limited to the damaged hemisphere. Bilateral monitorization may be more sensitive than unilateral monitorization for detecting metabolic disturbances not directly related to the course of the disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine

  • de Lazzari, Elisa|||0000-0003-2614-6545
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Tiraboschi, Juan Manuel|||0000-0002-0073-873X
  • Ribera, Esteban|||0000-0002-3752-8808
  • Abdulghani, Nadia
  • Alba, Verónica|||0000-0002-5925-9573
  • Fernández-Arroyo, Salvador
  • Vilades, Consuelo
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Gatell, José Mª|||0000-0002-4705-3244
  • Blanco Arévalo, José Luis|||0000-0003-2010-2744
  • Vidal, Francesc|||0000-0002-6692-6186
  • Rull, Anna|||0000-0002-8907-7754
  • Martínez, Esteban|||0000-0002-6911-8846
Introduction: The DOLAM trial revealed that switching from triple antiretroviral therapy (three-drug regimen; 3DR) to dolutegravir plus lamivudine (two-drug regimen; 2DR) was virologically non-inferior to continuing 3DR after 48weeks of follow-up. Weight increased with 2DR relative to 3DR but it did not impact on metabolic parameters. Methods: Multiomics plasma profile was performed to gain further insight into whether this therapy switch might affect specific biological pathways. DOLAM (EudraCT 201500027435) is a Phase 4, randomized, open-label, non-inferiority trial in which virologically suppressed persons with HIV treated with 3DR were assigned (1:1) to switch to 2DR or to continue 3DR for 48weeks. Untargeted proteomics, metabolomics and lipidomics analyses were performed at baseline and at 48eeks. Univariate and multivariate analyses were performed to identify changes in key molecules between both therapy arms. Results: Switching from 3DR to 2DR showed a multiomic impact on circulating plasma concentration of N-acetylmuramoyl-L-alanine amidase (Q96PD5), insulin-like growth factor-binding protein 3 (A6XND0), alanine and triglyceride (TG) (48:0). Correlation analyses identified an association among the up-regulation of these four molecules in persons treated with 2DR. Conclusions: Untargeted multiomics profiling studies identified molecular changes potentially associated with inflammation immune pathways, and with lipid and glucose metabolism. Although these changes could be associated with potential metabolic or cardiovascular consequences, their clinical significance remains uncertain. Further work is needed to confirm these findings and to assess their long-term clinical consequences.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development and Evaluation of an NTM-IGRA to Guide Pediatric Lymphadenitis Diagnosis

  • Villar-Hernández, Raquel|||0000-0002-2249-0579
  • Latorre, Irene|||0000-0001-8159-2455
  • Noguera-Julian, Antoni|||0000-0001-7485-0583
  • Martínez-Planas, Aina
  • Minguell Domingo, Laura
  • Vallmanya, Teresa
  • Méndez Hernández, Maria|||0000-0001-5697-2763
  • Soriano-Arandes, Antoni|||0000-0001-9613-7228
  • Baquero-Artigao, Fernando|||0000-0002-6903-3826
  • Rodríguez-Molino, Paula
  • Guillén-Martín, Sara
  • Toro Rueda, Carlos
  • De Souza Galvão, Maria Luiza|||0000-0001-9703-989X
  • Jiménez-Fuentes, María Ángeles|||0000-0001-5181-4192
  • Stojanovic, Zoran|||0000-0001-5082-0750
  • Sabriá, Josefina
  • Santos, José Ramón|||0000-0002-0886-7114
  • Puig, Jordi|||0000-0002-4075-0346
  • Domínguez-Álvarez, Marisol
  • Millet, Joan Pau|||0000-0003-0200-2459
  • Altet, Neus
  • Galea, Yolanda
  • Muriel-Moreno, Beatriz|||0000-0002-6683-9082
  • García-García, Esther
  • Bach Griera, Marc|||0000-0001-9845-7225
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
  • Julián, Esther|||0000-0002-6558-3978
  • Torrelles, Jordi B.|||0000-0001-7702-5941
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Domínguez, José|||0000-0001-7888-0309
Background: Diagnosis of nontuberculous mycobacteria (NTM) infections remains a challenge. In this study, we describe the evaluation of an immunological NTM-interferon (IFN)-γ release assay (IGRA) that we developed using glycopeptidolipids (GPLs) as NTM-specific antigens. Methods: We tested the NTM-IGRA in 99 samples from pediatric patients. Seventy-five were patients with lymphadenitis: 25 were NTM confirmed, 45 were of unknown etiology but compatible with mycobacterial infection and 5 had lymphadenitis caused by an etiologic agent other than NTM. The remaining 24 samples were from control individuals without lymphadenitis (latently infected with M.Tuberculosis, uninfected controls and active tuberculosis patients). Peripheral blood mononuclear cells were stimulated overnight with GPLs. Detection of IFN-γ producing cells was evaluated by enzyme-linked immunospot assay. Results: NTM culture-confirmed lymphadenitis patient samples had a significantly higher response to GPLs than the patients with lymphadenitis of unknown etiology but compatible with mycobacterial infection (P < 0.001) and lymphadenitis not caused by NTM (P < 0.01). We analyzed the response against GPLs in samples from unknown etiology lymphadenitis but compatible with mycobacterial infection cases according to the tuberculin skin test (TST) response, and although not statistically significant, those with a TST ≥5 mm had a higher response to GPLs when compared with the TST <5 mm group. Conclusions: Stimulation with GPLs yielded promising results in detecting NTM infection in pediatric patients with lymphadenitis. Our results indicate that the test could be useful to guide the diagnosis of pediatric lymphadenitis. This new NTM-IGRA could improve the clinical handling of NTM-infected patients and avoid unnecessary misdiagnosis and treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

APPRAISE-RS, Automated, updated, participatory, and personalized treatment recommender systems based on GRADE methodology

  • López, Beatriz|||0000-0001-9210-0073
  • Raya, Oscar|||0000-0002-0420-3038
  • Baykova, Evgenia
  • Saez, Marc|||0000-0003-1882-0157
  • Rigau, David|||0000-0003-0828-4872
  • Cunill, Ruth|||0000-0003-3247-393X
  • Mayoral, Sacramento
  • Carrion, Carme|||0000-0003-1479-7551
  • Serrano, Domènec
  • Castells Cervelló, Xavier|||0000-0002-2619-7273
Clinical practice guidelines (CPGs) have become fundamental tools for evidence-based medicine (EBM). However, CPG suffer from several limitations, including obsolescence, lack of applicability to many patients, and limited patient participation. This paper presents APPRAISE-RS, which is a methodology that we developed to overcome these limitations by automating, extending, and iterating the methodology that is most commonly used for building CPGs: the GRADE methodology. APPRAISE-RS relies on updated information from clinical studies and adapts and automates the GRADE methodology to generate treatment recommendations. APPRAISE-RS provides personalized recommendations because they are based on the patient's individual characteristics. Moreover, both patients and clinicians express their personal preferences for treatment outcomes which are considered when making the recommendation (participatory). Rule-based system approaches are used to manage heuristic knowledge. APPRAISE-RS has been implemented for attention deficit hyperactivity disorder (ADHD) and tested experimentally on 28 simulated patients. The resulting recommender system (APPRAISE-RS/TDApp) shows a higher degree of treatment personalization and patient participation than CPGs, while recommending the most frequent interventions in the largest body of evidence in the literature (EBM). Moreover, a comparison of the results with four blinded psychiatrist prescriptions supports the validation of the proposal. APPRAISE-RS is a valid methodology to build recommender systems that manage updated, personalized and participatory recommendations, which, in the case of ADHD includes at least one intervention that is identical or very similar to other drugs prescribed by psychiatrists.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Correction to 'TMSNP, a web server to predict pathogenesis of missense mutations in the transmembrane region of membrane proteins'

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PATH classification, a proposal for patients with HNSCC treated with salvage surgery

  • Llansana, Albert
  • Virós Porcuna, David|||0000-0002-2861-3672
  • Vásquez, Rosselin|||0000-0002-2483-9383
  • Parellada, Arnau
  • Valero Mayor, Cristina|||0000-0003-3397-2888
  • Holgado, Anna|||0000-0002-7478-8561
  • León i Vintró, Xavier|||0000-0001-6286-630X
Purpose: The aim of this study is to propose a classification for patients with recurrent head and neck squamous cell carcinoma (HNSCC) treated with salvage surgery based on the location of the primary tumor and data commonly found in the pathological report of the resection. Methods: Retrospective study of 665 patients with HNSCC treated with a salvage surgery after a local and/or regional recurrence of the tumor. Results: We propose a new postoperative classification for patients with recurrent HNSCC treated with salvage surgery. PATH classification stratifies patients into 4 stages based on the glottic or non-glottic location of the primary tumor, the local and regional pathologic extension of the tumor, the status of the surgical margins, and the presence of lymph node metastases with extracapsular spread. The PATH classification was more homogeneous in the prognosis of patients included in each of its stages, and it had a better prognostic discrimination capacity between stages than the rpTNM classification. According to the PATH classification, the 5-year disease-specific survival was: PATH I (n = 306) 82.8%; PATH II (n = 119) 47.1%; PATH III (n = 202) 24.4%; PATH IV (n = 38) 3.7%. For the rpTNM classification, the 5-year disease-specific survival was: stage I (n = 119) 85.1%; stage II (n = 134) 68.4%; stage III (n = 111) 59.5%; stage IV (n = 301) 33.3%. Conclusion: The PATH classification for HNSCC patients with local and/or regional recurrence treated with salvage surgery had a better prognostic capacity than the rpTNM classification. Level of evidence: Level IV.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Geometric, Biomechanic and Haemodynamic Aortic Abnormalities Assessed by 4D Flow Cardiovascular Magnetic Resonance in Patients Treated by TEVAR Following Blunt Traumatic Thoracic Aortic Injury

  • Gil-Sala, Daniel|||0000-0003-4885-5836
  • Guala, Andrea|||0000-0002-5006-8164
  • Garcia Reyes, Marvin
  • Azancot, María A.|||0000-0002-8447-1373
  • Dux-Santoy, Lydia|||0000-0001-8736-2095
  • Allegue Allegue, Nicolas
  • Teixido-Tura, Gisela|||0000-0003-4714-2420
  • Goncalves Martins, Gabriela
  • Ruiz Muñoz, Aroa|||0000-0002-1138-8528
  • Constenla Garcia, Ivan|||0000-0002-7107-2277
  • Evangelista Masip, Arturo|||0000-0001-8182-1174
  • Tello Díaz, Cristina
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
  • Rodríguez Palomares, José F.|||0000-0002-7229-9780
  • Bellmunt Montoya, Sergi|||0000-0002-2851-720X
Objective: Thoracic endovascular aortic repair (TEVAR) is widely used for the treatment of patients with blunt traumatic thoracic aortic injury (BTAI). However, aortic haemodynamic and biomechanical implications of this intervention are poorly investigated. This study aimed to assess whether patients treated by TEVAR following BTAI have thoracic aortic abnormalities in geometry, stiffness, and haemodynamics. Methods: Patients with BTAI treated by TEVAR at Vall d'Hebron Hospital between 1999 and 2019 were compared with propensity score matched healthy volunteers (HVs). All subjects underwent cardiovascular magnetic resonance (CMR) comprising a 4D flow CMR sequence. Spatially resolved aortic diameter, length, volume, and curvature were assessed. Pulse wave velocity, distensibility, and longitudinal strain (all measurements of aortic stiffness) were determined regionally. Moreover, advanced haemodynamic descriptors were quantified: systolic flow reversal ratio (SFRR), quantifying backward flow during systole, and in plane rotational flow (IRF), measuring in plane strength of helical flow. Results: Twenty-six BTAI patients treated by TEVAR were included and matched with 26 HVs. They did not differ in terms of age, sex, and body surface area. Patients with TEVAR had a larger and longer ascending aorta (AAo) and marked abnormalities in local curvature. Aortic stiffness was greater in the aortic segments proximal and distal to TEVAR compared with controls. Moreover, TEVAR patients presented strongly altered flow dynamics compared with controls: a reduced IRF from the distal AAo to the proximal descending aorta and an increased SFRR in the whole thoracic aorta. These differences persisted adjusting for cardiovascular risk factors and were independent of time elapsed since TEVAR implantation. Conclusion: At long term follow up, previously healthy patients who underwent TEVAR implantation following BTAI had increased diameter, length and volume of the ascending aorta, and increased aortic stiffness and abnormal flow patterns in the whole thoracic aorta compared with matched controls. Further studies should address whether these alterations have clinical implications.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Profiling TREM2 expression in amyotrophic lateral sclerosis

  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Vicuña-Urriza, J.
  • Blanco-Luquin, I.
  • Macias, M.
  • Martinez-Merino, L.
  • Roldán, M.
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Pagola-Lorz, Inma
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Zelaya, V.
  • Mendioroz, Maite|||0000-0002-4179-5781
There is growing evidence of the contribution of neuroinflammation, and in particular microglia, in the pathogenesis of amyotrophic lateral sclerosis (ALS). TREM2 gene plays a crucial role in shaping microglia in neurodegenerative conditions. To deepen the understanding of TREM2 in ALS and investigate the performance of TREM2 as a biomarker, we profiled TREM2 expression levels in spinal cord, cerebrospinal fluid and blood of patients with sporadic ALS. We also wanted to investigate whether the combined measurement of sTREM2 in fluids could improve the diagnostic yield of total and phosphorylated TDP-43 levels. We performed a case-control study to profile overall and transcript-specific TREM2 mRNA levels by RT-qPCR and protein expression levels by Western-blot in postmortem specimens of spinal cord from ALS patients and controls. In parallel, we measured soluble TREM2 (sTREM2) protein levels and full length and phosphorylated TDP-43 (tTDP-43 and pTDP-43) by ELISA in CSF and serum from ALS patients vs healthy controls. Patients were prospectively recruited from an ALS unit of a tertiary hospital and fulfilled El Escorial revised criteria. After bivariate analysis, a logistic regression model was developed to identify adjusted estimates of the association of sTREM2 levels in CSF and serum with ALS status. Overall and transcript-specific TREM2 mRNA were upregulated in the spinal cord of ALS patients (n = 21) compared to controls (n = 19). Similar changes were observed in TREM2 protein levels (p < 0.01) in spinal cord of ALS patients vs healthy controls. We also detected significantly higher sTREM2 levels in CSF (p-value < 0.01) of ALS patients (n = 46) vs controls (n = 46) and serum (p-value < 0.001) of ALS patients (n = 100) vs controls (n = 100). In a logistic regression model, both CSF and serum sTREM2 remained independently associated with ALS status with OR = 3.41 (CI 95 %=1.34-8.66) (p-value < 0.05) and OR = 3.38 (CI 95 %: 1.86-6.16) (p-value < 0.001), respectively. We also observed that pTDP-43 levels in CSF is an independent predictor of ALS (p-value < 0.05). Our results support the role of TREM2 in ALS pathophysiology and demonstrates that the three TREM2 transcripts are deregulated in ALS in postmortem human specimens of spinal cord. We hypothesise about the possible influence of systemic-peripheral inflammation in the disease. Finally, we conclude that pTDP-43 levels in CSF could be a biomarker of ALS, and sTREM2 measurement in CSF and blood emerge as potential non-invasive biomarker in ALS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden, A Nonrandomized Controlled Trial

  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Ortega Granados, Ana Laura|||0000-0002-5727-3371
  • Coves-Sarto, Juan
  • Calvo, Virginia|||0000-0002-3503-4847
  • Marsé-Fabregat, Raquel
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Guirado Risueño, Maria|||0000-0001-9086-204X
  • Carcereny, Enric|||0000-0001-5235-5602
  • Fernández, Natalia
  • Álvarez, Ruth
  • Blanco, Remei|||0000-0001-6748-0326
  • León-Mateos, Luis
  • Sánchez Torres, José Miguel
  • Sullivan, Ivana|||0000-0002-0434-3436
  • Cobo, Manuel|||0000-0003-3402-1144
  • Sánchez Hernández, Alfredo|||0000-0001-5826-8390
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Sierra Rodero, Belén|||0000-0003-0276-6088
  • Mártinez-Toledo, Cristina
  • Serna-Blasco, Roberto
  • Romero, Atocha|||0000-0002-1634-7397
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
Antiangiogenic drug combinations with anti-programmed cell death 1 protein and anti-programmed cell death 1 ligand 1 (PD-L1) agents are a novel treatment option for lung cancer. However, survival remains limited, and the activity of these combinations for tumors with high tumor mutation burden (TMB) is unknown. To assess the clinical benefits and safety of atezolizumab plus bevacizumab for patients with high-TMB advanced nonsquamous non-small cell lung cancer (NSCLC). This multicenter, single-arm, open-label, phase 2 nonrandomized controlled trial (Atezolizumab Plus Bevacizumab in First-Line NSCLC Patients [TELMA]) included treatment-naive patients aged 18 years or older with confirmed stage IIIB-IV nonsquamous NSCLC with TMB of 10 or more mutations/megabase and no EGFR, ALK, STK11, MDM2, or ROS1 alterations. From May 2019 through January 2021, patients were assessed at 13 sites in Spain, with follow-up until February 28, 2022. Participants were given atezolizumab, 1200 mg, plus bevacizumab, 15 mg/kg, on day 1 of each 21-day cycle. Treatment was continued until documented disease progression, unacceptable toxic effects, patient withdrawal, investigator decision, or death. Main Outcomes and Measures: The primary end point was 12-month progression-free survival (PFS) rate (according to Response Evaluation Criteria in Solid Tumours, version 1.1 criteria); PFS was defined as the time from enrollment to disease progression or death. Adverse events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. A total of 307 patients were assessed for trial eligibility, of whom 266 were ineligible for enrollment. Of the 41 patients enrolled, 3 did not fulfill all inclusion criteria and were excluded. The remaining 38 patients (28 [73.7%] male; mean [SD] age, 63.7 [8.3] years) constituted the per-protocol population. The 12-month PFS rate was 51.3% (95% CI, 34.2%-66.0%), which met the primary end point. The 12-month overall survival (OS) rate was 72.0% (95% CI, 54.1%-83.9%). The median PFS was 13.0 months (95% CI, 7.9-18.0 months), and the median OS was not reached. Of the 38 patients, 16 (42.1%) achieved an objective response and 30 (78.9%) achieved disease control. The median time to response was 2.8 months (IQR, 2.8-3.58 months), with a median duration of response of 11.7 months (range, 3.57-22.4 months; the response was ongoing at cutoff). Of 16 responses, 8 (50.0%) were ongoing. Most adverse events were grade 1 or 2. For atezolizumab, the most common adverse events were fatigue (6 [15.8%]) and pruritus (6 [15.8%]). For bevacizumab, they were hypertension (10 [26.3%]) and proteinuria (4 [10.5%]). Drug discontinuation occurred in 2 patients receiving atezolizumab (5.3%) and 3 patients receiving bevacizumab (7.9%). PD-L1 levels were not associated with response, PFS, or OS. These findings suggest that atezolizumab with bevacizumab is a potential treatment for high-TMB nonsquamous NSCLC. ClinicalTrials.gov Identifier: NCT03836066.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Validation of a Pathological Score for the Assessment of Bronchial Biopsies in Severe Uncontrolled Asthma, Beyond Blood Eosinophils

  • Cosio, Borja G.|||0000-0002-6388-8209
  • Shafiek, Hanaa|||0000-0002-4716-4809
  • Iglesias, Amanda|||0000-0003-2600-351X
  • Mosteiro, Mar
  • Gonzalez-Piñeiro, Ana
  • Rodríguez, Marta
  • García-Cosío, Mónica
  • Busto, Eladio
  • Martin, Javier
  • Mejías, Luis
  • Benito, Amparo
  • López Vilaró, Laura|||0000-0002-5428-8017
  • Gómez Cobo, Cristina|||0000-0002-9776-4730
Blood eosinophil count (BEC) is currently used as a surrogate marker of T2 inflammation in severe asthma but its relationship with tissue T2-related changes is elusive. Bronchial biopsy could add reliable information but lacks standardization. To validate a systematic assessment of the bronchial biopsy for the evaluation of severe uncontrolled asthma (SUA) by standardizing a pathological score. A systematic assessment of submucosal inflammation, tissue eosinophilic count/field (TEC), goblet cells hyperplasia, epithelial changes, basement membrane thickening, prominent airway smooth muscle and submucosal mucous glands was initially agreed and validated in representative bronchial biopsies of 12 patients with SUA by 8 independent pathologists. In a second phase, 62 patients with SUA who were divided according to BEC ≥ 300 cells/mm or less underwent bronchoscopy with bronchial biopsies and the correlations between the pathological findings and the clinical characteristics were investigated. The score yielded good agreement among pathologists regarding submucosal eosinophilia, TEC, goblet cells hyperplasia and mucosal glands (ICC = 0.85, 0.81, 0.85 and 0.87 respectively). There was a statistically significant correlation between BEC and TEC (r = 0.393, p = 0.005) that disappeared after correction by oral corticosteroids (OCS) use (r = 0.170, p = 0.307). However, there was statistically significant correlation between FeNO and TEC (r = 0.481, p = 0.006) that was maintained after correction to OCS use (r = 0.419, p = 0.021). 82.4% of low-BEC had submucosal eosinophilia, 50% of them moderate to severe. A standardized assessment of endobronchial biopsy is feasible and could be useful for a better phenotyping of SUA especially in those receiving OCS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CHARMS and PROBAST at your fingertips, a template for data extraction and risk of bias assessment in systematic reviews of predictive models

  • Fernandez-Felix, Borja M.
  • López Alcalde, Jesús|||0000-0002-1598-8790
  • Roqué i Figuls, Marta|||0000-0003-0043-1364
  • Muriel, Alfonso|||0000-0002-4805-4011
  • Zamora, Javier|||0000-0003-4901-588X
Systematic reviews of studies of clinical prediction models are becoming increasingly abundant in the literature. Data extraction and risk of bias assessment are critical steps in any systematic review. CHARMS and PROBAST are the standard tools used for these steps in these reviews of clinical prediction models. We developed an Excel template for data extraction and risk of bias assessment of clinical prediction models including both recommended tools. The template makes it easier for reviewers to extract data, to assess the risk of bias and applicability, and to produce results tables and figures ready for publication. We hope this template will simplify and standardize the process of conducting a systematic review of prediction models, and promote a better and more comprehensive reporting of these systematic reviews.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genotyping Hepatitis B virus by Next-Generation Sequencing, Detection of Mixed Infections and Analysis of Sequence Conservation

  • Dopico, Eva|||0000-0002-5306-3035
  • Vila, Marta|||0000-0001-9303-5189
  • Tabernero, David|||0000-0002-1146-4084
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Pacín Ruiz, Beatriz|||0000-0001-8718-6589
  • Guerrero, Laura|||0000-0003-1978-9067
  • Ubillos, Itziar|||0000-0002-0993-0058
  • Martínez, Miguel J.|||0000-0002-0682-1075
  • Costa, Josep|||0000-0001-7978-0748
  • Quer, Josep|||0000-0003-0014-084X
  • Pérez Garreta, Javier
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Cortese, Maria Francesca|||0000-0002-4318-532X
Our aim was to develop an accurate, highly sensitive method for HBV genotype determination and detection of genotype mixtures. We examined the preS and 5' end of the HBV X gene (5X) regions of the HBV genome using next-generation sequencing (NGS). The 1852 haplotypes obtained were subjected to genotyping via the Distance-Based discrimination method (DB Rule) using two sets of 95 reference sequences of genotypes A-H. In clinical samples from 125 patients, the main genotypes were A, D, F and H in Caucasian, B and C in Asian and A and E in Sub-Saharan patients. Genotype mixtures were identified in 28 (22.40%) cases, and potential intergenotypic recombination was observed in 29 (23.20%) cases. Furthermore, we evaluated sequence conservation among haplotypes classified into genotypes A, C, D, and E by computing the information content. The preS haplotypes exhibited limited shared conserved regions, whereas the 5X haplotypes revealed two groups of conserved regions across the genotypes assessed. In conclusion, we developed an NGS-based HBV genotyping method utilizing the DB Rule for genotype classification. We identified two regions conserved across different genotypes at 5X, offering promising targets for RNA interference-based antiviral therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunoaging at Early Ages Could Drive a Higher Comorbidity Burden in People with HIV on Antiretroviral Therapy Compared with the Uninfected Population

  • Loste, Cora
  • Trigueros Peña, Macedonia|||0000-0003-4156-1018
  • Muñoz-López, Francisco|||0000-0003-1789-1658
  • Urrea, Víctor|||0000-0002-2577-856X
  • Martínez, Ana
  • González, Sandra
  • Puig, Jordi|||0000-0002-4075-0346
  • Martín Flix, Marta|||0000-0001-7849-3616
  • Bonjoch, Anna|||0000-0002-5343-2881
  • Echeverría, Patricia|||0000-0003-2755-3695
  • Massanella, Marta|||0000-0002-3326-151X
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
This is an observational, cross-sectional, comparative case-control, pilot study aimed at assessing the impact of HIV infection and age on immunological markers in people with HIV (PWH) on antiretroviral therapy (ART). The study included 40 PWH on ART, divided into two age groups (40-45 years vs. ≥60 years), and 30 HIV-uninfected controls matched by sex and age. The results show that older PWH on ART had more comorbidities and a higher frequency of CD8 T cells compared to older controls, with a significant decrease in CD8 naïve T cells with age. Additionally, younger PWH on ART exhibited higher frequencies of activated CD8 T cells and elevated levels of inflammatory markers (sCD14, IL-6) compared to age-matched controls, with values similar to those of older PWH on ART. These findings suggest that younger PWH on ART may experience accelerated immunoaging, highlighting the need for early interventions in this population.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Video conference vs face-to-face group psychotherapy for distressed cancer survivors, A randomized controlled trial

  • Lleras, María|||0000-0002-7767-1625
  • Medina, Joan Carles|||0000-0002-4550-2157
  • Vives Brosa, Jaume|||0000-0001-5412-7275
  • Casellas-Grau, Anna|||0000-0003-2919-0509
  • Marzo, Jose Luis
  • Borras, Josep M|||0000-0001-7330-6308
  • Ochoa, Cristian|||0000-0002-4508-0951
Objective: This study assesses the effectiveness of face-to-face group positive psychotherapy for cancer survivors (PPC) compared to its online adaptation, online group positive psychotherapy for cancer survivors (OPPC), which is held via videoconference. A two-arm, pragmatic randomized controlled trial was conducted to examine the effects of both interventions on emotional distress, post-traumatic stress symptoms (PTSS), and post-traumatic growth (PTG) among cancer survivors and analyze attrition to treatment. Methods: Adult women with a range of cancer diagnoses were invited to participate if they experienced emotional distress at the end of their primary oncological treatment. Emotional distress, PTSS, and PTG were assessed at baseline, immediately after treatment, and 3 months after treatment. Intention-to-treat analyses were carried out using general linear mixed models to test the effect of the interventions overtime. Logistic regressions were performed to test differential adherence to treatment and retention to follow-up. Results: A total of 269 individuals participated. The observed treatment effect was significant in both modalities, PPC and OPPC. Emotional distress (b = -2.24, 95% confidence interval [CI] = -3.15 to -1.33) and PTSS (b = -3.25, 95% CI = -4.97 to -1.53) decreased significantly over time, and PTG (b = 3.08, 95% CI = 0.38-5.78) increased significantly. Treatment gains were sustained across outcomes and over time. Analyses revealed no significant differences between modalities of treatment, after adjusting for baseline differences, finding that OPPC is as effective and engaging as PPC. Conclusions: The OPPC treatment was found to be effective and engaging for female cancer early survivors. These results open the door for psycho-oncology interventions via videoconference, which are likely to lead to greater accessibility and availability of psychotherapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Towards clinical translation of urinary vitronectin for non-invasive detection and monitoring of renal fibrosis in kidney transplant patients

  • Clos Sansalvador, Marta|||0000-0001-8522-7818
  • Taco, Omar|||0000-0001-9081-5665
  • Rodríguez-Martínez, Paula|||0000-0002-9001-2501
  • Garcia, Sergio G.|||0000-0001-7698-3734
  • Font-Morón, Miriam|||0000-0002-4714-252X
  • Bover, Jordi|||0000-0003-3577-2273
  • Vila-Santandreu, Anna
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Juega-Mariño, Javier|||0000-0002-9927-9683
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Interstitial fibrosis and tubular atrophy (IFTA) is a critical factor in the prognosis of kidney health. Currently, IFTA quantitation in kidney biopsy samples is crucial for diagnosis and assessing disease severity, but the available non-invasive biomarkers are not satisfactory. Proteomic studies identified urinary vitronectin (VTN) as a potential biomarker for kidney fibrosis. As mass spectrometry techniques are not practical for use in clinical settings, we tested whether evaluation of urinary VTN levels through enzyme-linked immunosorbent assay (ELISA) can help monitor fibrotic changes in kidney transplant recipients and prove the clinical viability of the assay. A total of 58 kidney transplant (KTx) patients who underwent renal biopsy were included in the study. Patients were categorized into two groups referred as no fibrosis (0%) or with fibrosis (≥ 5%) based on their histological findings. In a subsequent/follow-up analysis, the time elapsed from transplantation was also considered. The urinary levels of VTN were measured using ELISA. VTN (p = 0.0180) and VTN normalized by urinary creatinine levels (p = 0.0037), were significantly increased in patients with fibrotic grafts. When focusing on patients with long-term grafts (> 3 years from transplantation, n = 36), VTN exhibited superior potential in identifying fibrotic grafts compared to albuminuria (VTN p = 0.0040 vs. albuminuria p = 0.0132). Importantly, in this group, while albuminuria correctly identified 71% of fibrotic patients, the combination of VTN plus albuminuria correctly classified 89% of fibrotic grafts detected by renal biopsy. VTN has emerged as a valid indicator of renal fibrosis. Of interest, urinary levels of VTN in combination with conventional clinical parameters (such as albuminuria) significantly improved the non-invasive detection of renal fibrosis in kidney transplant patients. The online version contains supplementary material available at 10.1186/s12967-024-05777-5.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Home exercise, branched-chain amino acids, and probiotics improve frailty in cirrhosis, A randomized clinical trial

  • Roman, Eva|||0000-0001-9084-8555
  • Kaur Gill, Naujot|||0009-0007-4184-0398
  • Sánchez, Elisabet|||0000-0002-3280-9301
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Padros i Valls, Josep
  • Nadal, Mª Josepa|||0000-0002-6700-057X
  • Cuyàs, Berta|||0000-0001-9988-7163
  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Vidal, Silvia|||0000-0002-3909-6682
  • Ortiz, M. Àngels|||0000-0002-1574-9861
  • Hernández Martínez-Esparza, Elvira|||0000-0002-9736-9052
  • Santesmases Masana, Rosalia|||0000-0002-6890-3279
  • Urgell, Eulàlia|||0000-0003-3519-1022
  • Juanes Borego, Elena|||0000-0001-8910-2123
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Escorsell, Àngels|||0000-0001-5083-8467
  • Guarner, Carlos|||0000-0001-5957-9481
  • Soriano, German|||0000-0002-9267-6811
Frailty is a predictive factor of hospitalization, falls, and mortality in patients with cirrhosis, regardless of the degree of liver failure. The aim was to analyze whether a multifactorial intervention consisting of home-based exercise, branched-chain amino acids, and a multistrain probiotic can improve frailty in these patients. Outpatients with cirrhosis were classified according to the Liver Frailty Index (LFI). Prefrail and frail patients were randomized into 2 groups. The intervention group was assigned to a multifactorial intervention consisting of exercise at home, branched-chain amino acid supplements, and a multistrain probiotic for 12 months. The control group received standard care. All patients were prospectively followed up every 3 months for 1 year to determine LFI, incidence of falls, emergency room visits, hospitalizations, and mortality. Thirty-two patients were included: 17 patients were assigned to the intervention group and 15 to the control group. In the intervention group, the baseline LFI decreased at 3, 6, 9, and 12 months (p = 0.019 for overall change with respect to the control group). The change in LFI (ΔLFI) at 12 months was -0.71 ± 0.24 in the intervention group and -0.09 ± 0.32 in the control group (p<0.001). During follow-up, patients in the intervention group had a lower 1-year probability of falls (6% vs. 47%, p = 0.03) and emergency room visits (10% vs. 44%, p = 0.04) than patients in the control group. A long-term multifactorial intervention that included exercise at home, branched-chain amino acids, and a multistrain probiotic improved frailty in outpatients with cirrhosis and was associated with a decrease in the incidence of clinical events such as falls and emergency room visits. 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tumor analysis of MMR genes in Lynch-like syndrome, Challenges associated with results interpretation

  • Rofes, Paula|||0000-0001-6045-7879
  • Dueñas Cid, Nuria|||0000-0001-6624-3265
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Navarro, Matilde
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Tuset, Noemí
  • Castillo, Carmen
  • González, Sara
  • Brunet, Joan|||0000-0003-1945-3512
  • Capella, Gabriel|||0000-0002-4669-7320
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Pineda, Marta|||0000-0002-5403-5845
Up to 70% of suspected Lynch syndrome patients harboring MMR deficient tumors lack identifiable germline pathogenic variants in MMR genes, being referred to as Lynch-like syndrome (LLS). Previous studies have reported biallelic somatic MMR inactivation in a variable range of LLS-associated tumors. Moreover, translating tumor testing results into patient management remains controversial. Our aim is to assess the challenges associated with the implementation of tumoral MMR gene testing in routine workflows. Methods: Here, we present the clinical characterization of 229 LLS patients. MMR gene testing was performed in 39 available tumors, and results were analyzed using two variant allele frequency (VAF) thresholds (≥5% and ≥10%). Results and Discussion: More biallelic somatic events were identified at VAF ≥ 5% than ≥10% (35.9% vs. 25.6%), although the rate of nonconcordant results regarding immunohistochemical pattern increased (30.8% vs. 20.5%). Interpretation difficulties question the current utility of the identification of MMR somatic hits in the diagnostic algorithm of suspected LS cases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Practice matters, The role of mindfulness skills in emotion dysregulation in borderline personality disorder

  • Schmidt, Carlos|||0000-0002-5927-4554
  • Soler, Joaquim|||0000-0001-8077-3641
  • Vega, Daniel|||0000-0002-5621-8987
  • Pascual, Juan Carlos|||0000-0001-8039-9346
Mindfulness skills training constitute a core element of dialectical behavior therapy (DBT) that has been proposed as a key component to improve emotion dysregulation (ED) in borderline personality disorder (BPD). However, the relationship between the time spent practicing mindfulness skills at home and changes in ED is not well-understood. This study aimed to determine whether daily mindfulness practice meaningfully improves ED, and, if so, the minimum dose needed to do so. A total of 75 BPD outpatients participated in a 10-week DBT mindfulness skill training program. We systematically tracked the participants' mindfulness practice and their ED levels throughout the sessions. A total of 499 observations were recorded. We used multilevel modeling with a time-lagged approach to investigate the association between weekly practice and ED over time. Greater mindfulness practice predicted improvements in ED in the following week. A bidirectional relationship was also found; a higher level of ED impaired subsequent mindfulness practice. When accounting for the previous week's ED level, participants who practiced ≥3 days and.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Mild Presentation of X-Linked Hypophosphatemia Caused by a Non-Canonical Splice Site Variant in the PHEX Gene

  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • Herreros García, Alba|||0009-0003-0451-7568
  • Pybus, Marc|||0000-0002-6195-5738
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Furlano, Monica|||0000-0003-1025-3901
  • Garcia Borau, Maria José|||0000-0002-8223-8033
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ars, Elisabet|||0000-0002-4118-4358
X-linked hypophosphatemia (XLH) is a rare inherited disorder of renal phosphate wasting with a highly variable phenotype caused by loss-of-function variants in the PHEX gene. The diagnosis of individuals with mild phenotypes can be challenging and often delayed. Here, we describe a three-generation family with a very mild clinical presentation of XLH. The diagnosis was unexpectedly found in a 39-year-old woman who was referred for genetic testing due to an unclear childhood diagnosis of a tubulopathy. Genetic testing performed by next-generation sequencing using a kidney disease gene panel identified a novel non-canonical splice site variant in the PHEX gene. Segregation analysis detected that the consultand's father, who presented with hypophosphatemia and decreased tubular phosphate reabsorption, and the consultand's son also carried this variant. RNA studies demonstrated that the non-canonical splice site variant partially altered the splicing of the PHEX gene, as both wild-type and aberrant splicing transcripts were detected in the two male members with only one copy of the PHEX gene. In conclusion, this case contributes to the understanding of the relationship between splicing variants and the variable expressivity of XLH disease. The mild phenotype of this family can be explained by the coexistence of PHEX transcripts with aberrant and wild-type splicing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

  • Torres Esquius, Sara|||0000-0001-7540-7284
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Romey, Marcel
  • Teule, Alex|||0000-0003-0028-7200
  • Llort, Gemma|||0000-0001-9987-7862
  • Herrero, Ana
  • Sánchez-Henarejos, Pilar
  • Vallmajó, Anna
  • González-Santiago, Santiago|||0000-0002-4787-0236
  • Chirivella, Isabel|||0000-0002-0733-3276
  • Cano, Juana María|||0000-0002-2493-0988
  • Graña, Begoña|||0000-0003-2008-8188
  • Simonetti, Sara|||0000-0003-2406-030X
  • Díaz de Corcuera, Isabel
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Sanz, Judit
  • Serrano, Sara
  • Otero, Andrea
  • Churruca, Cristina
  • Sánchez-Heras, Ana Beatriz|||0000-0003-1742-5374
  • Servitja, Sonia|||0000-0001-6988-4519
  • Guillén-Ponce, Carmen
  • Brunet, Joan|||0000-0003-1945-3512
  • Denkert, Carsten
  • Serra, Violeta|||0000-0001-6620-1065
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
IMPORTANCE RAD51C and RAD51D are involved in DNA repair by homologous recombination. Germline pathogenic variants (PVs) in these genes are associated with an increased risk of ovarian and breast cancer. Understanding the homologous recombination deficiency (HRD) status of tumors from patients with germline PVs in RAD51C/D could guide therapeutic decision-making and improve survival. OBJECTIVE To characterize the clinical and tumor characteristics of germline RAD51C/D PV carriers, including the evaluation of HRD status. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study included 91 index patients plus 90 relatives carrying germline RAD51C/D PV (n = 181) in Spanish hospitals from January 1, 2014, to December 31, 2021. Genomic and functional HRD biomarkers were assessed in untreated breast and ovarian tumor samples (n = 45) from June 2022 to February 2023. MAIN OUTCOMES AND MEASURES Clinical and pathologic characteristics were assessed using descriptive statistics. Genomic HRD by genomic instability scores, functional HRD by RAD51, and gene-specific loss of heterozygosity were analyzed. Associations between HRD status and tumor subtype, age at diagnosis, and gene-specific loss of heterozygosity in RAD51C/D were investigated using logistic regression or the t test. RESULTS A total of 9507 index patients were reviewed, and 91 patients (1.0%) were found to carry a PV in RAD51C/D; 90 family members with a germline PV in RAD51C/D were also included. A total of 157 of carriers (86.7%) were women and 181 (55.8%) had received a diagnosis of cancer, mainly breast cancer or ovarian cancer. The most prevalent PVs were c.1026+5_1026+7del (11 of 56 [19.6%]) and c.709C.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Symptom profile in suicide attempters during the COVID-19 pandemic, Relationships with suicide outcomes

  • Díaz-Carracedo, Patricia|||0000-0001-6595-2377
  • Marín, Carolina|||0000-0001-6628-9669
  • Díaz-Marsá, Marina|||0000-0003-1364-3163
  • Borges, Guilherme|||0000-0002-3269-0507
  • Torre-Luque, Alejandro de la|||0000-0003-0595-6127
  • Elices, M.|||0000-0002-7034-4242
  • Toll, Alba|||0000-0003-2399-5250
  • Grande, Iria|||0000-0002-0137-0666
  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • Vázquez, Mireia
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Ruiz-Veguilla, Miguel|||0000-0002-5790-7346
  • Canal-Rivero, Manuel|||0000-0002-5818-5103
  • Cebrià, Ana Isabel|||0000-0002-2632-8130
  • Palao, Diego|||0000-0002-3323-6568
  • Bobes-Bascarán, Maria T.|||0000-0002-5279-504X
  • Jiménez-Treviño, Luis|||0000-0002-9551-8587
  • Sáiz, Pilar A.|||0000-0002-5705-4523
  • Andreo Jover, Jorge|||0000-0002-6703-8017
  • March, Katya B.
  • Palao Tarrero, Ángela|||0000-0003-2717-5807
  • Pérez Solà, Víctor|||0000-0002-5825-2337
Suicidal behavior constitutes a multi-cause phenomenon that may also be present in people without a mental disorder. This study aims to analyze suicidal behavior outcomes in a sample of attempters, from a symptom-based approach. The sample comprised 673 patients (72% female; M = 40.9 years) who attended a hospital emergency department due to a suicide attempt. A wide range of clinical factors (e.g., psychopathology symptoms, psychiatric diagnoses, impulsivity, acquired capability), was administered within 15 days after the index attempt. Nine psychopathology domains were explored to identify the profile of symptoms, using latent profile analysis. The relationship between the profile membership and suicide outcome (i.e., intensity of suicidal ideation, number of suicide behaviors, and medical injury derived from index attempt) was also studied, using linear and logistic regression. Three psychopathology profiles were identified: high-symptom profile (45.02% of participants), moderate-symptom profile (42.50%), and low-symptom profile (12.48%). High-symptom profile members were more likely to show higher risk of non-suicidal self-injury, acquired capability for suicide, and more severe suicide behavior and ideation. On the other hand, a more severe physical injury was associated with low-symptom profile membership in comparison to membership from the other profiles (OR < 0.45, p <.05). A symptom-based approach may be useful to monitor patients and determine the risk of attempt repetition in the future and potential medical injury, and to optimize prevention and intervention strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A phenome-wide association and Mendelian randomisation study of alcohol use variants in a diverse cohort comprising over 3 million individuals

  • Jennings, Mariela V.
  • Martínez-Magaña, José Jaime
  • Courchesne-Krak, Natasia S.
  • Cupertino , Renata B.
  • Vilar-Ribó, L.|||0000-0001-8758-523X
  • Bianchi, Sevim B.
  • Hatoum, Alexander S.
  • Atkinson, Elizabeth G.
  • Giusti-Rodriguez, Paola
  • Montalvo-Ortiz, Janitza L.|||0000-0002-7657-8365
  • Gelernter, Joel|||0000-0002-4067-1859
  • Soler Artigas, María|||0000-0002-3213-1107
  • Elson, Sarah L.
  • Edenberg, Howard J.|||0000-0003-0344-9690
  • Fontanillas, Pierre
  • Palmer, Abraham A.
  • Sánchez Roige, Sandra|||0000-0001-6137-5699
Alcohol consumption is associated with numerous negative social and health outcomes. These associations may be direct consequences of drinking, or they may reflect common genetic factors that influence both alcohol consumption and other outcomes. We performed exploratory phenome-wide association studies (PheWAS) of three of the best studied protective single nucleotide polymorphisms (SNPs) in genes encoding ethanol metabolising enzymes (ADH1B : rs1229984-T, rs2066702-A; ADH1C : rs698-T) using up to 1109 health outcomes across 28 phenotypic categories (e.g., substance-use, mental health, sleep, immune, cardiovascular, metabolic) from a diverse 23andMe cohort, including European (N ≤ 2,619,939), Latin American (N ≤ 446,646) and African American (N ≤ 146,776) populations to uncover new and perhaps unexpected associations. These SNPs have been consistently implicated by both candidate gene studies and genome-wide association studies of alcohol-related behaviours but have not been investigated in detail for other relevant phenotypes in a hypothesis-free approach in such a large cohort of multiple ancestries. To provide insight into potential causal effects of alcohol consumption on the outcomes significant in the PheWAS, we performed univariable two-sample and one-sample Mendelian randomisation (MR) analyses. The minor allele rs1229984-T, which is protective against alcohol behaviours, showed the highest number of PheWAS associations across the three cohorts (N = 232, European; N = 29, Latin American; N = 7, African American). rs1229984-T influenced multiple domains of health. We replicated associations with alcohol-related behaviours, mental and sleep conditions, and cardio-metabolic health. We also found associations with understudied traits related to neurological (migraines, epilepsy), immune (allergies), musculoskeletal (fibromyalgia), and reproductive health (preeclampsia). MR analyses identified evidence of causal effects of alcohol consumption on liability for 35 of these outcomes in the European cohort. Our work demonstrates that polymorphisms in genes encoding alcohol metabolising enzymes affect multiple domains of health beyond alcohol-related behaviours. Understanding the underlying mechanisms of these effects could have implications for treatments and preventative medicine. MVJ, NCK, SBB, SSR and AAP were supported by T32IR5226 and 28IR-0070. SSR was also supported by DP1DA054394. NCK and RBC were also supported by R25MH081482. ASH was supported by funds from NIAAA K01AA030083. JLMO was supported by VA 1IK2CX002095. JLMO and JJMM were also supported by R21DA050160. JJMM was also supported by the for Academic Diversity. EGA was supported by K01MH121659 from the /, the and the at . MSA was supported by the and co-funded by the : (FSE+) (P19/01224, PI22/00464 and CP22/00128).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Precise Targeting of Autoantigen-Specific B Cells in Lupus Nephritis with Chimeric Autoantibody Receptor T Cells

  • Solé Marcé, Cristina|||0000-0002-4870-2824
  • Royo, Maria|||0000-0003-3289-2624
  • Sandoval, Sebastian
  • Moliné, Teresa|||0000-0003-4912-5114
  • Gabaldón, Alejandra
  • Cortés Hernández, Josefina|||0000-0003-4538-3538
Despite conventional therapy, lupus nephritis (LN) remains a significant contributor to short- and long-term morbidity and mortality. B cell abnormalities and the production of autoantibodies against nuclear complexes like anti-dsDNA are recognised as key players in the pathogenesis of LN. To address the challenges of chronic immunosuppression associated with current therapies, we have engineered T cells to express chimeric autoantibody receptors (DNA-CAART) for the precise targeting of B cells expressing anti-dsDNA autoantibodies. T cells from LN patients were transduced using six different CAAR vectors based on their antigen specificity, including alpha-actinin, histone-1, heparan sulphate, or C1q. The cytotoxicity, cytokine production, and cell-cell contact of DNA-CAART were thoroughly investigated in co-culture experiments with B cells isolated from patients, both with and without anti-dsDNA positivity. The therapeutic effects were further evaluated using an in vitro immune kidney LN organoid. Among the six proposed DNA-CAART, DNA4 and DNA6 demonstrated superior selectively cytotoxic activity against anti-dsDNA + B cells. Notably, DNA4-CAART exhibited improvements in organoid morphology, apoptosis, and the inflammatory process in the presence of IFNα-stimulated anti-dsDNA + B cells. Based on these findings, DNA4-CAART emerge as promising candidates for modulating autoimmunity and represent a novel approach for the treatment of LN.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Two Novel Variants in YARS2 Gene Are Responsible for an Extended MLASA Phenotype with Pancreatic Insufficiency

  • Carreño Gago, Lidia
  • Juarez-Flores, Diana Luz|||0000-0003-3615-7803
  • Grau, Josep M.|||0000-0001-7560-224X
  • Ramón, Javier|||0000-0002-0673-9338
  • Lozano, Ester|||0000-0002-6307-9807
  • Vila-Julià, Ferran
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Garrabou, Glòria|||0000-0001-8973-9933
  • García Arumí, Elena|||0000-0003-1848-005X
Pathogenic variants in the mitochondrial tyrosyl-tRNA synthetase gene (YARS2) were associated with myopathy, lactic acidosis, and sideroblastic anemia (MLASA). However, patients can present mitochondrial myopathy, with exercise intolerance and muscle weakness, leading from mild to lethal phenotypes. Genes implicated in mtDNA replication were studied by Next Generation Sequencing (NGS) and whole exome sequence with the TruSeq Rapid Exome kit (Illumina, San Diego, CA, USA). Mitochondrial protein translation was studied following the Sasarman and Shoubridge protocol and oxygen consumption rates with Agilent Seahorse XF24 Analyzer Mitostress Test, (Agilent, Santa Clara, CA, USA). We report two siblings with two novel compound heterozygous pathogenic variants in YARS2 gene: a single nucleotide deletion in exon 1, c.314delG (p.(Gly105Alafs*4)), which creates a premature stop codon in the amino acid 109, and a single nucleotide change in exon 5 c.1391T.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MptpB Inhibitor Improves the Action of Antibiotics against Mycobacterium tuberculosis and Nontuberculous Mycobacterium avium Infections

  • Rodríguez-Fernández, Pablo|||0000-0003-1273-0548
  • Botella, Laure
  • Cavet, Jennifer S.
  • Domínguez, José|||0000-0001-7888-0309
  • Gutierrez, Maximiliano G.|||0000-0003-3199-0337
  • Suckling, Colin J.
  • Scott, Fraser J.|||0000-0003-0229-3698
  • Tabernero, Lydia|||0000-0001-8867-455X
Treatment of Mycobacterium tuberculosis and Mycobacterium avium infections requires multiple drugs for long time periods. Mycobacterium protein-tyrosine-phosphatase B (MptpB) is a key M. tuberculosis virulence factor that subverts host antimicrobial activity to promote intracellular survival. Inhibition of MptpB reduces the infection burden in vivo and offers new opportunities to improve current treatments. Here, we demonstrate that M. avium produces an MptpB orthologue and that the MptpB inhibitor C13 reduces the M. avium infection burden in macrophages. Combining C13 with the antibiotics rifampicin or bedaquiline showed an additive effect, reducing intracellular infection of both M. tuberculosis and M. avium by 50%, compared to monotreatment with antibiotics alone. This additive effect was not observed with pretomanid. Combining C13 with the minor groove-binding compounds S-MGB-362 and S-MGB-363 also reduced the M. tuberculosis intracellular burden. Similar additive effects of C13 and antibiotics were confirmed in vivo using Galleria mellonella infections. We demonstrate that the reduced mycobacterial burden in macrophages observed with C13 treatments is due to the increased trafficking to lysosomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Trait anxiety is associated with attentional brain networks

  • De la Peña-Arteaga, Víctor|||0000-0001-8627-2653
  • Chavarría-Elizondo, Pamela|||0000-0002-8177-3771
  • Juaneda-Seguí, Asier|||0000-0003-1662-1605
  • Martínez-Zalacaín, Ignacio|||0000-0002-4036-0284
  • Morgado, Pedro|||0000-0003-3880-3258
  • Manuel Menchón, José
  • Picó-Pérez, Maria|||0000-0002-1573-2445
  • Fullana, Miguel|||0000-0003-3863-5223
  • Soriano-Mas, Carles|||0000-0003-4574-6597
Trait anxiety is a well-established risk factor for anxiety and depressive disorders, yet its neural correlates are not clearly understood. In this study, we investigated the neural correlates of trait anxiety in a large sample (n = 179) of individuals who completed the trait and state versions of the State-Trait Anxiety Inventory and underwent resting-state functional magnetic resonance imaging. We used independent component analysis to characterize individual resting-state networks (RSNs), and multiple regression analyses to assess the relationship between trait anxiety and intrinsic connectivity. Trait anxiety was significantly associated with intrinsic connectivity in different regions of three RSNs (dorsal attention network, default mode network, and auditory network) when controlling for state anxiety. These RSNs primarily support attentional processes. Notably, when state anxiety was not controlled for, a different pattern of results emerged, highlighting the importance of considering this factor in assessing the neural correlates of trait anxiety. Our findings suggest that trait anxiety is uniquely associated with resting-state brain connectivity in networks mainly supporting attentional processes. Moreover, controlling for state anxiety is crucial when assessing the neural correlates of trait anxiety. These insights may help refine current neurobiological models of anxiety and identify potential targets for neurobiologically-based interventions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Narrative Review on Gut Microbiome Disturbances and Microbial Preparations in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Implications for Long COVID

  • Jurek, Joanna Michalina|||0000-0002-7319-0672
  • Castro-Marrero, Jesús|||0000-0002-2481-3052
Myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID are complex, multisystemic and long-term disabling conditions characterized by debilitating post-exertional malaise and other core symptoms related to immune dysregulation resultant from post-viral infection, including mitochondrial dysfunction, chronic neuroinflammation and gut dysbiosis. The reported associations between altered microbiota composition and cardinal symptoms of ME/CFS and long COVID suggest that the use of microbial preparations, such as probiotics, by restoring the homeostasis of the brain-immune-gut axis, may help in the management of symptoms in both conditions. Therefore, this review aims to investigate the implications of alerted gut microbiome and assess the evidence supporting use of microbial-based preparations, including probiotics, synbiotics, postbiotics alone and/or in combination with other nutraceuticals in the management of fatigue, inflammation and neuropsychiatric and gastrointestinal symptoms among patients with ME/CFS and long COVID.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Needs assessment for creation of a platform trial network in metabolic-dysfunction associated steatohepatitis

  • Sena, Elena|||0000-0003-1220-5639
  • Tacke, Frank|||0000-0001-6206-0226
  • Anstee, Quentin M.|||0000-0002-9518-0088
  • Di Prospero, Nicholas
  • Skalshøi- Kjær, Mette
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Jiménez-Masip, Alba
  • Bañales, Jesús M.
  • Martínez-Gómez, María
  • Koenig, Franz
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Ratziu, Vlad
  • Pericàs, Juan M.|||0000-0002-3645-3293
The EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) project (IMI2-853966) aimed to develop tools to establish integrated research platforms (IRP) for conducting adaptive-design trials in various diseases, including metabolic-dysfunction associated steatohepatitis (MASH). One essential component of a successful MASH IRP is a robust and reliable Clinical Research Network (CRN). Herein, we outline the required elements and anticipated steps to set-up such a CRN. We identified European clinical research sites that could potentially serve as the foundation for MASH IRP and a CRN. A survey was sent to sites to assess their interest in joining a CRN, their familiarity with platform trials, and their capacity to participate in a future MASH IRP. A total of 141 investigators were invited to participate in the survey, and 40% responded. More than half of the answers (52%) identify MASH with advanced fibrosis (F3-4) as the subpopulation with the greatest unmet need. Regarding the difficulty in identifying candidates for trials, 65% find it is moderately difficult and 30% very difficult. Most respondents (94%) believe that a platform trial could offer substantial benefits to patients. Nearly all researchers express interest in participating in a platform trial (78%), with 22% indicating their interest would be contingent on initial industry funding. While preliminary, our findings on responding sites are encouraging for the potential establishment of a CRN for a MASH IRP. However, funding schemes and sustainability strategies to provide proof-of-platform in MASH seem key in the short-term scenario. Metabolic dysfunction-associated steatohepatitis (MASH) occurs when the liver becomes damaged due to the build up of fat, which is often related to obesity and diabetes. There is a lack of effective drug treatments for MASH, so strategies to strengthen clinical research in this area are needed. Here, we survey key European experts on MASH to assess their interest in joining a network of MASH researchers and their interest in participating in a new type of clinical trial called a platform trial, where multiple drugs can be tested simultaneously. Researchers largely agree that these are promising approaches to boost drug development in the field, although have concerns regarding funding and sustainability strategies. Our findings may inform the creation of a network of MASH researchers capable of running a platform trial, which in turn may speed up research into treatments for MASH. Sena et al. survey European clinical research sites that could potentially serve as the foundation for a MASH integrated research platform and clinical research network. Respondents generally believe that a MASH platform trial could benefit patients and are interested in participating, though securing industry funding is identified as a priority.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnostic performance of plasma pTau 217, pTau 181, Aβ 1-42 and Aβ 1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance in clinical practice is unknown. We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture in routine clinical practice in a specialized memory clinic (66 cognitively unimpaired, 130 participants with mild cognitive impairment, and 94 with dementia). Participants were classified as amyloid positive (A+) or negative (A-) according to CSF Aβ/Aβ ratio. Plasma pTau, pTau, Aβ and Aβ were measured in the fully-automated LUMIPULSE platform. We used linear regression to compare plasma biomarkers concentrations between A + and A- groups, evaluated Spearman's correlation between plasma and CSF and performed ROC analyses to assess their diagnostic accuracy to detect brain amyloidosis as determined by CSF Aβ/Aβ ratio. We analyzed the potential of pTau to predict amyloidosis in CSF. Plasma pTau and pTau concentration were higher in A + than A- while the plasma Aβ/Aβ ratio was lower in A + compared to A-. pTau and the Aβ/Aβ ratio showed moderate correlation between plasma and CSF (Rho = 0.66 and 0.69, respectively). The areas under the ROC curve to discriminate A + from A- participants were 0.94 (95% CI 0.92-0.97) for pTau, and 0.88 (95% CI 0.84-0.92) for both pTau and Aβ/Aβ. Chronic kidney disease (CKD) was related to increased plasma biomarker concentrations, but ratios were less affected. Plasma pTau had the highest fold change (x4.2) and showed high predictive capability in discriminating A + from A-, having 4-7% misclassification rate. The global accuracy of plasma pTau using a two-threshold approach was robust in symptomatic groups, exceeding 90%. The evaluation of blood biomarkers on an automated platform exhibited high diagnostic accuracy for AD pathophysiology, and pTau showed excellent diagnostic accuracy to identify participants with AD in a consecutive sample representing the routine clinical practice in a specialized memory unit.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biomarkers for Psychosis, Are We There Yet? Umbrella Review of 1478 Biomarkers

  • Fuentes-Claramonte, Paola|||0000-0002-1428-7976
  • Estradé, Andrés|||0000-0001-6871-5932
  • Solanes, Aleix|||0000-0002-2491-200X
  • Ramella-Cravaro, Valentina
  • Garcia-Leon, Maria Angeles
  • Diego-Adeliño, Javier de|||0000-0001-9708-2441
  • Molins, Conrad
  • Fung, Eric
  • Valentí, Marc
  • Anmella, Gerard|||0000-0002-6798-4054
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Oliver, Dominic|||0000-0002-8920-3407
  • Vieta, Eduard|||0000-0002-0548-0053
  • Radua, Joaquim|||0000-0003-1240-5438
  • Fusar-Poli, Paolo|||0000-0003-3582-6788
This umbrella review aims to comprehensively synthesize the evidence of association between peripheral, electrophysiological, neuroimaging, neuropathological, and other biomarkers and diagnosis of psychotic disorders. We selected systematic reviews and meta-analyses of observational studies on diagnostic biomarkers for psychotic disorders, published until February 1, 2018. Data extraction was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Evidence of association between biomarkers and psychotic disorders was classified as convincing, highly suggestive, suggestive, weak, or non-significant, using a standardized classification. Quality analyses used the Assessment of Multiple Systematic Reviews (AMSTAR) tool. The umbrella review included 110 meta-analyses or systematic reviews corresponding to 3892 individual studies, 1478 biomarkers, and 392 210 participants. No factor showed a convincing level of evidence. Highly suggestive evidence was observed for transglutaminase autoantibodies levels (odds ratio [OR] = 7.32; 95% CI: 3.36, 15.94), mismatch negativity in auditory event-related potentials (standardized mean difference [SMD] = 0.73; 95% CI: 0.5, 0.96), P300 component latency (SMD = -0.6; 95% CI: -0.83, -0.38), ventricle-brain ratio (SMD = 0.61; 95% CI: 0.5, 0.71), and minor physical anomalies (SMD = 0.99; 95% CI: 0.64, 1.34). Suggestive evidence was observed for folate, malondialdehyde, brain-derived neurotrophic factor, homocysteine, P50 sensory gating (P50 S2/S1 ratio), frontal N -acetyl-aspartate, and high-frequency heart rate variability. Among the remaining biomarkers, weak evidence was found for 626 and a non-significant association for 833 factors. While several biomarkers present highly suggestive or suggestive evidence of association with psychotic disorders, methodological biases, and underpowered studies call for future higher-quality research.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MYC, there is more to it than cancer

  • Zacarías-Fluck, Mariano F.|||0000-0002-7171-4268
  • Soucek, Laura|||0000-0002-4750-7971
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
MYC is a pleiotropic transcription factor involved in multiple cellular processes. While its mechanism of action and targets are not completely elucidated, it has a fundamental role in cellular proliferation, differentiation, metabolism, ribogenesis, and bone and vascular development. Over 4 decades of research and some 10,000 publications linking it to tumorigenesis (by searching PubMed for "MYC oncogene") have led to MYC becoming a most-wanted target for the treatment of cancer, where many of MYC's physiological functions become co-opted for tumour initiation and maintenance. In this context, an abundance of reviews describes strategies for potentially targeting MYC in the oncology field. However, its multiple roles in different aspects of cellular biology suggest that it may also play a role in many additional diseases, and other publications are indeed linking MYC to pathologies beyond cancer. Here, we review these physiological functions and the current literature linking MYC to non-oncological diseases. The intense efforts towards developing MYC inhibitors as a cancer therapy will potentially have huge implications for the treatment of other diseases. In addition, with a complementary approach, we discuss some diseases and conditions where MYC appears to play a protective role and hence its increased expression or activation could be therapeutic.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic value of single-subject grey matter networks in early multiple sclerosis

  • Fleischer, Vinzenz
  • González-Escamilla, Gabriel|||0000-0002-7209-1736
  • Pareto, Deborah|||0000-0001-7356-3769
  • Rovira, Alex|||0000-0002-2132-6750
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Høgestøl, Einar A.|||0000-0001-8446-2111
  • Harbo, Hanne F.
  • Bellenberg, Barbara|||0000-0001-7484-6787
  • Ruggieri, Serena|||0000-0001-5287-3290
  • Gasperini, Claudio|||0000-0002-3959-4067
  • Uher, Tomas|||0000-0003-3160-9022
  • Vaneckova, Manuela|||0000-0002-8784-7997
  • Bittner, Stefan|||0000-0003-2179-3655
  • Othman, Ahmed E.
  • Collorone, Sara|||0000-0003-1506-8983
  • Toosy, Ahmed T.|||0000-0002-4441-3750
  • Meuth, Sven G.
  • Zipp, Frauke|||0000-0002-1231-1928
  • Barkhof, Frederik|||0000-0003-3543-3706
  • Ciccarelli, Olga|||0000-0001-7485-1367
  • Groppa, Sergiu|||0000-0002-2551-5655
The identification of prognostic markers in early multiple sclerosis (MS) is challenging and requires reliable measures that robustly predict future disease trajectories. Ideally, such measures should make inferences at the individual level to inform clinical decisions. This study investigated the prognostic value of longitudinal structural networks to predict 5-year Expanded Disability Status Scale (EDSS) progression in patients with relapsing-remitting MS (RRMS). We hypothesized that network measures, derived from MRI, outperform conventional MRI measurements at identifying patients at risk of developing disability progression. This longitudinal, multicentre study within the Magnetic Resonance Imaging in MS (MAGNIMS) network included 406 patients with RRMS (mean age = 35.7 ± 9.1 years) followed up for 5 years (mean follow-up = 5.0 ± 0.6 years). EDSS was determined to track disability accumulation. A group of 153 healthy subjects (mean age = 35.0 ± 10.1 years) with longitudinal MRI served as controls. All subjects underwent MRI at baseline and again 1 year after baseline. Grey matter atrophy over 1 year and white matter lesion load were determined. A single-subject brain network was reconstructed from T1-weighted scans based on grey matter atrophy measures derived from a statistical parameter mapping-based segmentation pipeline. Key topological measures, including network degree, global efficiency and transitivity, were calculated at single-subject level to quantify network properties related to EDSS progression. Areas under receiver operator characteristic (ROC) curves were constructed for grey matter atrophy and white matter lesion load, and the network measures and comparisons between ROC curves were conducted. The applied network analyses differentiated patients with RRMS who experience EDSS progression over 5 years through lower values for network degree [H(2) = 30.0, P < 0.001] and global efficiency [H(2) = 31.3, P < 0.001] from healthy controls but also from patients without progression. For transitivity, the comparisons showed no difference between the groups [H(2) = 1.5, P = 0.474]. Most notably, changes in network degree and global efficiency were detected independent of disease activity in the first year. The described network reorganization in patients experiencing EDSS progression was evident in the absence of grey matter atrophy. Network degree and global efficiency measurements demonstrated superiority of network measures in the ROC analyses over grey matter atrophy and white matter lesion load in predicting EDSS worsening (all P -values < 0.05). Our findings provide evidence that grey matter network reorganization over 1 year discloses relevant information about subsequent clinical worsening in RRMS. Early grey matter restructuring towards lower network efficiency predicts disability accumulation and outperforms conventional MRI predictors. Fleischer et al. examine the prognostic value of brain networks derived from MRI for predicting disability progression in patients with multiple sclerosis. They conclude that early brain network alterations identify clinical deterioration in multiple sclerosis and outperform classical MRI predictors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice

  • Verberk, I.M.W.
  • Jutte, J.
  • Kingma, M.Y.
  • Vigneswaran, S.
  • Gouda, M.M.T.E.E.
  • van Engelen, M.P.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Chevalier, C.
  • Marizzoni, M.
  • van de Giessen, E.M.
  • Lemstra, A.W.
  • Pijnenburg, Y.A.L.
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • den Braber, A.
  • Wilson, D.
  • Schut, M.C.
  • van Harten, A.C.
  • Teunissen, C.E.
INTRODUCTION: We developed a multimarker blood test result interpretation tool for the clinical dementia practice, including phosphorylated (P-)tau181, amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). METHODS: We measured the plasma biomarkers with Simoa (n = 1199), applied LASSO regression for biomarker selection and receiver operating characteristics (ROC) analyses to determine diagnostic accuracy. We validated our findings in two independent cohorts and constructed a visualization approach. RESULTS: P-tau181, GFAP, and NfL were selected. This combination had area under the curve (AUC) = 83% to identify amyloid positivity in pre-dementia stages, AUC = 87%-89% to differentiate Alzheimer's or controls from frontotemporal dementia, AUC = 74%-76% to differentiate Alzheimer's or controls from dementia with Lewy bodies. Highly reproducible AUCs were obtained in independent cohorts. The resulting visualization tool includes UpSet plots to visualize the stand-alone biomarker results and density plots to visualize the biomarker results combined. DISCUSSION: Our multimarker blood test interpretation tool is ready for testing in real-world clinical dementia settings. Highlights: We developed a multimarker blood test interpretation tool for clinical dementia practice. Our interpretation tool includes plasma biomarkers P-tau, GFAP, and NfL. Our tool is particularly useful for Alzheimer's and frontotemporal dementia diagnosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CD66b+/CD68+ circulating extracellular vesicles, lactate dehydrogenase and neutrophil-to-lymphocyte ratio can differentiate coronavirus disease 2019 severity during and after infection

  • Suades, Rosa|||0000-0002-0193-3115
  • Greco, M.F.|||0000-0003-3613-5516
  • Prieto, P.
  • Padró, Teresa|||0000-0003-1921-954X
  • Devaux, Yvan|||0000-0002-5321-8543
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Badimon, Lina|||0000-0002-9162-2459
Coronavirus disease 2019 (COVID-19) has been a major public health burden. We hypothesised that circulating extracellular vesicles (cEVs), key players in health and disease, could trace the cell changes during COVID-19 infection and recovery. Therefore, we studied the temporal trend of cEV and inflammatory marker levels in plasma samples of COVID-19 patients that were collected within 24 h of patient admission (baseline, n = 80) and after hospital discharge at day-90 post-admission (n = 59). Inflammatory markers were measured by standard biochemical methods. cEVs were quantitatively and phenotypically characterized by high-sensitivity nano flow cytometry. In patients recovered from COVID-19 lower levels of inflammatory markers were detected. cEVs from vascular (endothelial cells) and blood (platelets, distinct immune subsets) cells were significantly reduced at day-90 compared to admission levels, a pattern also observed for cEVs from progenitor, perivascular and epithelial cells. The best discriminatory power for COVID-19 severity was found for inflammatory markers lactate dehydrogenase and neutrophil-to-lymphocyte ratio and for granulocyte/macrophage-released CD66b/CD68-cEVs. Albeit inflammatory markers were good indicators of systemic inflammatory response and discriminators of COVID-19 remission, they do not completely reveal cell stress and organ damage states. cEVs reaching baseline pre-infection levels at 90 days post-infection in recovered patients discriminate parental cells affected by disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SpadaHC, a database to improve the classification of variants in hereditary cancer genes in the Spanish population

  • Moreno-Cabrera, José Marcos|||0000-0001-8570-0345
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Pineda, Marta|||0000-0002-5403-5845
  • Prada Dacasa, Patricia|||0000-0003-0689-9072
  • Ramos-Muntada, Mireia|||0000-0002-5531-1442
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Brunet, Joan|||0000-0003-1945-3512
  • Gel, Bernat|||0000-0001-8878-349X
  • Currás-Freixes, M.
  • Calsina Pla Giribert, Bruna|||0000-0002-6922-9415
  • Salazar-Hidalgo, Milton E.
  • Rodríguez-Balada, M.
  • Roig, Bàrbara
  • Fernández-Castillejo, Sara|||0000-0002-8109-9713
  • Durán, Mercedes|||0000-0002-6301-9732
  • Arranz Ledo, Mónica
  • Infante, Mar
  • Castillejo Castillo, Adela|||0000-0002-9581-6285
  • Dámaso, Estela|||0000-0002-9650-7791
  • Soto, José Luis
  • de Miguel, Montserrat
  • Hidalgo Calero, Beatriz
  • Sánchez-Zapardiel, José M.
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Lasa, Adriana|||0000-0001-9957-9646
  • Gisbert-Beamud, Alexandra|||0000-0001-6515-3081
  • López Novo, Anael
  • Ruiz-Ponte, C.
  • Potrony, Miriam|||0000-0003-2766-0765
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Osorio, Ana|||0000-0001-8124-3984
  • Lorda Sánchez, Isabel
  • Robledo, Mercedes|||0000-0001-6256-5902
  • Cascón, Alberto|||0000-0003-2119-891X
  • Ruiz, Anna|||0000-0001-7314-5962
  • Spataro, Nino|||0000-0002-2127-2238
  • Hernán Sendra, Imma
  • Borràs, Emma
  • Moles-Fernández, Alejandro|||0000-0003-0252-6084
  • Earl, Julie
  • Cadiñanos, J.
  • Sánchez-Heras, Ana Beatriz|||0000-0003-1742-5374
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Capella, Gabriel|||0000-0002-4669-7320
  • Lázaro, C.
Accurate classification of genetic variants is crucial for clinical decision-making in hereditary cancer. In Spain, genetic diagnostic laboratories have traditionally approached this task independently due to the lack of a dedicated resource. Here we present SpadaHC, a web-based database for sharing variants in hereditary cancer genes in the Spanish population. SpadaHC is implemented using a three-tier architecture consisting of a relational database, a web tool and a bioinformatics pipeline. Contributing laboratories can share variant classifications and variants from individuals in Variant Calling Format (VCF) format. The platform supports open and restricted access, flexible dataset submissions, automatic pseudo-anonymization, VCF quality control, variant normalization and liftover between genome builds. Users can flexibly explore and search data, receive automatic discrepancy notifications and access SpadaHC population frequencies based on many criteria. In February 2024, SpadaHC included 18 laboratory members, storing 1.17 million variants from 4306 patients and 16 343 laboratory classifications. In the first analysis of the shared data, we identified 84 genetic variants with clinically relevant discrepancies in their classifications and addressed them through a three-phase resolution strategy. This work highlights the importance of data sharing to promote consistency in variant classifications among laboratories, so patients and family members can benefit from more accurate clinical management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hypoxia Increases Nitric Oxide-Dependent Inhibition of Angiogenic Growth

  • Arce, Cristina
  • Vicente, Diana
  • Monto, Fermí
  • González, Laura
  • Nuñez, Cristina
  • Victor, Victor Manuel|||0000-0002-3027-3945
  • Jiménez Altayó, Francesc|||0000-0002-9034-2041
  • D'Ocon, Pilar|||0000-0001-8544-7124
Nitric oxide (NO) is a proangiogenic factor acting through the soluble guanylate cyclase (sGC) pathway. However, angiogenic growth increases energy demand, which may be hampered by NO inhibition of cytochrome c oxidase (CcO). Then, NO activity would be the balanced result of sGC activation (pro-angiogenic) and CcO inhibition (anti-angiogenic). NO activity in a rat and eNOS mice aortic ring angiogenic model and in a tube formation assay (human aortic endothelial cells) were analyzed in parallel with mitochondrial O consumption. Studies were performed with NO donor (DETA-NO), sGC inhibitor (ODQ), and NOS or nNOS inhibitors (L-NAME or SMTC, respectively). Experiments were performed under different O concentrations (0-21%). Key findings were: (i) eNOS-derived NO inhibits angiogenic growth by a mechanism independent on sGC pathway and related to inhibition of mitochondrial O consumption; (ii) NO inhibition of the angiogenic growth is more evident in hypoxic vessels; (iii) in the absence of eNOS-derived NO, the modulation of angiogenic growth, related to hypoxia, disappears. Therefore, NO, but not lower O levels, decreases the angiogenic response in hypoxia through competitive inhibition of CcO. This anti-angiogenic activity could be a promising target to impair pathological angiogenesis in hypoxic conditions, as it occurs in tumors or ischemic diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biomarkers of Frailty in Patients with Advanced Chronic Liver Disease Undergoing a Multifactorial Intervention Consisting of Home Exercise, Branched-Chain Amino Acids, and Probiotics

  • Laghi, Luca|||0000-0003-1593-7376
  • Ortiz, M. Àngels|||0000-0002-1574-9861
  • Rossi, Giacomo|||0000-0001-8617-5984
  • Roman, Eva|||0000-0001-9084-8555
  • Mengucci, C.|||0000-0003-0602-3003
  • Cantó, Elisabet|||0000-0002-1782-1855
  • Biagini, L.|||0000-0001-5990-1514
  • Sánchez, Elisabet|||0000-0002-3280-9301
  • Mulet Gual, Maria|||0000-0003-3639-3291
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Urgell, Eulàlia|||0000-0003-3519-1022
  • Kaur Gill, Naujot|||0009-0007-4184-0398
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Padros i Valls, Josep
  • Nadal, Mª Josepa|||0000-0002-6700-057X
  • Cuyàs, Berta|||0000-0001-9988-7163
  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Vidal, Silvia|||0000-0002-3909-6682
  • Juanes Borego, Elena|||0000-0001-8910-2123
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Escorsell, Àngels|||0000-0001-5083-8467
  • Soriano, German|||0000-0002-9267-6811
Frailty in cirrhosis or advanced chronic liver disease (ACLD) is a relevant prognostic factor. In the present study, we aimed to analyze potential biomarkers associated with frailty and its improvement in patients with ACLD. We analyzed the serum of outpatients with ACLD who participated in a previous study (Román, Hepatol Commun 2024) in which frailty was assessed using the liver frailty index (LFI), and patients who were frail or prefrail were randomized to a multifactorial intervention (home exercise, branched-chain amino acids, and probiotics) or control for 12 months. We determined a biomarker battery of inflammation, bacterial translocation, and liver damage in blood and urine and blood metabolomics by H-NMR. Thirty-seven patients were included. According to the LFI, 32 patients were frail or prefrail, and 5 were robust. At baseline, LFI correlated with LBP, sCD163, mtDNA, FGF-21, urinary NGAL, urinary claudin-3, and the metabolites mannose, ethanol, and isoleucine. During the study, patients in the intervention group showed an improvement in LFI and a decrease in CRP, LBP, sCD163, and ccK18 compared to the control group. Metabolomics showed a decrease in dimethyl sulfone and creatinine and an increase in malonate, ornithine, isoleucine, and valine in the intervention group. We conclude that frailty in patients with ACLD is associated with biomarkers of systemic inflammation, bacterial translocation, and liver damage, and alterations of amino acid and short-chain fatty acid metabolism.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Contextual-compassion training for borderline personality disorder with long lasting symptoms, A randomized clinical trial

  • Casellas Pujol, Elisabet|||0000-0001-8496-0719
  • Soler, Joaquim|||0000-0001-8077-3641
  • Schmidt, C.
  • Soria-Madrid, A.
  • Elices, M.|||0000-0002-7034-4242
  • Pascual, J.C.
Long-term follow-up studies have shown that the symptoms of borderline personality disorder (BPD) tend to remit over time. However, many patients present long lasting symptoms (LLS), including low mood, emptiness, and persistent impairment in psychosocial adjustment. Given the high rate of LLS in BPD patients, new treatment strategies are needed. We conducted a randomized clinical trial (RCT) to evaluate the efficacy of a novel intervention that combines self-compassion and contextual-based skills for patients with persistent symptoms. Sixty BPD individuals with LLS who had received dialectical behavior therapy skills training (DBT-ST) in the previous six months were recruited and randomized to receive the experimental intervention or treatment as usual (TAU) for 12 weeks. All participants were evaluated pre- and post-intervention and at 3-months follow-up. The primary outcome measure was self-reported well-being. Other clinical variables were also evaluated, including depressive symptoms, BPD symptoms, functionality, self-compassion, and self-criticism. Participants in the experimental arm showed a significant increase in indicators of well-being (e.g., happiness and quality of life) and a significant decrease in depressive symptoms. These results were sustained-and even continued to improve-at the three-month follow-up. No significant changes were observed in BPD severity, self-criticism, or self-compassion. More RCTs are needed to test the efficacy of new interventions targeting this population with persistent symptoms, not only to reduce symptoms but also to promote well-being and personal recovery.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Atherogenic circulating lipoproteins in ischemic stroke

  • Benitez, Sonia|||0000-0003-3565-0743
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
The fundamental role of qualitative alterations of lipoproteins in the early development of atherosclerosis has been widely demonstrated. Modified low-density lipoproteins (LDL), such as oxidized LDL (oxLDL), small dense LDL (sdLDL), and electronegative LDL [LDL(-)], are capable of triggering the atherogenic process, favoring the subendothelial accumulation of cholesterol and promoting inflammatory, proliferative, and apoptotic processes characteristic of atherosclerotic lesions. In contrast, high-density lipoprotein (HDL) prevents and/or reverses these atherogenic effects. However, LDL's atherogenic and HDL's anti-atherogenic actions may result altered in certain pathological conditions. The molecular mechanisms underlying the impaired effects of altered lipoproteins have been studied in numerous in vitro and in vivo studies, and have been extensively analyzed in coronary atherosclerosis, especially in the context of pathologies such as dyslipidemia, diabetes, obesity, and metabolic syndrome. However, the corresponding studies are scarcer in the field of ischemic stroke, despite carotid arteriosclerosis progression underlies at least 20% of ischemic strokes. The present review relates qualitative alterations of LDL and HDL with the development of carotid arteriosclerosis and the occurrence of ischemic stroke.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of Immune Cell Populations and Acid-Sensing Receptors in the Human Esophagus

  • Fortea, Marina|||0000-0001-8885-7495
  • Hacour, Leen
  • Sancho, Francesc
  • Boada, Carlos
  • Sevillano-Aguilera, Cesar
  • González Castro, Ana Maria|||0000-0003-3955-3318
  • Salvo-Romero, Eloisa|||0000-0002-7187-8131
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Guagnozzi, Danila|||0000-0002-6171-1901
  • Ceulemans, Laurens J.
  • Pirenne, Jacques
  • Alonso Cotoner, Carmen|||0000-0002-3483-2919
  • Santos, Javier|||0000-0002-4798-5033
  • Farré, Ricard|||0000-0001-7158-171X
  • Vicario Perez, Maria|||0000-0001-9622-3185
Introduction: Esophageal inflammatory diseases are frequent diagnoses in clinical practice and have diverse etiologies, the most common being those associated with the exposure to gastric content, drugs and allergens. In diseases, the immunological component is well identified in endoscopic biopsies, which mainly contain the epithelium and the lamina propria; however, deeper layers are less studied. Moreover, the esophageal capacity of sensing luminal compounds is poorly understood. Methods: In transmural sections from proximal, middle and distal esophagus obtained from deceased patients, we performed a phenotypic analysis of the main immune cell populations and acid-sensing receptors by immunohistochemistry and immunofluorescence methods. Results: A total of nine donors were studied (absence of pathology, optimal tissue preservation and orientation). We found the following: (1) the vascular papillae and the lamina propria are the most infiltrated layers by the lymphoid lineage (T and B lymphocytes), followed by the epithelium, while the smooth muscular layers are mainly populated by the myeloid lineage (macrophages and mast cells); (2) intraepithelial macrophages are consistently found along the esophagus; and (3) eosinophils are absent in all the esophageal layers. The acid-sensing receptors ASIC-1, ASIC-2 and δENAC are expressed in the esophageal epithelium and in the lamina propria, yet only ASIC-2 is expressed in the muscularis mucosae. Conclusions: The human esophagus contains a differential distribution of immune cells and acid-sensing receptors across its layers. This study extends the esophageal histological knowledge previously described and reinforces its role as a defensive and sensing organ.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinic

  • Cano, Amanda|||0000-0001-9567-4283
  • Capdevila, María
  • Puerta, Raquel|||0000-0002-1191-5893
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • García-González, Pablo|||0000-0003-0125-5403
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • García-Gutiérrez, Fernando
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Aguilera, Nuria
  • Ramis, Maribel
  • Rosende-Roca, Maite
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Tartari, Juan Pablo
  • Lafuente, Asunción
  • Vargas, Liliana|||0000-0001-5685-5903
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Muñoz, Nathalia
  • Sanabria, Ángela|||0000-0002-7501-9895
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Morató, Xavier|||0000-0002-3012-2864
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Fernández, Victoria
  • Marquié, Marta|||0000-0002-0660-0950
  • Valero, Sergi|||0000-0002-6599-948X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
The identification of patients with an elevated risk of developing Alzheimer's disease (AD) dementia and eligible for the disease-modifying treatments (DMTs) in the earliest stages is one of the greatest challenges in the clinical practice. Plasma biomarkers has the potential to predict these issues, but further research is still needed to translate them to clinical practice. Here we evaluated the clinical applicability of plasma pTau181 as a predictive marker of AD pathology in a large real-world cohort of a memory clinic. Methods: Three independent cohorts (modelling [n = 991, 59.7% female], testing [n = 642, 56.2% female] and validation [n = 441, 55.1% female]) of real-world patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD dementia, and other dementias were included. Paired cerebrospinal fluid (CSF) and plasma samples were used to measure AT(N) CSF biomarkers and plasma pTau181. CSF and plasma pTau181 showed correlation in all phenotypes except in SCD and other dementias. Age significantly influenced the biomarker's performance. The general Aβ(+) vs Aβ(-) ROC curve showed an AUC = 0.77 [0.74-0.80], whereas the specific ROC curve of MCI due to AD vs non-AD MCI showed an AUC = 0.89 [0.85-0.93]. A cut-off value of 1.30 pg/ml of plasma pTau181 exhibited a sensitivity of 93.57% [88.72-96.52], specificity of 72.38% [62.51-79.01], VPP of 77.85% [70.61-83.54], and 8.30% false negatives in the subjects with MCI of the testing cohort. The HR of cox regression showed that patients with MCI up to this cut-off value exhibited a HR = 1.84 [1.05-3.22] higher risk to convert to AD dementia than patients with MCI below the cut-off value. Plasma pTau181 has the potential to be used in the memory clinics as a screening biomarker of AD pathology in subjects with MCI, presenting a valuable prognostic utility in predicting the MCI conversion to AD dementia. In the context of a real-world population, a confirmatory test employing gold-standard procedures is still advisable. This study has been mainly funded by Ace Alzheimer Center Barcelona, Instituto de Salud Carlos III (ISCIII), Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Spanish Ministry of Science and Innovation, Fundación ADEY, Fundación Echevarne and Grífols S.A.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Delabelling beta-lactam allergy

  • Molina-Molina, Gustavo-Jorge|||0000-0002-3577-8512
  • Garnica Velandia, Diana Rocío|||0000-0001-7933-8001
  • Andrés-López, Blanca
  • Perales, Carolina
  • Marin-Asensio, Laura
  • Jurgens, Yanina
  • Esteso, Olga
  • Escobar Bolaños, Carolina|||0000-0002-1024-7854
  • Vidal Guitart, Xavier|||0000-0001-6705-4298
  • Vendrell Bosch, Lourdes
  • Gómez-Ganda, Laura|||0000-0003-2441-8607
  • Rodríguez Cumplido, Dolores|||0000-0001-5588-7153
  • Montané Esteva, Eva|||0000-0002-1691-7652
  • Cardona, Victoria|||0000-0003-2197-9767
  • Agustí Escasany, M. Antònia|||0000-0003-4594-1122
Background: Hypersensitivity to beta-lactam (BL) antibiotics is one of the most frequent reported drug allergies. In our population, it is common to find labels of BL allergy in electronic medical records (EMRs) that have not been assessed. The objective of our study was to detect patients with beta-lactam allergy labels in their EMRs and to assess how many of them are false after a correct diagnostic evaluation. Methods: A multicentre prospective study was performed with patients labelled as allergic to BLs in their EMRs in the previous 5 years. Demographical and clinical data, as well as variables regarding the BL allergy label and the characteristics of the index reaction from clinical history and EMRs, were recorded. Then, diagnostic assessments including clinical history, skin tests (STs), and drug provocation tests (DPTs) were conducted in order to confirm or exclude the diagnosis of BL allergy. Results: A total of 249 patients completed the study, of which 160 (64.3%) were women with a median age of 57 years (interquartile range [IQR], 45-68). The most frequent BL allergy labels detected were for penicillin (124), amoxicillin/clavulanic acid (61), and amoxicillin (54). Of the 204 patients who underwent STs, 20.1% were positive. DPTs were performed in 224 patients, showing good tolerance in 87.1% of cases. After the allergy diagnosis work-up, 186 patients (74.7%) were diagnosed as non-allergic to BL antibiotics. Conclusion: In our study population, the number of patients labelled as allergic to BLs in their EMRs was similar to that in previously published studies, with proportions near to 75%-80% being falsely labelled as allergic to BLs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability

  • Therriault, J.
  • Janelidze, S.
  • Benedet, A.L.
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Gonzalez-Escalante, A.
  • Bellaver, B.|||0000-0002-2212-3373
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Vrillon, A.
  • Karim, H.
  • Mielke, M.M.
  • Hyung Hong, C.
  • Roh, H.W.
  • Contador, José
  • Puig Pijoan, A.
  • Algeciras-Schimnich, A.
  • Vemuri, P.|||0000-0003-4286-0589
  • Graff-Radford, J.
  • Lowe, V.J.
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Jonaitis, E.
  • Brum, W.
  • Tissot, C.
  • Servaes, S.
  • Rahmouni, N.
  • Macedo, A.C.
  • Stevenson, J.
  • Fernandez-Arias, J.
  • Wang, Y.T.
  • Woo, M.S.
  • Friese, M.A.|||0000-0001-6380-2420
  • Jia, W.L.
  • Dumurgier, J.
  • Hourregue, C.
  • Cognat, E.
  • Ferreira, P.L.
  • Vitali, P.|||0000-0001-8953-1542
  • Johnson, S.
  • Pascoal, Tharick|||0000-0001-9057-8014
  • Gauthier, S.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Paquet, C.
  • Petersen, R.C.
  • Salmon, D.
  • Mattsson-Carlgren, N.
  • Palmqvist, S.
  • Stomrud, E.
  • Galasko, D.
  • Son, S.J.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Fortea, Juan|||0000-0002-1340-638X
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Jack Jr, Clifford R.|||0000-0001-7916-622X
  • Blennow, Kaj|||0000-0002-1890-4193
  • Hansson, Oskar|||0000-0001-8467-7286
  • Rosa-Neto, P.
Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce the need for PET or CSF testing; however, their interpretation at the individual level and the circumstances requiring confirmatory testing are poorly understood. Individual-level interpretation of diagnostic test results requires knowledge of disease prevalence in relation to clinical presentation (clinical pretest probability). Here, in a study of 6,896 individuals evaluated from 11 cohort studies from six countries, we determined the positive and negative predictive value of five plasma biomarkers for amyloid-β pathology in cognitively impaired individuals in relation to clinical pretest probability. We observed that p-tau217 could rule in amyloid-β pathology in individuals with probable AD dementia (positive predictive value above 95%). In mild cognitive impairment, p-tau217 interpretation depended on patient age. Negative p-tau217 results could rule out amyloid-β pathology in individuals with non-AD dementia syndromes (negative predictive value between 90% and 99%). Our findings provide a framework for the individual-level interpretation of plasma biomarkers, suggesting that p-tau217 combined with clinical phenotyping can identify patients where amyloid-β pathology can be ruled in or out without the need for PET or CSF confirmatory testing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Blastocystis occurrence and subtype diversity in European wild boar (Sus scrofa) from the Iberian Peninsula

  • Köster, Pamela C.|||0000-0001-5963-8824
  • Figuereido, Ana M.
  • Maloney, Jenny G.|||0000-0002-6405-883X
  • Dashti, Alejandro|||0000-0001-8707-5731
  • Bailo, Begoña|||0000-0002-9453-9431
  • Tinoco Torres, Rita|||0000-0003-4570-459X
  • Fonseca, Carlos|||0000-0001-6559-7133
  • Mysterud, Atle|||0000-0001-8993-7382
  • Habela, Miguel Ángel
  • Rivero-Juarez, Antonio|||0000-0002-5813-6889
  • Vicente, Joaquín|||0000-0001-8416-3672
  • Serrano Ferron, Emmanuel|||0000-0002-9799-9804
  • Arnal, Maria C.|||0000-0002-6770-3400
  • Fernández de Luco, Daniel|||0000-0003-3289-4267
  • Armenteros, José A.|||0000-0001-8776-1299
  • Balseiro, Ana|||0000-0002-5121-7264
  • Cardona, Guillermo A.|||0000-0002-4156-4174
  • Carvalho, João|||0000-0002-3166-450X
  • Hipólito, Dário|||0000-0002-2985-1314
  • Fernandes, Joana M.|||0000-0001-5602-1490
  • Palmeira, Josman Dantas
  • Calero-Bernal, Rafael|||0000-0003-2323-0135
  • González-Barrio, David|||0000-0001-5083-8854
  • Santín, Mónica
  • Carmena, David|||0000-0002-4015-8553
The ongoing increase in wild boar populations across Europe has fostered human-wildlife conflicts, including the transmission of emerging pathogens with zoonotic importance. Blastocystis is a ubiquitous, faecal-oral transmitted protist that can cause gastrointestinal illnesses and is observed in humans and animals worldwide. The role of wildlife in the epidemiology of Blastocystis is insufficiently understood. Thus, we investigated the occurrence and subtype diversity of Blastocystis in free-ranging wild boars from the Iberian Peninsula using conventional PCR and next-generation amplicon sequencing of a fragment of the ssu RNA gene. A total of 459 wild boar faecal samples were collected across Spain (n = 360) and Portugal (n = 99) between 2014 and 2021. Blastocystis was present in 15.3% (70/459; 95% CI 12.1-18.9) of the wild boars analysed, and its occurrence was significantly higher in Portugal (34.3%, 34/99; 95% CI 25.1-44.6) than in Spain (10.0%, 36/360; 95% CI 7.1-13.6). Seven Blastocystis subtypes (ST5, ST10b, ST13-ST15, ST24b, and ST43) were detected among the surveyed wild boar populations, with greater variability detected in Portuguese samples. ST5 was identified in all the Blastocystis-positive animals, whereas 14.3% of them harboured ST mixed colonisations. Our results demonstrate that Blastocystis ST5 is particularly adapted to infect wild boars. The additional identification of zoonotic STs reinforces the role of wild boars as spreaders of zoonotic infections with public health significance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cardiovascular risk assessment in women at high risk for pre-eclampsia in first half of pregnancy

  • Ullmo, Johana|||0000-0002-9313-917X
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Bos-Real, L.|||0000-0002-6159-0644
  • Padilla-Lopez, Mireia|||0000-0002-4374-3870
  • Coma-Barbarà, Marina
  • Martorell, Silvia
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Llurba, Elisa|||0000-0003-4048-6407
Background: Women diagnosed with pre-eclampsia (PE), especially those with early-onset and severe forms, are at heightened risk of future cardiovascular disease (CVD). It is uncertain if women at high-risk for PE present cardiovascular impairment at the beginning of pregnancy. The aim of this study was to assess cardiovascular biomarkers and cardiac function in the first half of pregnancy in women at high-risk for PE. Methods: This was a prospective cohort study including women attending first trimester screening for PE. Risk of PE in the first trimester was calculated using a previously validated model, which includes maternal factors and biophysical markers. A cut-off of 1 in 250 was used to classify high-risk for developing PE. Maternal echocardiographic function and morphometry were evaluated, and peripheral blood samples were obtained to assess hematological and biochemical variables, including lipid profile and cardiovascular and angiogenic factors. Results: A total of 349 pregnant individuals were included; 257 at high-risk and 92 at low-risk for PE. Maternal echocardiography was performed at a mean ± SD gestational age of 14.9 ± 1.3 weeks and blood sampling at 16.3 ± 1.9 weeks. The high-risk PE group exhibited a significantly worse lipid profile (lower levels of high-density lipoproteins 69.7 ± 14.2 vs 74.0 ± 14.6 mg/dL, p=0.020), lower placental growth factor (0.89 ± 0.63 vs 1.15 ± 0.58 MoM, p<0.001), and significantly lower levels of N-terminal pro-brain natriuretic peptide (51.0 ± 2.1 vs 52.1 ± 2.0 ng/L, p=0.008). Echocardiographic evaluation indicated concentric remodeling, along with an altered diastolic pattern in the high-risk group. Conclusions: Women at high risk of developing PE exhibit differences in lipid profile, angiogenic factors, and echocardiographic parameters, indicative of cardiac maladaptation or impairment during the first half of pregnancy. These findings suggest a link between subclinical cardiovascular dysfunction, PE development and later CVD risk.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

C-reactive protein-complement factor H axis as a biomarker of activity in early and intermediate age-related macular degeneration

  • Giralt, Lena
  • Figueras-Roca, Marc|||0000-0002-0548-0539
  • Eguileor, Beatriz De Luis
  • Romero, Barbara
  • Zarranz-Ventura, Javier|||0000-0003-2338-8143
  • Alforja, Socorro
  • Santiago, Francisca
  • Bolaños, Jennifer
  • Lozano, Francisco
  • Dotti-Boada, Marina
  • Sala-Puigdollers, Anna
  • Dura, Paula
  • Izquierdo-Serra, Jordi
  • Valero, Oliver|||0000-0003-0014-9916
  • Adan Civera, Alfredo|||0000-0002-0849-8814
  • Fonollosa, Alex
  • Molins, Blanca|||0000-0003-0941-9134
To determine and compare the serum levels of complement Factor H (FH), monomeric C-Reactive Protein (mCRP) and pentameric C-Reactive protein (pCRP) in patients with age-related macular degeneration (AMD) and to correlate them with clinical, structural and functional parameters. Cross-sectional observational study. One hundred thirty-nine individuals (88 patients and 51 healthy controls) from two referral centers were included and classified into three groups: early or intermediate AMD (n=33), advanced AMD (n=55), and age and sex matched healthy controls (n=51). Serum levels of FH, mCRP, and pCRP were determined and correlated with clinical and imaging parameters. Patients with intermediate AMD presented FH levels significantly lower than controls [186.5 (72.1-931.8) µg/mL vs 415.2 (106.1-1962.2) µg/mL; p=0.039] and FH levels <200 µg/mL were associated with the presence of drusen and pigmentary changes in the fundoscopy (p=0.002). While no differences were observed in pCRP and mCRP levels, and mCRP was only detected in less than 15% of the included participants, women had a significantly higher detection rate of mCRP than men (21.0% vs. 3.8%, p=0.045). In addition, the ratio mCRP/FH (log) was significantly lower in the control group compared to intermediate AMD (p=0.031). Visual acuity (p<0.001), macular volume (p<0.001), and foveal thickness (p=0.034) were significantly lower in the advanced AMD group, and choroidal thickness was significantly lower in advanced AMD compared to early/intermediate AMD (p=0.023). Intermediate AMD was associated in our cohort with decreased serum FH levels together with increased serum mCRP/FH ratio. All these objective serum biomarkers may suggest an underlying systemic inflammatory process in early/intermediate AMD patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Staniszewska, Anna D.
  • Domènech-Vivó, Joanna|||0000-0002-8049-7488
  • García-Galea, Eduardo|||0000-0003-4699-0786
  • Moles-Fernández, Alejandro|||0000-0003-0252-6084
  • Pedretti, Flaminia
  • Domènech, Heura
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Guzmán, Marta|||0000-0002-0924-9887
  • Arenas, Enrique
  • Verdaguer, Helena|||0000-0001-6163-382X
  • Calero-Nieto, Fernando|||0000-0003-3358-8253
  • Talbot, Sara
  • Tobalina, Luis
  • Leo, Elisabetta
  • Lau, Alan|||0000-0003-1055-9812
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Macarulla Mercadé, Teresa|||0000-0002-5856-4082
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Diez, Orland|||0000-0001-7339-0570
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Forment, Josep V.|||0000-0002-7797-2583
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Albertella, Mark Robert
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
Background: Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are targeted therapies approved for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Since inhibition of PARP1 is sufficient to cause synthetic lethality in tumors with homologous recombination deficiency (HRD), PARP1 selective inhibitors such as saruparib (AZD5305) are being developed. It is expected that selective PARP1 inhibition leads to a safer profile that facilitates its combination with other DNA damage repair inhibitors. Here, we aimed to characterize the antitumor activity of AZD5305 in patient-derived preclinical models compared to the first-generation PARP1/2 inhibitor olaparib and to identify mechanisms of resistance. Methods: Thirteen previously characterized patient-derived tumor xenograft (PDX) models from breast, ovarian, and pancreatic cancer patients harboring germline pathogenic alterations in BRCA1, BRCA2, or PALB2 were used to evaluate the efficacy of AZD5305 alone or in combination with carboplatin or an ataxia telangiectasia and Rad3 related (ATR) inhibitor (ceralasertib) and compared it to the first-generation PARPi olaparib. We performed DNA and RNA sequencing as well as protein-based assays to identify mechanisms of acquired resistance to either PARPi. Results: AZD5305 showed superior antitumor activity than the first-generation PARPi in terms of preclinical complete response rate (75% vs. 37%). The median preclinical progression-free survival was significantly longer in the AZD5305-treated group compared to the olaparib-treated group (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL

  • Rivas Delgado, Alfredo|||0000-0003-0385-3415
  • López, Cristina
  • Clot, Guillem|||0000-0003-2588-7413
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Grau Vorster, Marta|||0000-0003-3779-0387
  • Frigola, Gerard|||0000-0001-6794-6456
  • Bosch-Schips, Jan
  • Radke, Josefine
  • Ishaque, Naveed|||0000-0002-8426-901X
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Luizaga Velasco, Luis|||0000-0001-9314-5783
  • Barcena, Carmen
  • Kelleher, Nicholas|||0000-0003-4610-2718
  • Villamor, Neus|||0000-0001-6538-4111
  • Baumann, Tycho|||0000-0003-4421-0088
  • Muntañola, Ana|||0000-0001-7839-6648
  • Sancho-Cia, Juan M.
  • Martín García-Sancho, Alejandro|||0000-0001-6330-1028
  • González Barca, Eva|||0000-0002-1323-1508
  • Matutes, Estella|||0000-0001-6745-7046
  • Brito, Jordi A.
  • Karube, Kennosuke
  • Salaverria Frigola, Itziar|||0000-0002-2427-9822
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Wiemann, Stefan|||0000-0003-4683-3174
  • Heppner, Frank L.
  • Siebert, Reiner
  • Climent, Fina|||0000-0002-4360-8388
  • Campo, Elias|||0000-0001-9850-9793
  • Giné, Eva|||0000-0002-0532-1204
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Bea, Sílvia|||0000-0001-7192-2385
Testicular large B-cell lymphoma (TLBCL) is an infrequent and aggressive lymphoma arising in an immune-privileged site and has recently been recognized as a distinct entity from diffuse large B-cell lymphoma (DLBCL). We describe the genetic features of TLBCL and compare them with published series of nodal DLBCL and primary large B-cell lymphomas of the CNS (PCNSL). We collected 61 patients with TLBCL. We performed targeted next-generation sequencing, copy number arrays, and fluorescent in situ hybridization to assess chromosomal rearrangements in 40 cases with available material. Seventy percent of the cases showed localized stages. BCL6 rearrangements were detected in 36% of cases, and no concomitant BCL2 and MYC rearrangements were found. TLBCL had fewer copy number alterations (p < 0.04) but more somatic variants (p < 0.02) than nodal DLBCL and had more frequent 18q21.32-q23 (BCL2) gains and 6q and 9p21.3 (CDKN2A/B) deletions. PIM1, MYD88, CD79B, TBL1XR1, MEF2B, CIITA, EP300, and ETV6 mutations were more frequent in TLBCL, and BCL10 mutations in nodal DLBCL. There were no major genetic differences between TLBCL and PCNSL. Localized or disseminated TLBCL displayed similar genomic profiles. Using LymphGen, the majority of cases were classified as MCD. However, we observed a subgroup of patients classified as BN2, both in localized and disseminated TLBCL, suggesting a degree of genetic heterogeneity in the TLBCL genetic profile. TLBCL has a distinctive genetic profile similar to PCNSL, supporting its recognition as a separate entity from DLBCL and might provide information to devise targeted therapeutic approaches.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Amyloid deposition in adults with drug-resistant temporal lobe epilepsy

  • Fonseca, Elena|||0000-0002-3895-1237
  • Lallana, Sofía|||0000-0002-5999-9889
  • Ortega, Gemma
  • Cano, Amanda|||0000-0001-9567-4283
  • Sarria Estrada, Silvana|||0000-0003-0083-362X
  • Pareto, Deborah|||0000-0001-7356-3769
  • Quintana, Manuel|||0000-0003-0288-9088
  • Lorenzo Bosquet, Carles|||0000-0002-8824-4602
  • López Maza, Samuel|||0000-0003-3660-2604
  • Gifreu, Ariadna
  • Campos Fernández, Daniel|||0000-0003-4795-5309
  • Abraira del Fresno, Laura|||0000-0002-5119-7929
  • Santamarina Perez, Estevo|||0000-0003-1915-0335
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Puerta, Raquel|||0000-0002-1191-5893
  • Aguilera, Núria
  • Ramis, Maribel
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Rovira, Alex|||0000-0002-2132-6750
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Toledo, Manuel|||0000-0003-1550-3316
Objective: Pathological amyloid-β (Aβ) accumulation and hyperphosphorylated tau proteins have been described in resected temporal lobe specimens of epilepsy patients. We aimed to determine cerebrospinal fluid (CSF) Aβ1-42 and p181-tau levels and cerebral Aβ deposits on positron emission tomography (Aβ PET) and correlate these findings with cognitive performance in adults with drug-resistant temporal lobe epilepsy (TLE). Methods: In this cross-sectional study, we enrolled individuals with drug-resistant TLE who were 25-55 years old. Each participant underwent F-flutemetamol PET, determination of CSF Aβ1-42, p181-tau, and total tau, and a comprehensive neuropsychological assessment. We evaluated normalized standard uptake value ratios (SUVRs) for different brain regions on Aβ PET. Results: Thirty patients (mean age = 41.9 ± SD 8.1 years, 57% men) were included. The median disease duration was 9.5 (interquartile range = 4-24) years. Twenty-six patients (87%) had a clinically significant cognitive impairment on neuropsychological evaluation, 18 (69%) of the amnesic type. On Aβ PET, high uptake was observed in both mesial temporal regions (ipsilateral: SUVR z-score =.90, 95% confidence interval [CI] =.60-1.20; contralateral: SUVR z-score =.92, 95% CI =.57-1.27; p <.001), which was higher when compared to SUVR z-scores in all the remaining regions (p <.001) and in the ipsilateral anterior cingulate (SUVR z-score =.27, 95% CI =.04-.49, p =.020). No significant deposition was observed in other regions. Seven patients (23%) had low Aβ1-42 levels, and two (7%) had elevated p181-tau levels in CSF. Higher p181-tau levels correlated with poorer verbal fluency (R = -.427, p =.044). Significance: Our findings reveal a considerable Aβ deposition in mesial temporal regions and ipsilateral anterior cingulate among adults with drug-resistant TLE. Additionally, abnormal CSF Aβ1-42 levels were observed in a significant proportion of patients, and p181-tau levels were associated with verbal fluency. These results suggest that markers of neuronal damage can be observed in adults with TLE, warranting further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS

  • Carvajal, René|||0000-0003-3583-8412
  • Guananga-Álvarez, David
  • Tur, Carmen|||0000-0003-1849-3184
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Rodríguez Barranco, Marta|||0000-0001-5454-3041
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Borras Bermejo, Blanca|||0000-0003-4111-5632
  • Cobo-Calvo, Álvaro|||0000-0002-2574-0721
  • Carbonell-Mirabent, Pere|||0000-0003-1349-9261
  • Zules-Oña, Ricardo|||0000-0002-3648-4321
  • Rodrigo-Pendas, Jose Angel|||0000-0003-0400-8766
  • Martínez Gómez, Xavier|||0000-0003-4583-9734
  • Montalban, Xavier|||0000-0002-0098-9918
  • Tintoré, Mar|||0000-0001-9999-5359
  • Otero-Romero, Susana|||0000-0002-6798-568X
BACKGROUND AND OBJECTIVES: Hepatitis B vaccination (HBV) requires 6 months to complete and is recommended for patients with multiple sclerosis (PWMS), particularly those who are candidates for anti-CD20 therapy. However, limited data exist on HBV immunogenicity in PWMS receiving disease-modifying therapies (DMTs) and the impact of starting anti-CD20 therapy during immunization. We aimed to evaluate HBV immunogenicity in PWMS starting anti-CD20 therapy during vaccination, focusing on the number of doses received before anti-CD20 initiation. METHODS: We conducted a retrospective analysis of a prospective cohort of adult PWMS at a single center in Spain, from April 2015 to May 2023. Eligible participants completed a 4-dose HBV course and underwent postvaccination serologic testing. We assess seroprotection rates (SRs), defined as the percentage of patients achieving anti-hepatitis B surface antibody titers ≥10 IU/L, focusing on those who switched to anti-CD20 therapy during vaccination, based on doses received before starting anti-CD20 and type of DMT at vaccination start. A multivariate generalized linear model (GLM) was used to identify factors associated with higher seroconversion. RESULTS: A total of 289 PWMS (median [interquartile range (IQR)] age, 47.7 [42.8-54.4] years; 65.7% female; median [IQR] disease duration, 14.8 [6.7-21.2] years) were included. SRs progressively declined with fewer doses before anti-CD20 initiation, from 92.8% (95% CI 87.1-96.5) for 4 doses to 24.0% (95% CI 9.4-45.1) for 1 dose. Patients transitioning from sphingosine 1-phosphate (S1P) modulators showed the lowest SR at 25.0% (95% CI 7.3-52.4). The multivariate GLM confirmed these findings, with 3 doses (SR ratio 3.23 [95% CI 1.68-6.23]; p = 0.0005) or 4 doses (SR ratio 3.76 [95% CI 1.96-7.24]; p < 0.0001) before anti-CD20 therapy significantly associated with higher SRs, while starting S1P modulators at vaccination onset was significantly associated with lower SRs (SR ratio 0.42 [95% CI 0.23-0.78]; p = 0.0058). Female sex (SR ratio 1.15 [95% CI 1.01-1.32]; p = 0.0389) and younger age (SR ratio 0.90 [95% CI 0.83-0.97]; p = 0.0036) were also significantly associated with higher SRs. DISCUSSION: Initiating anti-CD20 therapy during HBV negatively affects SRs, with a direct correlation with the number of doses received before anti-CD20 initiation. Early planning and execution of required vaccinations are crucial in managing PWMS. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that HBV during initiation of anti-CD20 therapy is less effective in establishing seroprotection to hepatitis B than in patients in whom HBV is completed before initiation of anti-CD20 therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Primary Cilia as a Tumor Marker in Pituitary Neuroendocrine Tumors

  • Martínez-Hernández, Rebeca
  • Serrano-Somavilla, Ana
  • Fernández-Contreras, Raul
  • Sanchez-Guerrero, Cristina
  • Sánchez de la Blanca, Nuria
  • Sacristán-Gómez, Pedro
  • Sebastian-Valles, Fernando|||0000-0002-4127-0483
  • Sampedro Núñez, Miguel Antonio
  • Fraga, Javier
  • Calatayud, María|||0000-0002-6737-7289
  • Vicente, Almudena
  • García-de-Casasola, G.|||0000-0002-5171-7373
  • Sanz-García, Ancor
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Ruz-Caracuel, Ignacio|||0000-0002-2298-4683
  • Puig Domingo, Manuel|||0000-0002-6744-7195
  • Marazuela, Mónica|||0000-0003-1158-9618
Pituitary neuroendocrine tumors (PitNETs) account for approximately 15% of all intracranial neoplasms. Although they usually appear to be benign, some tumors display worse behavior, displaying rapid growth, invasion, refractoriness to treatment, and recurrence. Increasing evidence supports the role of primary cilia (PC) in regulating cancer development. Here, we showed that PC are significantly increased in PitNETs and are associated with increased tumor invasion and recurrence. Serial electron micrographs of PITNETs demonstrated different ciliation phenotypes (dot-like versus normal-like cilia) that represented PC at different stages of ciliogenesis. Molecular findings demonstrated that 123 ciliary-associated genes (eg, doublecortin domain containing protein 2, Sintaxin-3, and centriolar coiled-coil protein 110) were dysregulated in PitNETs, representing the upregulation of markers at different stages of intracellular ciliogenesis. Our results demonstrate, for the first time, that ciliogenesis is increased in PitNETs, suggesting that this process might be used as a potential target for therapy in the future.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A systematic review of cognitive behavioral therapy-based interventions for comorbid chronic pain and clinically relevant psychological distress

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Fernández-Vázquez, Óscar
  • Noboa-Rocamora, Georgina
  • Cardona-Ros, Gemma
  • McCracken, Lance M.|||0000-0002-9734-0153
  • Montes-Pérez, Antonio
  • Castaño Asins, Juan Ramon|||0000-0001-6571-503X
  • Edo Izquierdo, Sílvia|||0000-0002-6564-3475
  • Borràs, Xavier|||0000-0003-3972-1385
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Luciano, Juan Vicente|||0000-0003-0750-1599
Chronic pain frequently co-occurs with clinically relevant psychological distress. A systematic review was conducted to identify the efficacy of cognitive behavioral therapy-based interventions for patients with these comorbid conditions. The systematic search was carried out in Medline, PsycINFO, Web of Science, and Scopus up to March 18th, 2023. Four reviewers independently conducted screenings, extraction, and quality assessment. Twelve randomized controlled trials and one non-randomized controlled trial involving 1,661 participants that examined the efficacy of Cognitive Behavioral Therapy (nine studies), Mindfulness-based Interventions (three studies), Acceptance and Commitment Therapy (one study), and Behavioral Activation Therapy for Depression (one study) were included. Compared to treatment as usual, six out of eight studies of traditional Cognitive Behavioral Therapy reported significant differences in the reduction of depressive symptoms at post-treatment (d from 1.31 to 0.18) and four out of six at follow-up (d from 0.75 to 0.26); similarly, five out of six reported significant differences in the reduction of anxiety symptoms at post-treatment (d from 1.08 to 0.19) and three out of four at follow-up (d from 1.07 to 0.27). Overall, no significant differences between traditional Cognitive Behavioral Therapy and treatment as usual were reported at post-treatment and follow-up in the studies exploring pain intensity and pain catastrophizing. The available evidence suggests that traditional Cognitive Behavioral Therapy may produce significant benefits for the improvement of depression, anxiety, and quality of life, but not for pain intensity and pain catastrophizing. More evidence is needed to determine the effects of MBI, ACT, and BATD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early automated cerebral edema assessment following endovascular therapy: impact on stroke outcome

  • Guasch Jiménez, Marina|||0000-0001-6024-8348
  • Dhar, Rajat|||0000-0002-5167-5097
  • Kumar, Atul
  • Cifarelli, Julien
  • Ezcurra Diaz, Garbiñe|||0000-0002-9511-3117
  • Lambea-Gil, Álvaro|||0000-0003-1785-9201
  • Ramos-Pachón, Anna|||0000-0002-7136-4245
  • Martínez-Domeño, Alejandro|||0000-0002-9933-3192
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Guisado-Alonso, Daniel|||0000-0002-5799-3184
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Aguilera-Simón, Ana|||0000-0003-1428-8212
  • Marín-Bueno, Rebeca|||0000-0002-0354-6602
  • Martínez-González, José Pablo|||0000-0002-5925-1010
  • Ortega-Quintanilla, Joaquin
  • Fernandez-Perez, Isabel|||0000-0002-9949-1393
  • Avellaneda-Gómez, Carla|||0000-0003-4851-1224
  • Rodríguez-Pardo, Jorge
  • Celis Ruiz, Elena de|||0000-0002-9224-9422
  • Moniche, Francisco|||0000-0001-8613-2909
  • Freijo, María del Mar
  • Cortijo, Elisa
  • Trillo, Santiago
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
Background: Cerebral edema (CED) is associated with poorer outcome in patients with acute ischemic stroke (AIS). The aim of the study was to investigate the factors contributing to greater early CED formation in patients with AIS who underwent endovascular therapy (EVT) and its association with functional outcome. Methods: We conducted a multicenter cohort study of patients with an anterior circulation AIS undergoing EVT. The volume of cerebrospinal fluid (CSF) was extracted from baseline and 24-hour follow-up CT using an automated algorithm. The severity of CED was quantified by the percentage reduction in CSF volume between CT scans (∆CSF). The primary endpoint was a shift towards an unfavorable outcome, assessed by modified Rankin Scale (mRS) score at 3 months. Multivariable ordinal logistic regression analyses were performed. The ∆CSF threshold that predicted unfavorable outcome was selected using receiver operating characteristic curve analysis. Results: We analyzed 201 patients (mean age 72.7 years, 47.8% women) in whom CED was assessable for 85.6%. Higher systolic blood pressure during EVT and failure to achieve modified Thrombolysis In Cerebral Infarction (mTICI) 3 were found to be independent predictors of greater CED. ∆CSF was independently associated with the probability of a one-point worsening in the mRS score (common odds ratio (cOR) 1.05, 95% CI 1.03 to 1.08) after adjusting for age, baseline mRS, National Institutes of Health Stroke Scale (NIHSS), and number of passes. Displacement of more than 25% of CSF was associated with an unfavorable outcome (OR 6.09, 95% CI 3.01 to 12.33) and mortality (OR 6.72, 95% CI 2.94 to 15.32). Conclusions: Early CED formation in patients undergoing EVT was affected by higher blood pressure and incomplete reperfusion. The extent of early CED, measured by automated ∆CSF, was associated with worse outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

JAK-STAT Pathway, A Novel Target to Tackle Viral Infections

  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Ballana, Ester|||0000-0002-5215-7363
Modulation of the antiviral innate immune response has been proposed as a putative cellular target for the development of novel pan-viral therapeutic strategies. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is especially relevant due to its essential role in the regulation of local and systemic inflammation in response to viral infections, being, therefore, a putative therapeutic target. Here, we review the extraordinary diversity of strategies that viruses have evolved to interfere with JAK-STAT signaling, stressing the relevance of this pathway as a putative antiviral target. Moreover, due to the recent remarkable progress on the development of novel JAK inhibitors (JAKi), the current knowledge on its efficacy against distinct viral infections is also discussed. JAKi have a proven efficacy against a broad spectrum of disorders and exhibit safety profiles comparable to biologics, therefore representing good candidates for drug repurposing strategies, including viral infections.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Impact of the Mediterranean Diet and Lifestyle Intervention on Lipoprotein Subclass Profiles among Metabolic Syndrome Patients, Findings of a Randomized Controlled Trial

  • Candás-Estébanez, Beatriz|||0000-0001-9154-5193
  • Fernández-Cidón, Bárbara|||0000-0001-5547-480X
  • Corbella, Emili|||0000-0001-8818-1907
  • Tebé, Cristian|||0000-0003-2320-1385
  • Fanlo-Maresma, Marta|||0000-0002-5666-8726
  • Esteve-Luque, Virginia|||0000-0002-7631-8301
  • Salas-Salvadó, Jordi|||0000-0003-2700-7459
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Riera Mestre, Antoni|||0000-0001-9411-804X
  • Ros, Emilio|||0000-0002-2573-1294
  • Pintó, Xavier|||0000-0002-2216-2444
Metabolic syndrome (MetS) is associated with alterations of lipoprotein structure and function that can be characterized with advanced lipoprotein testing (ADLT). The effect of the Mediterranean diet (MedDiet) and weight loss on the lipoprotein subclass profile has been scarcely studied. Within the PREDIMED-Plus randomized controlled trial, a sub-study conducted at Bellvitge Hospital recruiting center evaluated the effects of a weight loss program based on an energy-reduced MedDiet (er-MedDiet) and physical activity (PA) promotion (intervention group) compared with energy-unrestricted MedDiet recommendations (control group) on ADLT-assessed lipoprotein subclasses. 202 patients with MetS (n = 107, intervention; n = 95, control) were included. Lipid profiles were determined, and ADLT was performed at baseline, 6, and 12 months. Linear mixed models were used to assess the effects of intervention on lipoprotein profiles. Compared to the control diet, at 12 months, the er-MedDiet+PA resulted in a significant additional 4.2 kg of body weight loss, a decrease in body mass index by 1.4 kg/m 2, reduction in waist circumference by 2.2 cm, decreased triglycerides, LDL-cholesterol and non-HDL-cholesterol, and increased HDL-cholesterol. In er-MedDiet+PA participants, ADLT revealed a decrease in small dense-LDL-cholesterol (sd-LDL-C), intermediate-density lipoproteins, VLDL-triglyceride, and HDL-Triglyceride, and an increase in large LDL and large VLDL particles. In conclusion, compared to an ad libitum MedDiet (control group), er-MedDiet+PA decreased plasma triglycerides and the triglyceride content in HDL and VLDL particles, decreased sd-LDL-C, and increased large LDL particles, indicating beneficial changes against cardiovascular disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Association between muscle strength and echogenicity using greyscale ultrasound software, a diagnostic accuracy study in kidney transplant candidates

  • Acuña-Pardo, Carolina
  • Muñoz-Redondo, Elena|||0000-0002-6288-0408
  • Delcros-Forestier, Lou
  • Curbelo P, Yulibeth G.
  • Rodríguez-Hernández, Carlos
  • Meza-Valderrama, Delky|||0000-0001-9259-7745
  • Sánchez Rodríguez, Dolores|||0000-0001-8662-5172
  • Pascual, Julio|||0000-0002-4735-7838
  • Pérez-Sáez, Maria J.
  • Marco, Ester|||0000-0002-3412-0356
BACKGROUND: Advanced chronic kidney disease disrupts the delicate equilibrium between protein anabolism and catabolism, leading to alterations in muscle quantity, quality, and function. Musculoskeletal ultrasound emerges as a promising assessment tool due to its widespread availability and high reliability. AIM: To evaluate the efficacy of rectus femoris (RF) echogenicity, measured using greyscale software, in identifying diminished muscle quality and strength in candidates for kidney transplant. DESIGN: Post-hoc diagnostic accuracy study. SETTING: Outpatients in a multimodal prehabilitation program pre kidney transplantation (KT). POPULATION: Patients on the waiting list for KT. METHODS: Sensitivity, specificity, likelihood ratios and area under the curve (AUC) for diagnostic efficacy of echogenicity (index test) assessed with the ImageJ software greyscale as a potential marker of quadriceps muscle weakness (reference test) were calculated. Muscle weakness was considered as maximal voluntary isometric contraction of the quadriceps (Q-MVIC) <40% of body weight. Other variables included body composition parameters derived from multifrequency electrical bioimpedance, upper limb muscle strength (handgrip), and RF thickness assessed by ultrasound. Statistical tests: Chi-square, t-Student, Pearson correlation coefficients (r), bivariate and multivariate logistic regression models. Statistical significance level ≤0.05. RESULTS: Of 112 patients (mean age: 63.6, 76% male), 72 (63.7%) exhibited quadriceps weakness, while 80 (70.8%) had some degree of overhydration (extracellular water/total body water ratio.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

  • Jimenez-Leon, Maria Reyes|||0000-0003-2723-319X
  • Gasca-Capote, Carmen|||0000-0002-7211-8599
  • Roca-Oporto, Cristina|||0000-0003-0079-5491
  • Espinosa, Nuria|||0000-0003-2249-2352
  • Sobrino, Salvador
  • Fontillon-Alberdi, Maria|||0000-0003-4031-8067
  • Gao, Ce
  • Roseto, Isabelle
  • Gladkov, Gregory
  • Rivas-Jeremias, Inmaculada
  • Neukam, Karin
  • Sánchez Hernández, José Germán
  • Rigo Bonnin, Raül|||0000-0001-5511-074X
  • Cervera-Barajas, Antonio J.
  • Mesones, Rosario
  • García, Federico
  • Alvarez-Rios, Ana Isabel
  • Bachiller, Sara
  • Vitalle, Joana
  • Perez-Gomez, Alberto
  • Camacho-Sojo, María Inés
  • Gallego, Isabel
  • Brander, Christian|||0000-0002-0548-5778
  • McGowan, Ian
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Viciana, Pompeyo|||0000-0001-5606-0166
  • Yu, Xu
  • Lichterfeld, Mathias
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
BACKGROUND. We evaluated the safety and viral rebound, after analytical treatment interruption (ATI), of vedolizumab and ART in recent HIV-1 infection. We used this model to analyze the effect of α4β7 on the HIV-1 reservoir size. METHODS. Participants started ART with monthly vedolizumab infusions, and ATI was performed at week 24. Biopsies were obtained from ileum and cecum at baseline and week 24. Vedolizumab levels, HIV-1 reservoir, flow cytometry, and cell-sorting and antibody competition experiments were assayed. RESULTS. Vedolizumab was safe and well tolerated. No participant achieved undetectable viremia off ART 24 weeks after ATI. Only a modest effect on the time to achieve more than 1,000 HIV-1 RNA copies/mL and the proportion of participants off ART was observed, being higher in the vedolizumab group compared with historical controls. Just before ATI, α4β7 expression was associated with HIV-1 DNA and RNA in peripheral blood and with PD1 and TIGIT levels. Importantly, a complete blocking of α4β7 was observed on peripheral CD4 T cells but not in gut (ileum and cecum), where α4β7 blockade and vedolizumab levels were inversely associated with HIV-1 DNA. CONCLUSION. Our findings support α4β7 as an important determinant in HIV-1 reservoir size, suggesting the complete α4β7 blockade in tissue as a promising tool for HIV-cure combination strategies. TRIAL REGISTRATION. ClinicalTrials.gov NCT03577782. FUNDING. This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, "a way to make Europe," research contracts FI17/00186 and FI19/00083 and research projects PI18/01532, PI19/01127, PI22/01796), Conserjería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (research projects P20/00906), the Red Temática de Investigación Cooperativa en SIDA (RD16/0025/0020), and the Spanish National Research Council.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Detection of germline CNVs from gene panel data, benchmarking the state of the art

  • Munté, Elisabet|||0000-0001-8396-8284
  • Roca, Carla|||0000-0003-1171-0588
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Pineda, Marta|||0000-0002-5403-5845
  • Gel, Bernat|||0000-0001-8878-349X
  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • Rivera, Bárbara
  • Cordero, David
  • Lázaro, Contxi
  • Moreno-Cabrera, José Marcos|||0000-0001-8570-0345
Germline copy number variants (CNVs) play a significant role in hereditary diseases. However, the accurate detection of CNVs from targeted next-generation sequencing (NGS) gene panel data remains a challenging task. Several tools for calling CNVs within this context have been published to date, but the available benchmarks suffer from limitations, including testing on simulated data, testing on small datasets, and testing a small subset of published tools. In this work, we conducted a comprehensive benchmarking of 12 tools (Atlas-CNV, ClearCNV, ClinCNV, CNVkit, Cobalt, CODEX2, CoNVaDING, DECoN, ExomeDepth, GATK-gCNV, panelcn.MOPS, VisCap) on four validated gene panel datasets using their default parameters. We also assessed the impact of modifying 107 tool parameters and identified 13 parameter values that we suggest using to improve the tool F1 score. A total of 66 tool pair combinations were also evaluated to produce better meta-callers. Furthermore, we developed CNVbenchmarker2, a framework to help users perform their own evaluations. Our results indicated that in terms of F1 score, ClinCNV and GATK-gCNV were the best CNV callers. Regarding sensitivity, GATK-gCNV also exhibited particularly high performance. The results presented here provide an evaluation of the current state of the art in germline CNV detection from gene panel data and can be used as a reference resource when using any of the tools.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation

  • Pedraza, Alexandra|||0000-0002-6039-8140
  • Salas, María Queralt|||0000-0003-4567-3682
  • Rodríguez-Lobato, Luis Gerardo
  • Escribano Serrat, Silvia|||0000-0001-9499-8999
  • Suárez-Lledó Grande, María|||0009-0004-4573-0581
  • Martínez Cibrián, Núria|||0000-0002-8688-1202
  • Solano, María Teresa
  • Arcarons, Jordi|||0000-0002-1356-6260
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Gutiérrez-García, Gonzalo|||0000-0003-4084-8279
  • Fernandez Aviles, Francesc|||0000-0003-3051-3926
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Molina, Patricia
  • Pino, Marc
  • Carreras, E.
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Rovira, Montserrat
  • Palomo, Marta|||0000-0002-3261-6577
  • Martínez, Carmen|||0000-0002-8401-7306
Plasma biomarkers of endothelial dysfunction have been postulated for the diagnosis and prognosis of acute graft-versus-host disease (aGVHD). However, their use is not validated in clinical practice yet. The endothelial activation and stress index (EASIX), a simple score based on routine laboratory parameters, is considered to be an indirect marker of endothelial damage. High value of EASIX was correlated with worse non-relapse mortality (NRM) and overall survival (OS) and a high risk of sinusoidal obstructive syndrome and transplant-associated thrombotic microangiopathy (TA-TMA). This study investigates the predictive value of plasma biomarkers and the EASIX score for the prediction of aGVHD. We assessed vascular cell adhesion molecule-1 (VCAM-1), tumor necrosis factor receptor 1 (TNFR1), and VWF:Ag plasma levels and the EASIX score before allogeneic hematopoietic stem cell transplantation (allo-HSCT) and on days 0, 3, 7, 14, and 21 in an experimental cohort (n = 33). EASIX was transformed to a base-2 logarithm to perform the analysis. For the most relevant biomarkers, we estimate the optimal cutoff values and the discriminatory ability to differentiate patients with high-risk of aGVHD. The conclusions obtained in the experimental cohort were validated in a large cohort of 321 patients at the same institution. Plasma biomarkers and EASIX showed similar post-transplantation dynamics consisting of a progressive increase. Multivariate analysis showed an association between high TNFR1 levels and Log-2 EASIX score on day 7 after transplantation with an increased likelihood of developing aGVHD (hazard ratio [HR] = 1, P =.002; HR = 2.31, P =.013, respectively). Patients with TNFR1 ≥1300 ng/mL (HR = 7.19, P =.006) and Log2-EASIX ≥3 (HR = 14.7, P <.001) at day 7 after transplantation were more likely to develop aGVHD with high predictive accuracy (C-index of 74% and 81%, respectively). In the validation cohort, patients with Log2-EASIX ≥3 on day 7 after transplantation presented a significantly higher incidence of grade II-IV aGVHD (HR = 1.94, P =.004) independent of GVHD prophylaxis (HR = 0.38, P =.004), conditioning regimen (HR = 0.59, P =.02) and type of donor (HR = 2.38, P =.014). Differential degree of endothelial damage can be measured using both EASIX score and plasma biomarkers in the early post-transplantation period. Patients at risk of developing aGVHD could be easily identified by a high EASIX score. Both indicators of endothelial activation represent a promising approach to predict aGVHD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Use of Attention Maps to Enrich Discriminability in Deep Learning Prediction Models Using Longitudinal Data from Electronic Health Records

  • Carrasco-Ribelles, Lucía Amalia|||0000-0001-9263-1747
  • Cabrera-Bean, Margarita|||0000-0001-9058-3825
  • Llanes-Jurado, Jose|||0000-0001-6778-5912
  • Violán, Concepció|||0000-0003-3309-5360
Featured Application: A better discrimination in a prediction model does not imply a better interpretability. In healthcare, where transparency is crucial, both discriminability and interpretability should be checked before stating that a new model is better. Background: In predictive modelling, particularly in fields such as healthcare, the importance of understanding the model's behaviour rivals, if not surpasses, that of discriminability. To this end, attention mechanisms have been included in deep learning models for years. However, when comparing different models, the one with the best discriminability is usually chosen without considering the clinical plausibility of their predictions. Objective: In this work several attention-based deep learning architectures with increasing degrees of complexity were designed and compared aiming to study the balance between discriminability and plausibility with architecture complexity when working with longitudinal data from Electronic Health Records (EHRs). Methods: We developed four deep learning-based architectures with attention mechanisms that were progressively more complex to handle longitudinal data from EHRs. We evaluated their discriminability and resulting attention maps and compared them amongst architectures and different input processing approaches. We trained them on 10 years of data from EHRs from Catalonia (Spain) and evaluated them using a 5-fold cross-validation to predict 1-year all-cause mortality in a subsample of 500,000 people over 65 years of age. Results: Generally, the simplest architectures led to the best overall discriminability, slightly decreasing with complexity by up to 8.7%. However, the attention maps resulting from the simpler architectures were less informative and less clinically plausible compared to those from more complex architectures. Moreover, the latter could give attention weights both in the time and feature domains. Conclusions: Our results suggest that discriminability and more informative and clinically plausible attention maps do not always go together. Given the preferences within the healthcare field for enhanced explainability, establishing a balance with discriminability is imperative.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The use of text messages as an alternative invitation method for breast cancer screening, A randomized controlled trial (M-TICS study)

  • Vives, Nuria|||0000-0002-5490-6110
  • Vidal, Carmen|||0000-0003-2768-2710
  • Niño de Guzmán, Ena Pery|||0000-0001-6587-2780
  • Farre, Albert|||0000-0001-8970-6146
  • Panera, Jon Aritz
  • Binefa, Gemma|||0000-0003-4652-0100
  • García, Montserrat|||0000-0002-3437-3185
This study aimed to determine whether a text message is as good as a postal letter as an invitation method for previous screenees in a breast cancer screening program, considering a non-inferiority margin of -2 percent points on participation rate. A non-inferiority randomized control trial was conducted. Women in the intervention group (n = 5,362) were invited by text message, and women in the control group (n = 5,482) were invited by letter, which is the standard invitation procedure of the program. In both groups, the invitation included a fixed appointment for mammography and a text message reminder 96 hours before the appointment. The primary outcome was screening participation rate (completing mammography within 12 weeks of invitation). Secondary outcomes included mammography attendance to initial or rescheduled appointments and cancellation rate. The intention-to-treat analysis showed a participation rate of 87.3% and 86.6% in the control and intervention groups, respectively. The difference in participation rate was -0.7 percentage points (95% confidence interval [CI], -1.8 to∞), indicating non-inferiority of text messages compared to letter invitations. The per-protocol analysis showed similar results. Attendance at the initial appointment was higher in women who received the text message invitation compared to those in the control group (P<0.002). Women who received the invitation by letter canceled more the initial appointment scheduled compared to the text message group (21.1% and 15.1%, P<0.007). In conclusion, we found that a text message invitation for women who had previously participated in breast cancer screening was not inferior to the standard letter. This randomized controlled trial provides valuable insights into the use of alternative invitation methods for population-based cancer screening programs. However, further research is needed to determine the best timing and frequency of text messages for better outcomes and identify strategies for facilitating rescheduling or cancellation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis, data from the prospective INNOVA4TB cohort study in Ukraine

  • Dudnyk, Andrii|||0000-0002-8780-9480
  • Hempel, M.
  • Lytvyniuk, O.
  • Liudkevych, H.
  • Matsera, V.
  • Nikitchenko, T.
  • Blyzniuk, S.
  • Molina-Moya, Barbara|||0000-0001-5144-2165
  • Preyer, R.
  • Domínguez, José|||0000-0001-7888-0309
Background: Ukraine remains a high World Health Organization priority country for drug-resistant tuberculosis (TB). Rifampicin-resistant TB (RR-TB) has a more protracted, more complicated, and more expensive treatment. In 2021, Ukraine reported 4025 RR-TB cases - 5.4 times more (751) than all 30 European Union/ European Economic Area countries together. Objectives: The objective of the study was to determine the diagnostic accuracy of line probe assay (LPA), AID Autoimmun Diagnostika GmbH, for detecting resistance to anti-TB drugs and its clinical application for selecting treatment regimens. Design: A prospective observational cohort study. Methods: From May 2019 to June 2020, we consecutively enrolled patients with active TB hospitalized at the Regional Phthisiopulmonology Center (Vinnytsia, Ukraine), aged between 18 and 82 years. The LPA was performed in the Genetic Research Laboratory at National Pirogov Memorial Medical University, Vinnytsia, Ukraine. Results: A total of 84 clinical specimens and 97 culture isolates from 126 TB patients were tested during the study. Accuracy (95% confidence interval) of LPA for clinical samples in comparison with phenotypic drug susceptibility test (DST) was 80.1 (68.5-89.0) for isoniazid (H), 74.7 (62.4-84.6) for rifampicin (R), 74.4 (62.5-84.1) for ethambutol, 71.4 (41.9-91.6) for streptomycin, 84.6 (62.4-96.5) for prothionamide/ethionamide, and 84.6 (73.6-92.3) for levofloxacin (Lfx), respectively. We found a significantly higher sensitivity of LPA for H, R, and Lfx for the culture isolates compared to clinical specimens (p < 0.05). LPA detected different mutations in 6 out of 17 (35.5%) patients susceptible to R by Xpert. A shorter treatment regimen with an injectable agent demonstrated a low suitability rate of 5% (8/156) in a cohort of RR-TB patients from Ukraine. Conclusion: Initial LPA testing accurately identifies resistance to anti-TB drugs and facilitates the selection of an appropriate treatment regimen, minimizing exposure to empirical therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Network analysis of influential risk factors in adolescent suicide attempters

  • Fernandez-Fernandez, Jennifer
  • Jiménez-Treviño, Luis|||0000-0002-9551-8587
  • Andreo Jover, Jorge|||0000-0002-6703-8017
  • Ayad-Ahmed, Wala|||0000-0002-0786-0076
  • Bobes-Bascarán, Maria T.|||0000-0002-5279-504X
  • Canal-Rivero, Manuel|||0000-0002-5818-5103
  • Cebrià, Ana Isabel|||0000-0002-2632-8130
  • Crespo-Facorro, Benedicto|||0000-0003-0033-7132
  • Torre-Luque, Alejandro de la|||0000-0003-0595-6127
  • Díaz-Marsá, Marina|||0000-0003-1364-3163
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Gómez Vallejo, Sandra|||0000-0003-0963-6585
  • Grande, Iria|||0000-0002-0137-0666
  • Iglesias, Noelia
  • Ortin, Francisco
  • March, Katya B.
  • Palao Tarrero, Ángela|||0000-0003-2717-5807
  • Pérez-Díez, Iván|||0000-0002-9972-2825
  • Pérez-Guerra, Carla
  • Ruiz-Veguilla, Miguel|||0000-0002-5790-7346
  • Vieta, Eduard|||0000-0002-0548-0053
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Sáiz, Pilar A.|||0000-0002-5705-4523
Objective: This study aims to investigate the interrelationship of risk factors for suicidal behaviour and their influence on attempt severity in a sample of adolescents who have recently attempted suicide. For it a network analyse was performed. Method: Data from a sample of adolescents from 12 to 17 years of age with documented suicide attempts were collected and analysed in the context of a larger study conducted in Spain called SURVIVE. Several factors were examined including age, sex, depression, trauma, impulsivity, and substance abuse. Graph analysis was performed to identify relationships and centrality measures among these factors. Results: A total of 267 participants were enrolled: 233 females and 34 males with a mean age of 15.00 years (SD = 1.52). The results indicate that age and sex do not have a notable relationship with attempt severity in adolescents. Emotional and behavioural difficulties, measured by the Strengths and Difficulties Questionnaire (SDQ), have the greatest influence on other variables. Depression and childhood trauma show varying degrees of association with suicidal behaviour, as does motor impulsivity. Substance use does not appear to be strongly related to suicide attempt severity. The number of suicide attempts is strongly correlated with emotional and behavioural difficulties, depression, and childhood trauma. Lethality of suicide attempts and intensity of suicidal ideation do not show significant associations with the other variables. Conclusion: This study identifies significant risk factors for adolescent suicide. Emotional and behavioural symptoms, depression, and childhood trauma are strongly linked to suicidal behaviour. However, age, sex, and substance abuse show minimal correlation. Assessing emotional difficulties and depressive symptoms using specific questionnaires could be crucial in evaluating suicidal behaviour in adolescents.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Placebo Response and Its Predictors in Attention Deficit Hyperactivity Disorder, A Meta-Analysis and Comparison of Meta-Regression and MetaForest

  • Castells Cervelló, Xavier|||0000-0002-2619-7273
  • Saez, Marc|||0000-0003-1882-0157
  • Barcheni, Maghie|||0000-0002-5093-3330
  • Cunill, Ruth|||0000-0003-3247-393X
  • Serrano Sarbosa, Domènec|||0000-0001-8214-2448
  • López, Beatriz|||0000-0001-9210-0073
  • van Lissa, Caspar J.|||0000-0002-0808-5024
Background: High placebo response in attention deficit hyperactivity disorder (ADHD) can reduce medication-placebo differences, jeopardizing the development of new medicines. This research aims to (1) determine placebo response in ADHD, (2) compare the accuracy of meta-regression and MetaForest in predicting placebo response, and (3) determine the covariates associated with placebo response. Methods: A systematic review with meta-analysis of randomized, placebo-controlled clinical trial investigating pharmacological interventions for ADHD was performed. Placebo response was defined as the change from baseline in ADHD symptom severity assessed according to the 18-item, clinician-rated, DSM-based rating scale. The effect of study design-, intervention-, and patient-related covariates in predicting placebo response was studied by means of meta-regression and MetaForest. Results: Ninety-four studies including 6614 patients randomized to placebo were analyzed. Overall, placebo response was -8.9 points, representing a 23.1% reduction in the severity of ADHD symptoms. Cross-validated accuracy metrics for meta-regression were R = 0.0012 and root mean squared error = 3.3219 for meta-regression and 0.0382 and 3.2599 for MetaForest. Placebo response among ADHD patients increased by 63% between 2001 and 2020 and was larger in the United States than in other regions of the world. Conclusions: Strong placebo response was found in ADHD patients. Both meta-regression and MetaForest showed poor performance in predicting placebo response. ADHD symptom improvement with placebo has markedly increased over the last 2 decades and is greater in the United States than the rest of the world.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hepatitis B and C Screening and Linkage to Care in Migrants From Endemic Countries in Barcelona Through a Community Action

  • Not, Anna|||0000-0001-8756-1094
  • Ouaarab-Essadek, Hakima|||0000-0002-8245-772X
  • Montoro-Fernandez, Marcos|||0000-0003-2425-4120
  • Treviño Maruri, Begoña|||0000-0003-4633-8288
  • Buti, Maria|||0000-0002-0732-3078
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Bordoy, Antoni E.|||0000-0002-1165-542X
  • Folch, Cinta|||0000-0001-8400-2668
  • Majó, Xavier|||0000-0003-4338-6014
  • Casabona-Barbarà, Jordi|||0000-0003-4816-5536
  • Gómez i Prat, Jordi|||0000-0001-7041-9526
  • Martró, Elisa|||0000-0002-2867-6649
Background and Aims: Migrants from endemic areas are key populations for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection screening in Europe. This study assessed the feasibility and outcomes of a community action that combined education, screening, and simplified access to care for migrants in Barcelona. Methods: Adult migrants from Pakistan, Romania, and Senegal were included from 2021 to 2023, through a community action involving education, an epidemiological questionnaire, and rapid testing for HBV surface antigen (HBsAg) and HCV antibodies. If positive, DBS samples were collected for laboratory confirmation. Viremic cases were referred to an International Health Unit (IHU). Results: Overall, 786 participants were included (346 from Pakistan, 304 from Senegal and 136 from Romania). Previous screening for HBV and HCV was 8.0% and 7.7%, respectively. HBsAg prevalence was 0.9% for migrants from Pakistan, 8.2% for those from Senegal and 1.4% for those from Romania (n = 30/786, 23 new diagnoses). Among these, 69.6% attended the IHU and were HBV-DNA positive, but none met treatment criteria. Anti-HCV prevalence was 3.5%, 0.7% and 1.4% for migrants from Pakistan, Senegal and Romania, respectively (n = 16/768, 12 new diagnoses), and HCV-RNA prevalence was 0.9%, 0.3% and 0.7%, respectively (N = 6, all new diagnoses); 4 (66.6%) cases were linked to treatment and two were cured. Conclusions: This novel community action successfully reached migrants in a situation of vulnerability and provided them access to testing and care. The high prevalence observed and the limited self-knowledge of their HBV and HCV status justify targeted screening in these groups.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer

  • Pons, Laura|||0000-0003-0784-4110
  • Hernández, Laura
  • Urbizu, Aintzane|||0000-0001-8458-1209
  • Osorio, Paula
  • Rodríguez-Martínez, Paula|||0000-0002-9001-2501
  • Castellà Fernández, Eva
  • Muñoz-Mármol, Ana Maria|||0000-0003-1008-7763
  • Sanz, Carolina|||0009-0001-9228-755X
  • Arnaldo, Laura|||0000-0003-1654-0573
  • Felip, Eudald|||0000-0002-3812-1313
  • Quiroga García, Vanesa
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Margelí, Mireia|||0000-0003-3594-4530
  • Fernández, Pedro Luis|||0000-0002-8618-4597
HER2+ and triple negative breast cancers are widely known for their aggressiveness, frequent resistance to treatment and poor prognosis. Neoadjuvant management has provided promising results for both subtypes, but there is still a subset of patients with no or low response. Consequently, a non-negligible number of patients is receiving a treatment regimen that might not be adequate. Identification of these patients is essential to avoid overtreatment and provide more effective treatment options. Neoadjuvant treatment (NAT) is one of the most widely used options for HER2+ and triple negative (TN) early breast cancer (BC). Since around half of the patients treated with NAT do not achieve a pathologically complete response (pCR), biomarkers to predict resistance are urgently needed. The correlation of clinicopathological factors with pCR was studied in 150 patients (HER2 = 81; TN = 69) and pre- and post-NAT differences in tumour biomarkers were compared. Low estrogen receptor (ER) expression, high tumour-infiltrating lymphocytes (TILs) and low cT-stage were associated with pCR in HER2+ tumours (p = 0.022; p = 0.032 and p = 0.005, respectively). Furthermore, ER expression was also associated with residual cancer burden (RCB; p = 0.046) in the HER2+ subtype. Similarly, pre-NAT, low progesterone receptor expression (PR; 1-10%) was associated with higher RCB (p < 0.001) in TN tumours. Only clinical and pathological T-stage (cpT-stage) had prognostic capacity in HER2+ tumours, whereas pre-NAT cpT-stage and post-NAT TILs had this capacity for the prognosis of TN tumours. We conclude that ER and PR expression may help predict response to NAT in HER2 and TN BC and should be taken into account in residual tumours. Also, changes observed in the phenotype after NAT suggest the need to reevaluate biomarkers in surviving residual tumour cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exercise-Based Prehabilitation for Kidney Transplant Candidates: The FRAILMar Randomized Controlled Trial

  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Muñoz-Redondo, Elena|||0000-0002-6288-0408
  • Morgado Pérez, Andrea|||0000-0002-6162-2191
  • Delcros-Forestier, Lou
  • Bach Pascual, Anna|||0000-0003-0571-6131
  • Faura, Anna|||0000-0002-1440-3922
  • Redondo-Pachón, Dolores|||0000-0002-0458-0052
  • Chamoun, Betty|||0000-0002-4267-2273
  • Burballa, Carla|||0000-0002-0091-1459
  • Buxeda, Anna|||0000-0001-7305-3259
  • Crespo, Marta|||0000-0001-6992-6379
  • Marco, Ester|||0000-0002-3412-0356
  • Pascual, Julio|||0000-0002-4735-7838
Rationale & Objective: Kidney transplantation (KT) is the preferred treatment for kidney failure but carries significant post-transplant risks, particularly for frail patients. This study evaluated the effects of an exercise-based prehabilitation program on exercise capacity, muscle function, and muscle size among KT candidates. Study Design: Analysis of functional outcomes within the FRAILMar study, a randomized controlled trial. Setting & Participants: 121 KT candidates on the KT waiting list. Intervention: The intervention group participated in a prehabilitation program comprising 24 exercise sessions (1 hour, 3 times per week for 8 weeks), the control group received standard care. Randomization was stratified by frailty status. Outcomes: The primary outcome was exercise capacity assessed by maximal workload during a cardiopulmonary exercise test. Secondary outcomes included peripheral muscle function, respiratory muscle function, muscle size, and changes in frailty status. Results: The mean age of the 121 individuals who were randomized was 63.4 years, 76% were men, and 40% were frail (Fried phenotype ≥ 2). 106 patients completed the prehabilitation program and, among them, compared to standard care, prehabilitation significantly improved exercise capacity (+12.8 watts; [95% CI: 3.4 to 22.2]; p=0.008), handgrip strength (+1.8 kg; [95% CI: 0.7 to 2.8]; p<0.001), and rectus femoris thickness (+1.2 mm; [95% CI: 0.3 to 2.0]; p=0.007). Frail patients showed significant improvements across most measures, demonstrating potential benefits for this subgroup. Limitations: This analysis was limited by a short follow-up period and the risk of type I error due to multiple comparisons, even though outcomes were pre-specified. Conclusions: An 8-week exercise-based prehabilitation program may improve KT candidates' exercise capacity, muscle function, and muscle size, effects also observed among frail patients. These findings may inform future research in this area and the evaluation of the value of standardized prehabilitation protocols.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Internal structure, reliability and cross-cultural validity of the Warwick-Edinburgh Mental Wellbeing Scale in three European populations

  • Yadav, Prateek
  • Arias de la Torre, Jorge|||0000-0001-6908-9611
  • Bakolis, Ioannis|||0000-0002-4800-1630
  • Bartoll, Xavier|||0000-0001-6865-8034
  • Casajuana Kogel, Cristina
  • Colom, Joan
  • Dregan, Alex
  • Garcia Forero, Carlos
  • Botella-Juan, Lorena
  • Martín, Vicente|||0000-0003-0552-2804
  • Molina de la Torre, Antonio José
  • Mortier, Philippe|||0000-0003-2113-6241
  • Nielsen, Line
  • Pérez, Catherine|||0000-0001-5892-2807
  • Puertolas, Beatriz
  • Ronaldson, Amy|||0000-0001-8369-9168
  • Santini, Ziggi
  • Schiaffino, Anna|||0000-0001-8787-2634
  • Serrano-Blanco, Antoni|||0000-0001-6123-0633
  • Stewart-Brown, Sarah
  • Valderas, Jose M.|||0000-0002-9299-1555
  • Alonso, Jordi|||0000-0001-8627-9636
  • Vilagut, Gemma|||0000-0002-3714-226X
The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS), a questionnaire designed for the assessment of mental well-being, is widely used in different countries and cultures worldwide. However, there is a lack of studies examining its metric performance and measurement invariance across countries. This study aims to examine the internal structure, reliability and cross-country validity of the WEMWBS in three European populations. WEMWBS data collected in 2016 from three representative population health surveys from an autonomous region in Spain (Catalonia) and two countries (Denmark and the UK) were used (n=13 940). The mean WEMWBS Scores were compared between populations. The internal consistency (ω coefficients), internal structure (confirmatory factor analyses (CFA) and bifactor exploratory structural equation models), reliability (item response theory models, item and test information functions), and cross-cultural comparability (multigroup CFA) of the WEMWBS were assessed. Differences in mean scores observed between regions merit further study. The WEMWBS showed high internal consistency across countries (ω=0.942). The unidimensionality of the scale was confirmed overall and for each population. Evidence of reliability and of measurement invariance at the configural, scalar and metric levels was found. The results support the use of the WEMWBS in different cultures to inform the understanding of population well-being in public health and its possible use as an outcome measure in clinical studies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation

  • Donadeu, Laura|||0000-0002-5089-5047
  • Gómez-Ollés, Susana|||0000-0002-8935-7641
  • Casanova, Franc|||0000-0001-7427-1987
  • Torija, Alba
  • López-Meseguer, Manuel|||0000-0003-2650-9238
  • Boada Pérez, Meritxell|||0000-0002-8774-8593
  • Kervella, Delphine|||0000-0001-8069-6105
  • Crespo, Elena
  • Carrera-Muñoz, Claudia
  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Castells, Lluís|||0000-0002-6672-5931
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Fernandez-Naval, Candela|||0000-0002-5584-3537
  • Quintero, Jesús|||0000-0002-6456-9031
  • Muñoz, Marina
  • Agüero, Fernando
  • González-Costello, José|||0000-0002-7437-3630
  • Lladó, Laura|||0000-0002-3717-3306
  • Favà, Alexandre|||0000-0003-1664-6001
  • Cañas, Laura
  • de la Hoz-Caballero, María del Mar
  • Meneghini, Maria|||0000-0001-7307-923X
  • Torres, Irina B.|||0000-0003-3304-0810
  • Juvé, Mariona|||0000-0001-8431-3757
  • Hafkamp, Florianne
  • Vila, Marta|||0000-0001-9303-5189
  • González Robles, Alba
  • Buzón, Maria José|||0000-0003-4427-9413
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Zúñiga, José Miguel
  • Monforte, Víctor|||0000-0002-2918-7679
  • Sáez-Giménez, Berta|||0000-0002-9307-728X
  • Len, Oscar|||0000-0002-1819-3141
  • Los-Arcos, Ibai|||0000-0001-8835-2702
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Pardo, Emma|||0000-0001-8703-5457
  • Martínez, Xavier
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
Solid organ transplant (SOT) recipients display weak seroconversion and neutralizing antibody (NAb) responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and remain at risk of severe coronavirus disease 2019 (COVID-19). While B-cell memory is the hallmark of serological immunity, its role in driving successful vaccine responses and providing immune protection in SOT patients remains unclear. We investigated the function and interplay of SARS-CoV-2-specific memory B cells (mBc), different cytokineproducing T cells, and cross-reactive NAb in driving seroconversion and protection against COVID-19 in two cohorts. First, we studied a large cohort of 148 SOT recipients and 32 immunocompetent individuals who underwent several vaccinations. Subsequently, we assessed 25 SOT patients participating in a randomized controlled trial to compare two different immunosuppressive strategies for allowing successful seroconversion and memory-cell responses after booster vaccination. We corroborate previous findings that B- and T-cell memory responses are weaker and more delayed in SOT patients than in immunocompetent (IC) individuals; however, within the SOT cohort, we found that these responses are relatively stronger and more robust in patients not receiving mycophenolate mofetil (MMF)-based therapies. Anti- spike IgG titers strongly correlated with RBD-specific IgG-producing mBc, with both displaying broad viral cross reactivity. Prebooster SARS-CoV-2-specific mBc and IL-2- producing T cells accurately predicted Nab seroconversion (AUC, 0.828) and protection against severe COVID-19. While switching unresponsive SOT patients from calcineurin inhibitors (CNI)/MMF to a low-exposure CNI/mTOR-i regimen favored wider SARS-CoV-2-specific immune responses after a fourth booster vaccination, preformed RBD-specific mBc predicted NAb seroconversion. Our study adds new insights into the pathobiology of immune memory and highlights the pivotal role of SARS-CoV-2-specific mBc in promoting immune protection inSOT patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Benefits of Living Over Deceased Donor Kidney Transplantation in Elderly Recipients. A Propensity Score Matched Analysis of a Large European Registry Cohort

  • Toapanta, Néstor|||0000-0001-5983-6863
  • Comas, Jordi|||0000-0001-5257-7029
  • Revuelta, Ignacio|||0000-0002-3584-4516
  • Manonelles, Anna|||0000-0003-2456-388X
  • Facundo, Carme|||0000-0003-1254-5553
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Vila, Anna
  • Arcos, Emma
  • Tort, Jaume
  • Giral, Magali|||0000-0001-7641-1592
  • Naesens, Maarten|||0000-0002-5625-0792
  • Kuypers, Dirk RJ.|||0000-0001-5546-9680
  • Åsberg, Anders|||0000-0002-0628-1769
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
Although kidney transplantation from living donors (LD) offers better long-term results than from deceased donors (DD), elderly recipients are less likely to receive LD transplants than younger ones. We analyzed renal transplant outcomes from LD versus DD in elderly recipients with a propensity-matched score. This retrospective, observational study included the first single kidney transplants in recipients aged ≥65 years from two European registry cohorts (2013-2020, n = 4,257). Recipients of LD (n = 408), brain death donors (BDD, n = 3,072), and controlled cardiocirculatory death donors (cDCD, n = 777) were matched for donor and recipient age, sex, dialysis time and recipient diabetes. Major graft and patient outcomes were investigated. Unmatched analyses showed that LD recipients were more likely to be transplanted preemptively and had shorter dialysis times than any DD type. The propensity score matched Cox's regression analysis between LD and BDD (387-pairs) and LD and cDCD (259-pairs) revealing a higher hazard ratio for graft failure with BDD (2.19 [95% CI: 1.16-4.15], p = 0.016) and cDCD (3.38 [95% CI: 1.79-6.39], p < 0.001). One-year eGFR was higher in LD transplants than in BDD and cDCD recipients. In elderly recipients, LD transplantation offers superior graft survival and renal function compared to BDD or cDCD. This strategy should be further promoted to improve transplant outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

  • Bastard, Paul|||0000-0002-5926-8437
  • Gervais, A.
  • Taniguchi, M.
  • Saare, L.
  • Särekannu, K.
  • Voyer, T.L.
  • Philippot, Q.
  • Rosain, J.
  • Bizien, L.
  • Asano, T.
  • Garcia-Prat, Marina|||0000-0001-5387-1908
  • Parra-Martínez, Alba|||0000-0002-9564-8912
  • Migaud, M.
  • Tsumura, M.
  • Conti, F.
  • Belot, Alexandre|||0000-0003-4902-5332
  • Rivière, Jacques G.|||0000-0003-1055-2063
  • Morio, T.
  • Tanaka, J.
  • Javouhey, E.
  • Haerynck, F.
  • Duvlis, S.
  • Ozcelik, Tayfun|||0000-0001-5937-1082
  • Keles, S.
  • Tandjaoui-Lambiotte, Y.
  • Escoda, S.
  • Husain, M.
  • Pan-Hammarström, Q.
  • Hammarström, L.
  • Ahlijah, G.
  • Haidar, A.A.
  • Soudee, C.
  • Arseguel, V.
  • Abolhassani, Hassan|||0000-0002-4838-0407
  • Sahanic, S.
  • Tancevski, I.
  • Nukui, Y.
  • Hayakawa, S.
  • Chrousos, G.P.
  • Michos, A.
  • Tatsi, E.B.
  • Filippatos, F.
  • Rodriguez-Palmero, A.
  • Troya, Jesús|||0000-0001-7323-114X
  • Tipu, I.
  • Meyts, I.
  • Roussel, L.
  • Ostrowski, S.R.
  • Schidlowski, L.
  • Prando, C.
  • Condino-Neto, Antonio|||0000-0002-1069-3117
  • Cheikh, N.
  • Bousfiha, A.A.
  • Bakkouri, J.E.
  • Peterson, P.
  • Pujol, Aurora|||0000-0002-9606-0600
  • Lévy, R.
  • Quartier, P.
  • Vinh, D.C.
  • Boisson, Bertrand|||0000-0001-5240-3555
  • Béziat, V.
  • Zhang, S.Y.
  • Borghesi, A.
  • Pession, A.
  • Andreakos, E.
  • Marr, N.
  • Mentis, A.F.A.
  • H.mogensen, T.
  • Rodríguez-Gallego, C.
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Tillmann, V.
  • Neven, B.
  • Trouillet-Assant, S.
  • Brodin, P.
  • Abel, Laurent|||0000-0001-7016-6493
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Zhang, Q.
  • Martinón Torres, Federico|||0000-0002-9023-581X
  • Salas, A.
  • Gómez-Carballa, A.
  • Gonzalez-Granado, L.I.
  • Kisand, K.
  • Okada, S.
  • Puel, A.
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • AlKhater, Suzan|||0000-0001-7315-6581
  • Alkan, G.
  • Castagnoli, R.
  • Cyrus, C.|||0000-0001-7333-6486
  • Bozdemir, S.E.
  • Emiroglu, M.
  • Gulhan, Belgin|||0000-0003-0839-1301
  • Erdeniz, E.H.
  • Hatipoglu, N.
  • Bayhan, G.I.|||0000-0002-1423-4348
  • Jabandziev, P.
  • Yuksek, S.K.
  • Karbuz, A.
  • Öz, Ş.K.T.
  • Marseglia, G.L.
  • Akcan, O.M.
  • Kılıç, A.O.
  • Parlakay, A.O.
  • Papadaki, M.
  • Slaba, K.
  • Sevketoglu, Esra|||0000-0002-8330-2877
  • Valencia-Ramos, J.
  • Yahşi, A.
  • Tuala, C.
  • Urbieta, A.I.D.
  • Esteban, B.D.
  • Santalla, M.J.D.
  • Pérez, C.F.
  • Villaverde, J.F.
  • Rodríguez, C.G.
  • Allut, J.L.G.
  • Vicente, L.G.
  • Vázquez, E.G.
  • Carballa, A.G.
  • Rial, J.G.
  • Barcala, F.J.G.
  • Liñares, B.G.
  • Iglesias, P.L.
  • Massa, B.L.
  • Fuentes, M.L.
  • Franco, M.L.
  • Lago, A.L.
  • Cruz, D.N.D.l
  • Masid, E.N.
  • Devesa, J.B.O.
  • Seco, J.P.
  • Núñez, M.P.
  • Bernal, M.P.D.M.
  • Freixo, H.P.
  • Rodríguez, L.P.
  • Pischedda, S.
  • Romero, M.P.
  • Reino, A.P.
  • Hervella, G.M.P.
  • Verdes, T.Q.
  • Redondo Collazo, Lorenzo|||0000-0002-3521-678X
  • Casuso, P.R.
  • García, S.R.
  • Vázquez, S.R.
  • Blanco, V.R.
  • Calle, I.R.
  • Velasco, C.R.
  • Núñez, N.R.
  • Sánchez, C.R.T.
  • Paz, E.S.
  • Orayyou, J.M.S.
  • Villanueva, C.S.
  • Fernández, S.S.
  • Sanmartín, P.S.
  • Muñiz, M.T.
  • Pena, R.T.
  • Castellano, M.T.
  • Cuadrado, L.V.
  • García, P.V.
  • Iglesias, M.S.V.
  • Lasheras, S.V.
  • Ferreiro Iglesias, Rocío|||0000-0002-0469-4332
  • Bastón-Rey, I.
  • Calviño-Suárez, C.
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Al-Muhsen, S.
  • Al-Mulla, F.
  • Amara, A.
  • Anderson, M.S.
  • Arias, A.A.
  • Arkin, L.M.
  • Feldman, H.B.
  • Biggs, C.M.
  • Bogunovic, Dusan|||0000-0002-9277-3232
  • Bolze, Alexandre|||0000-0001-7399-2766
  • Bondarenko, A.|||0000-0002-9737-2868
  • Bryceson, Y.
  • Butte, M.J.
  • Casari, G.
  • Christodoulou, J.
  • Constantinescu, S.N.
  • Cooper, M.A.
  • Dalgard, C.L.
  • Desai, M.
  • Drolet, B.A.
  • Duval, X.
  • Baghdadi, J.E.
  • Eloy, P.
  • Espinosa-Padilla, S.
  • Fellay, Jacques|||0000-0002-8240-939X
  • Flores, Carlos|||0000-0001-5352-069X
  • Franco, J.L.
  • Froidure, A.
  • Gorochov, G.
  • Gregersen, P.K.
  • Grimbacher, B.
  • Hagin, D.
  • Halwani, R.
  • Heath, J.R.
  • Hsieh, E.W.Y.
  • Husebye, Eystein Sverre|||0000-0002-7886-2976
  • Imai, K.
  • Itan, Yuval
  • Jarvis, E.D.
  • Kaja, E.
  • Karamitros, T.
  • Ku, C.L.
  • Lau, Y.L.
  • Ling, Y.
  • Lucas, C.L.
  • Mansouri, D.
  • Maródi, L.
  • Mentré, F.
  • Milner, J.D.
  • Mironska, K.
  • Mogensen, T.H.
  • Ng, L.F.P.
  • Notarangelo, L.D.
  • Novelli, A.
  • Novelli, G.
  • O'Farrelly, C.
  • Okamoto, K.
  • Pape, J.W.
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Perez-Tur, J.
  • Perlin, D.S.
  • Pesole, G.
  • Planas, A.M.
  • Quintana-Murci, L.
  • Ramaswamy, S.
  • Renia, L.
  • Resnick, I.
  • Sancho-Shimizu, V.
  • Sediva, A.
  • Seppänen, M.R.J.
  • Shahrooei, M.
  • Shcherbina, A.
  • Slaby, O.
  • Snow, A.L.
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Soumelis, V.
  • Spaan, A.N.
  • Su, H.C.
  • Tangye, S.G.
  • Tayoun, A.A.
  • Temel, Ş.G.
  • Thorball, C.
  • Tiberghien, P.
  • Turvey, S.E.
  • Uddin, K.M.F.
  • Uddin, M.J.
  • Beek, D.v.d
  • Bernuth, H.v
  • Wauters, J.
  • Zatz, Mayana|||0000-0003-3970-8025
  • Zawadzki, Pawel
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7-9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2-5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6-35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1-9.6]) of IFN-ω and/or IFN-α2.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands

  • Díaz-Tejedor, A.
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ciudad, Laura|||0000-0002-5219-6792
  • Lorenzo-Mohamed, M.
  • González-Rodríguez, M.
  • Castellanos, B.
  • Sotolongo-Ravelo, J.
  • San-Segundo, L.
  • Corchete, L.A.
  • González-Méndez, L.
  • Martín Sánchez, Montserrat
  • Mateos, M. V.|||0000-0003-2390-1218
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Garayoa, M.
  • Paíno, T.
Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of immune surveillance. Histone deacetylase inhibitors have been shown to promote the expression of silenced molecules and hold potential to increase the anti-MM efficacy of immunotherapy. The aim of the present work was to assess the potential effect of tinostamustine (EDO-S101), a first-in-class alkylating deacetylase inhibitor, in combination with daratumumab, an anti-CD38 monoclonal antibody (mAb), through different preclinical studies. Tinostamustine increases CD38 expression in myeloma cell lines, an effect that occurs in parallel with an increment in CD38 histone H3 acetylation levels. Also, the expression of MICA and MICB, ligands for the NK cell activating receptor NKG2D, augments after tinostamustine treatment in myeloma cell lines and primary myeloma cells. Pretreatment of myeloma cell lines with tinostamustine increased the sensitivity of these cells to daratumumab through its different cytotoxic mechanisms, and the combination of these two drugs showed a higher anti-myeloma effect than individual treatments in ex vivo cultures of myeloma patients' samples. In vivo data confirmed that tinostamustine pretreatment followed by daratumumab administration significantly delayed tumor growth and improved the survival of mice compared to individual treatments. In summary, our results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 mAbs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vertical transmission of maternal DNA through extracellular vesicles associates with altered embryo bioenergetics during the periconception period

  • Bolumar, David
  • Moncayo-Arlandi, Javier|||0000-0002-3564-4063
  • Gonzalez-Fernandez, Javier|||0000-0002-9625-5264
  • Ochando Hernandez, Ana|||0000-0001-5255-8813
  • Moreno, Inmaculada
  • Monteagudo-Sánchez, Ana|||0000-0002-1432-1185
  • Marin, Carlos
  • Diez, Antonio
  • Fabra, Paula
  • Checa, Miguel Angel|||0000-0002-0226-3416
  • Espinós, Juan José|||0000-0003-4838-8940
  • Gardner, David K.
  • Simon, Carlos
  • Vilella, Felipe|||0000-0002-0039-9846
The transmission of DNA through extracellular vesicles (EVs) represents a novel genetic material transfer mechanism that may impact genome evolution and tumorigenesis. We aimed to investigate the potential for vertical DNA transmission within maternal endometrial EVs to the pre-implantation embryo and describe any effect on embryo bioenergetics. We discovered that the human endometrium secretes all three general subtypes of EV - apoptotic bodies (ABs), microvesicles (MVs), and exosomes (EXOs) - into the human endometrial fluid (EF) within the uterine cavity. EVs become uniformly secreted into the EF during the menstrual cycle, with the proportion of different EV populations remaining constant; however, MVs contain significantly higher levels of mitochondrial (mt)DNA than ABs or EXOs. During the window of implantation, MVs contain an eleven-fold higher level of mtDNA when compared to cells-of-origin within the receptive endometrium, which possesses a lower mtDNA content and displays the upregulated expression of mitophagy-related genes. Furthermore, we demonstrate the internalization of EV-derived nuclear-encoded (n)DNA/mtDNA by trophoblast cells of murine embryos, which associates with a reduction in mitochondrial respiration and ATP production. These findings suggest that the maternal endometrium suffers a reduction in mtDNA content during the preconceptional period, that nDNA/mtDNA become packaged into secreted EVs that the embryo uptakes, and that the transfer of DNA to the embryo within EVs occurs alongside the modulation of bioenergetics during implantation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acute stress triggers sex-dependent rapid alterations in the human small intestine microbiota composition

  • Rodiño-Janeiro, Bruno K.|||0000-0002-0633-6774
  • Khannous-Lleiffe, Olfat
  • Pigrau Pastor, Marc|||0000-0001-6801-3017
  • Willis, Jesse R.
  • Salvo-Romero, Eloísa
  • Nieto Ruiz, Adoración|||0000-0002-3421-2840
  • Expósito, Elba|||0000-0001-6088-3149
  • Fortea, Marina|||0000-0001-8885-7495
  • Pardo-Camacho, Cristina
  • Albert-Bayo, Mercé|||0000-0002-9726-8083
  • González Castro, Ana Maria|||0000-0003-3955-3318
  • Guagnozzi, Danila|||0000-0002-6171-1901
  • Martínez, Cristina|||0000-0002-9368-1356
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Vicario Perez, Maria|||0000-0001-9622-3185
  • Santos, Javier|||0000-0002-4798-5033
  • Gabaldón, Toni|||0000-0003-0019-1735
  • Alonso Cotoner, Carmen|||0000-0002-3483-2919
Digestive disorders of gut-brain interaction (DGBI) are very common, predominant in females, and usually associated with intestinal barrier dysfunction, dysbiosis, and stress. We previously found that females have increased susceptibility to intestinal barrier dysfunction in response to acute stress. However, whether this is associated with changes in the small bowel microbiota remains unknown. We have evaluated changes in the small intestinal microbiota in response to acute stress to better understand stress-induced intestinal barrier dysfunction. Jejunal biopsies were obtained at baseline and 90 min after cold pain or sham stress. Autonomic (blood pressure and heart rate), hormonal (plasma cortisol and adrenocorticotropic hormone) and psychological (Subjective Stress Rating Scale) responses to cold pain and sham stress were monitored. Microbial DNA from the biopsies was analyzed using a 16S metabarcoding approach before and after cold pain stress and sham stress. Differences in diversity and relative abundance of microbial taxa were examined. Cold pain stress was associated with a significant decrease in alpha diversity (P = 0.015), which was more pronounced in females, along with significant sex differences in the abundance of specific taxa and the overall microbiota composition. Microbiota alterations significantly correlated with changes in psychological responses, hormones, and gene expression in the intestinal mucosal. Cold pain stress was also associated with activation of autonomic, hormonal and psychological response, with no differences between sexes. Acute stress elicits rapid alterations in bacterial composition in the jejunum of healthy subjects and these changes are more pronounced in females. Our results may contribute to the understanding of female predominance in DGBI.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Efficacy of cognitive rehabilitation in cognition and brain networks, A randomised clinical trial in patients with multiple sclerosis

  • Lopez-Soley, Elisabet
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Vivó Pascual, Francesc|||0000-0002-6409-1197
  • Calvi, Alberto|||0000-0002-1953-2803
  • Alba-Arbalat, Salut|||0000-0003-1662-2317
  • Romero Pinel, Lucía|||0000-0001-8054-0565
  • Martínez Yélamos, Sergio|||0000-0001-9889-2040
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Munteis, Elvira|||0000-0002-6195-9106
  • Martínez-Rodríguez, José Enrique
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Anglada, E.|||0000-0001-5074-4970
  • Meza-Murillo, Edwin Roger|||0000-0001-6065-3546
  • Arévalo, María Jesús|||0000-0003-0626-5555
  • Sánchez Carrión, Rocío
  • Pelayo, Raúl|||0000-0002-1313-0686
  • Bernabeu Guitart, Montserrat|||0000-0003-2037-3069
  • Sola-Valls, Nuria
  • Hervas, M.
  • Sepúlveda, María
  • Saiz, Albert|||0000-0002-5793-8791
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Solana, Elisabeth|||0000-0001-7973-2439
  • Llufriu, Sara|||0000-0003-4273-9121
This study evaluated the efficacy of the computerised Guttmann, NeuroPersonalTrainer® (GNPT) cognitive rehabilitation (CR) and characterised the induced changes in cerebral networks in patients with multiple sclerosis (MS). This multicentre, double-blind, randomised clinical trial compared upward intensity training (active treatment) to low-intensity static training (static treatment). Cognition was assessed using the Brief Repeatable battery before and after 12 weeks of training and at 10-months follow-up, and patients were classified as having a mild or severe cognitive impairment (CI). Brain MRI pre- and post-CR were analysed using an advanced tractography algorithm, based on multishell diffusion MRI, to obtain node-based graph metrics (local efficiency and strength) from microscopic fractional anisotropy. Seventy MS patients completed the study (age 48.9 ± 8.8, disease duration 16.8 ± 9.0 years); active treatment: 36, static treatment: 34. Verbal memory improved significantly post-CR in both groups (55 % active; 34 % static treatment), accompanied by increases in local efficiency and strength in multimodal regions. At follow-up, verbal memory declined in both groups but remained above the pre-CR assessment (-25 % and -17 %, respectively). Patients with severe-CI (n = 36) showed improvement only with active treatment, while those with mild-CI (n = 34) improved regardless of intensity treatment. Network changes were more pronounced in patients in active treatment and in those with severe-CI. Quality of life did not change at post-CR, and cognitive improvement was influenced by cognitive reserve (p = 0.011). In MS, GNPT temporarily improves verbal memory and increases network connectivity, reinforcing the CR as a valuable tool for enhancing cognitive skills and promoting neuronal plasticity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension, a randomized, single-blind clinical trial

  • Pérez Campuzano, Valeria|||0000-0002-5997-9511
  • Olivas, Pol|||0000-0002-1919-0284
  • Ferrusquía-Acosta, José|||0000-0001-8034-1291
  • Torres, Sonia
  • Borràs, Roger|||0000-0002-8585-2522
  • Baiges, Anna|||0000-0002-6963-9203
  • Orts, Lara|||0000-0002-3070-0310
  • Vizcarra, Pamela
  • Falgà Tirado, Angeles
  • Codina, Joana|||0000-0002-1768-9460
  • Shalaby, Sarah|||0000-0002-8700-6282
  • Ojeda, Asunción
  • Turon, Fanny|||0000-0001-5940-2838
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
  • Cárdenas, Andrés|||0000-0002-0764-7873
  • García-Pagán, JC.|||0000-0001-9032-4954
Background & Aims: Continuous infusion of terlipressin may result in a more sustained reduction in portal pressure with fewer adverse effects than administered as a bolus. This study aimed to compare the hepatic and cardiopulmonary hemodynamic effects and safety profiles of bolus vs. terlipressin continuous infusion. Methods: This is a single-center, single-blinded, double-dummy, parallel-group, clinical trial in which 38 patients with cirrhosis and portal hypertension were randomized to receive the following: 1 mg bolus of terlipressin + continuous infusion of placebo (TERLBOL, n = 12), a bolus of placebo + continuous infusion of terlipressin (2 or 4 mg/day if <10% reduction in hepatic venous pressure gradient [HVPG] at 30 min of infusion) (TERLINF, n = 14), or a bolus of octreotide (50 μg) + continuous infusion of octreotide (50 μg/h) (OCTR, n = 12) as an additional control group. HVPG, cardiopulmonary pressures, and cardiac output were measured at baseline and after 30, 60, and 120 min. Results: Sixty-eight percent of patients were male, with a median age of 59 years. There were no significant differences in baseline characteristics. In the TERLBOL group, there was a nonsignificant reduction in HVPG (at 120 min, -4.9%; p = 0.14). However, cardiopulmonary and mean arterial pressures significantly increased, whereas cardiac output and heart rate significantly decreased. In the TERLINF group, there were nonsignificant changes in cardiopulmonary hemodynamics or HVPG (NS) despite doubling the infusion dose after 30 min in 13/14 patients. In the OCTR group, there was a nonsignificant reduction in HVPG (at 120 min, -4.9%; p = 0.08), and pulmonary capillary pressure significantly decreased. All treatments were well tolerated, and no adverse events were observed. Conclusions: There were nonsignificant reductions in HVPG with the three therapeutic strategies. Further investigations are warranted to determine the optimal dosing strategy for continuous infusion of terlipressin in patients with cirrhosis and portal hypertension. Impact and implications: The results of our study do not show a significant reduction in portal pressure, at least in the first 2 h after the selected dose. Although the study was not performed in the setting of acute variceal bleeding and terlipressin was used as a standard therapy, these results do not support the treatment strategy of terlipressin infusion alone at the doses studied for the management of acute variceal bleeding, where a quick reduction in portal pressure is thought to play a major role controlling variceal bleeding. It is important to highlight that the continuously infused terlipressin regimen is better tolerated and appears to have a better cardiopulmonary safety profile. Other treatment strategies of continuous terlipressin infusion, such as initial bolus administration or higher infusion doses, should be evaluated to support its use in managing variceal bleeding. Clinical trial identifier: EudraCT No. 2019-004328-39.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Oral vs. Outpatient Parenteral Antimicrobial Treatment for Infective Endocarditis, Study Protocol for the Spanish OraPAT-IE GAMES Trial

  • Cuervo, Guillermo|||0000-0002-7075-943X
  • Hernández Meneses, Marta|||0000-0001-9991-1127
  • Alarcón González, Arístides de|||0000-0002-4548-4462
  • Luque, Rafael
  • Alonso-Socas, M.M.
  • López-Lirola, A.
  • González-Ramallo, V.
  • Goikoetxea-Agirre, A.J.
  • Nicolás, David
  • Goenaga, Miguel Ángel
  • Merino de Lucas, Esperanza|||0000-0003-3854-4874
  • Escrihuela-Vidal, Francesc|||0000-0003-3652-3121
  • Martín-Dávila, P.
  • Loeches, Belén
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Gasch, Oriol|||0000-0001-8518-458X
  • Campreciós, Marta|||0000-0002-4851-492X
  • Hernández-Torres, A.
  • García-Álvarez, L.
  • Pajarón, M.
  • Ribas, M.A.
  • Blanes-Hernández, R.
  • López Montesinos, Inmaculada|||0000-0002-2675-4412
  • López Cortés, Luis Eduardo|||0000-0002-9347-527X
  • Vidal, Barbara|||0000-0003-4303-0851
  • Fernandez-Pittol, Mariana|||0000-0002-1685-7127
  • Navarro, Daniel
  • Moreno Camacho, Asunción|||0000-0001-6382-0039
  • Sala, Coral
  • Ambrosioni, Juan|||0000-0001-9931-6686
  • Miró, José M.|||0000-0001-8057-7755
  • Olivares, P.
  • Morales Fariña, Inmaculada
  • Méndez, I.
  • de Cueto, M.
  • Calvo-Jambrina, R.
  • Barquero, J.M.
  • Araji, O.
  • Almendro-Delia, Manuel|||0000-0001-7144-4782
  • Brasé, A.
  • Calvo-Fernández, Alicia|||0000-0001-6504-3528
  • Tauron, Manel|||0000-0002-5864-519X
  • Recasens, L.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Suárez, M.
  • Silverio, A.
  • Sánchez Barrera, Florencio|||0000-0002-5314-453X
  • Ribas, N.
  • Serrat, R.
  • Molina, L.
  • Mestres, Antoni
  • Mas, A.
  • Ginel, Antonino|||0000-0002-8820-7545
  • Horcajada-Gallego, J.P.
  • Ble, M.
  • López-Montesinos, I.
  • Salavert-Lleti, M.
  • García-Bustos, V.
  • Fernández-Navarro, J.A.
  • Calabuig-Muñoz, E.
  • Montero Alonso, Marta
  • Tasias-Pitarch, M.
  • Domingo-Valero, D.
  • Arnau-Vives, M.Á.
  • Vives-Borràs, M.
  • Vidal-Bonet, L.
  • Ruiz de Gopegui-Bordes, E.
  • Ribas-Blanco, M.Á.
  • Zarauza, J.
  • Teira, R.
  • Ruiz-Alonso, N.
  • Parra, J.A.
  • Gutiérrez-Díez, J.
  • Gutiérrez-Cuadra, M.
  • Gutiérrez-Fernández, L.
  • González-Rico, C.
  • Garrido, R.
  • García, I.
  • Fernández-Sampedro, M.
  • Fariñas-Álvarez, C.
  • Fariñas, M.C.
  • Cobo-Belaustegui, M.
  • Arnaiz de las Revillas, F.
  • Armiñanzas-Castillo, C.
  • Amado-Fernández, C.
  • Agüero-Balbín, J.
  • Martín-Blanco, N.
  • Oteo, José A.|||0000-0001-7080-6542
  • Corral-Armas, E.
  • Blanco, J.R.
  • Azcona-Gutiérrez, J.M.
  • Azcárate Goded, Pilar|||0000-0002-1306-5140
  • Alonso, Luis Javier
  • Saura, D.
  • Roura-Piloto, A.
  • Pérez-Andreu, J.
  • Ortín, A.
  • Oliva, M.J.
  • Moral-Escudero, E.
  • Martínez-Toldos, M.C.
  • de Gea, J.H.
  • de la Morena Valenzuela, G.
  • Blázquez, A.
  • Vázquez, E.G.
  • Cánovas, S.
  • Albert Fàbregas, Lara|||0000-0003-3711-918X
  • Rivera-Martínez, M.A.
  • López-Contreras, Joaquín|||0000-0002-3166-4016
  • Leta, Rubén|||0000-0003-4691-381X
  • Grillo, Sara|||0000-0002-3596-8690
  • Barros-Membrilla, Antonio J.|||0000-0003-4053-2821
  • Campreciós, Marta|||0000-0002-4851-492X
  • Gasch, O.
  • Monsálvez, Víctor|||0009-0003-0126-3224
  • Gomila, Aina|||0000-0001-6979-9269
  • Calzado, Sonia|||0000-0002-2975-6448
  • Díaz, E.
  • Lozano, L.
  • Capilla, Silvia|||0000-0002-7274-2973
  • Guillamon, L.
  • Guillaumet, E.
  • Castaldo, F.
  • Araujo, G.
  • Dietl, B.
  • Ibars, S.
  • Xercavins, M.|||0000-0003-1463-6344
  • Badía, C.
  • Rosillo, S.
  • Romero, María
  • Rial-Bastón, V.
  • Ramírez, Ulises
  • Moreno Yangüela, Mar
  • Antorrena, I.
  • Ruiz-Janer, Sabina|||0000-0002-8073-9504
  • Rodríguez-Roda-Stuart, J.
  • Rio, Alejandro del
  • Oliva, E.
  • Navas, Enrique|||0000-0001-9561-1338
  • Moya, J.L.
  • Hermida, J.M.
  • Centella, Tomasa
  • Sánchez-Rodríguez, I.
  • Gràcia Sánchez, Laura Maria
  • Blasco Cordellat, Ana|||0000-0001-5889-0382
  • Sbraga, F.
  • Ruiz-Majoral, A.
  • Alegre, O.
  • Sánchez Salado, José Carlos
  • Berbel, D.
  • Ardanuy, Carmen|||0000-0003-0225-607X
  • Grau, I.
  • Carratalà, Jordi|||0000-0003-3209-2563
  • Escrihuela-Vidal, F.
  • González-de-la-Aleja, P.
  • Pinargote-Celorio, H.
  • Reus, Sergio|||0000-0002-3320-9754
  • Plazas, J.
  • Llamas, P.
  • Climent, V.
  • Carrasco, R.
  • Goyeneche, M.
  • Bidegain, M.
  • Sánchez, Sara
  • Zabalo-Arrieta, M.
  • Villanueva-Benito, I.
  • Vicente-Anza, D.
  • Unamuno-Ugartemendia, I.
  • Solla-Ruiz, I.
  • Sebastián-Alda, R.
  • Sánchez-Haza, E.
  • Sáez-Berbejillo, A.
  • Reviejo, K.
  • Rengel-Jiménez, A.
  • Pérez-Moreiras-López, J.I.
  • Kortajarena-Urkola, X.
  • Iribarren, José Antonio
  • Granda-Bauza, Á.
  • Goyeneche del Río, M.
  • Fuentes, A.
  • Eizaguirre-Yarza, A.
  • Echeverría, T.
  • del Bosque-Martín, C.
  • Bustinduy-Odriozola, M.J.
  • Berritu-Boronat, E.
  • Azkune-Galparsoro, H.
  • Camino, X.
  • Álvarez-Rodriguez, Ignacio
  • Voces, R.
  • Vitoria, Y.
  • Rodríguez, R.
  • Rodrigo, D.
  • Nieto, J.
  • Montejo, Miguel
  • López-Soria, L.
  • Irurzun-Zuazabal, J.
  • Iruretagoyena, J.R.
  • Ibarrola-Hierro, M.
  • Goikoetxea, A.J.
  • Euba-Ugarte, G.
  • Del Álamo Martínez de Lagos, M.
  • Guio-Carrión, L.
  • Crespo, Alejandro
  • Campaña-Lázaro, M.
  • Boado, M.V.
  • Blanco, Ricardo|||0000-0003-2344-2285
  • Blanco-Vidal, M.J.
  • Bereciartua, Elena|||0000-0002-8603-779X
  • de la Villa, S.
  • Verde-Moreno, E.
  • Vázquez, Pilar
  • Valerio, Maricela|||0000-0001-6394-2861
  • Segado, A.
  • Sánchez-Pérez, Eduardo
  • Rodríguez Abella, Hugo
  • Rincón, Cristina
  • Pinto, Ángel
  • Pinilla, Blanca
  • Pedraz, Á.
  • Olmedo, M.
  • Monzón, D.
  • Muñoz, Patricia
  • Melero, Rosa
  • Martínez-Sellés, Manuel|||0000-0003-0289-6229
  • Marín, Mercedes
  • Machado, Marina|||0000-0002-8370-2248
  • Hualde, Amaia Mari
  • Kestler-Hernández, M.
  • González-Moraga, Francisco José|||0000-0001-8303-3788
  • Mansilla, A.G.
  • García-Leoni, M.E.
  • Gargallo, E.
  • Fortuny-Ribas, R.
  • Estévez, A.
  • Delgado-Montero, A.|||0000-0002-9307-0918
  • Cuerpo-Caballero, G.
  • Calatayud, J.
  • Bouza, Emilio
  • Bermejo, Javier|||0000-0002-5241-2758
  • Álvarez-Uría, A.
  • Castellote, Jose|||0000-0002-8528-3112
  • Adán, Iván
  • Rodríguez-Moreno, F.
  • Prada-Arrondo, P.
  • Pérez-Ramírez, A.
  • Lorenzo de la Peña, L.
  • Lacalzada, J.
  • González González, J.
  • García-Rosado, D.
  • Fernández-Sarabia, J.
  • Delgado-Melian, T.
  • Castro, B.
  • Alonso, M.d.M.
  • Poyato-Borrego, M.|||0000-0002-2749-355X
  • Sánchez Domínguez, Eladio
  • Ortiz-Carrellán, A.
  • Marín, G.
  • López-Haldón, J.
  • Lepe, J.A.
  • Gutiérrez-Carretero, E.
  • Navarro-Amuedo, D.
  • Vila, Jorgina|||0000-0001-9715-0627
  • Tuset, Montse
  • Vidal, B.
  • Urra, X.
  • Tolosana, J.M.
  • Téllez, A.
  • Soy, D.
  • Sitges, M.
  • Sanchis, Laura|||0000-0003-2516-8953
  • Sandoval, E.
  • Rovira, I.
  • Roque, M.
  • Roca, C.
  • Regueiro, Ander|||0000-0001-5201-447X
  • Ramírez, J.
  • Quintana, Eduard|||0000-0002-5386-7463
  • Pomar, José Luis|||0000-0003-2469-6084
  • Perissinotti, A.
  • Pericás, J.M.
  • Pereda, D.
  • Paré, C.
  • Ortiz, Joana|||0000-0002-2236-154X
  • Ninot, S.
  • Nicolás, D.
  • Miró, José M.|||0000-0001-8057-7755
  • Marco, Francesc|||0000-0002-1863-6379
  • López, T.
  • Llopis-Pérez, J.
  • Hernández Meneses, Marta|||0000-0001-9991-1127
  • García-Pares, D.
  • García de la Mària, Cristina|||0000-0002-0585-9469
  • Fuster, David
  • Fita, Guillermina
  • Fernández-Pittol, M.
  • Espasa, Mateu|||0000-0003-4822-1024
  • Falces, Carles|||0000-0002-3483-3786
  • de Diego, O.
  • Cuervo, Guillermo|||0000-0002-7075-943X
  • Cañas, M.A.
  • Castellá, Manuel
  • Cartañá, Ramón
  • Brunet, Mercè|||0000-0002-7154-916X
  • Azqueta, Manel
  • Ascaso, M.
  • Alcocer, J.
  • Almela, Manuel
  • Andrea, R.
Introduction: The POET trial demonstrated that moving from intravenous to oral antibiotics in stable patients with left-sided infective endocarditis (IE) was noninferior to fully parenteral treatment. However, it did not compare outpatient strategies. Methods: The OraPAT-IE GAMES trial is a noninferiority, multicenter, randomized, open-label study aimed to compare partial oral versus outpatient parenteral antibiotic therapy (OPAT) for consolidation of antibiotic treatment in left-sided IE. A total of 342 stable patients with IE caused by selected micro-organisms will eventually be included. After a minimum of 10 days of parenteral treatment, stable patients are randomized to oral therapy or OPAT. The primary end-point is a composite of all-cause mortality, unplanned cardiac surgery, relapse of positive blood cultures and/or unplanned hospital admission. Patients are followed-up for 6 months after completing antibiotic therapy. Planned Outcome: This trial seeks to demonstrate the equivalent efficacy of the two outpatient strategies currently available for stable patients with IE in the consolidation phase of antibiotic treatment. Conclusion: In a global context of limited healthcare resources and a sustained increase in elderly and frail patients, it is of great importance to demonstrate the effectiveness and safety of outpatient management strategies that could reduce the duration of conventional hospitalizations with their potential complications and inherent costs. Trial Registration: EudraCT: 2020-001024-34. ClinicalTrials.gov identifier: NCT05398679.